{"ba1ab411e62b278e72259c8203b76991c3efbc7d": [["H I G H L I G H T S\u2022 Data for the pathogens found in AD and their potential health risk was presented. \u2022 Research on the sanitation performance of AD has been reviewed. \u2022 Mechanism and factors affecting biosludge hygienization have been reviewed. \u2022 Hotspots and challenges for future work on biosludge sanitation have been evaluated. \u2022 Suggestions to mitigate the pathogen problems for biosolids were proposed.G R A P H I C A L A B S T R A C Ta b s t r a c t a r t i c l e i n f oIntroductionMunicipal wastewater may carry various kinds of waterborne infectious pathogens which migrate within municipal wastewater treatment plant (WWTP) between liquid and biosludge.", [["AD", "DISEASE", 53, 55], ["AD", "DISEASE", 147, 149], ["waterborne infectious pathogens", "DISEASE", 540, 571], ["H I C A L A B S T R A C", "CHEMICAL", 418, 441], ["S\u2022 Data", "TEST", 18, 25], ["the pathogens", "PROBLEM", 30, 43], ["AD", "PROBLEM", 53, 55], ["biosludge hygienization", "TREATMENT", 203, 226], ["biosludge sanitation", "TREATMENT", 292, 312], ["the pathogen problems", "PROBLEM", 360, 381], ["biosolids", "TREATMENT", 386, 395], ["A L A B S", "TEST", 424, 433], ["A C Ta", "TEST", 438, 444], ["oIntroduction", "TREATMENT", 479, 492], ["Municipal wastewater", "TREATMENT", 492, 512], ["waterborne infectious pathogens", "PROBLEM", 540, 571], ["liquid and biosludge", "TREATMENT", 645, 665], ["waterborne", "OBSERVATION_MODIFIER", 540, 550], ["infectious", "OBSERVATION", 551, 561]]], ["It had been reported that about 6.5 million metric ton (dry weight) of sewage sludge were generated annually, in which waterborne pathogens may be concentrated substantially (Shen et al., 2015) .", [["sewage sludge", "PROBLEM", 71, 84]]], ["As such, biosolid disposal sites might act as the sources of pathogens, leading to a potential risk of uncontrollable spread into surface water, ground water and soils (Fr\u00f6schle et al., 2015a (Fr\u00f6schle et al., , 2015b .", [["surface", "ANATOMY", 130, 137], ["biosolid disposal sites", "TREATMENT", 9, 32], ["pathogens", "PROBLEM", 61, 70], ["pathogens", "OBSERVATION", 61, 70], ["uncontrollable", "OBSERVATION_MODIFIER", 103, 117]]], ["Without proper control, sludge-associated pathogens could continue to grow, causing potential threats to the human health.", [["human", "ORGANISM", 109, 114], ["human", "SPECIES", 109, 114], ["human", "SPECIES", 109, 114], ["sludge-associated pathogens", "PROBLEM", 24, 51], ["sludge", "OBSERVATION", 24, 30], ["pathogens", "OBSERVATION", 42, 51]]], ["In addition to pathogen-associated diseases, sludge pathogen is also a source of antibiotic resistance genes (ARGs).", [["pathogen-associated diseases", "DISEASE", 15, 43], ["antibiotic resistance genes", "DNA", 81, 108], ["ARGs", "DNA", 110, 114], ["pathogen-associated diseases", "PROBLEM", 15, 43], ["sludge pathogen", "PROBLEM", 45, 60], ["antibiotic resistance genes", "TREATMENT", 81, 108], ["pathogen", "OBSERVATION", 15, 23], ["diseases", "OBSERVATION", 35, 43], ["sludge pathogen", "OBSERVATION", 45, 60]]], ["Increasing evidence suggests that ARGs in municipal wastewater are transferrable to biosludge and crops fertilized with human waste, leading to severer and longlasting influence on public health (Devarajan et al., 2015; Su et al., 2015) .", [["ARGs", "CHEMICAL", 34, 38], ["ARGs", "SIMPLE_CHEMICAL", 34, 38], ["human", "ORGANISM", 120, 125], ["human", "SPECIES", 120, 125], ["human", "SPECIES", 120, 125], ["ARGs", "PROBLEM", 34, 38], ["municipal wastewater", "TREATMENT", 42, 62], ["human waste", "TREATMENT", 120, 131], ["ARGs", "OBSERVATION", 34, 38], ["municipal wastewater", "OBSERVATION", 42, 62]]], ["Although several natural processes have been employed for inactivation of pathogens in waste sewage sludge (e.g. sun exposure, soil adsorption etc.), anaerobic digestion (AD) of biosludge has been considered as a highly efficient technology for killing pathogenic microorganisms (Fig. 1) .IntroductionAD widely used for biosludge treatment with the aims of volume reduction and biogas generation is a complex biological process with the multiple-steps of reactions, i.e. hydrolysis, acidogenesis, acetogenesis and methanogenesis by which organic fraction of bio sludge being Fig. 1 .", [["acidogenesis", "DISEASE", 483, 495], ["acetogenesis", "DISEASE", 497, 509], ["pathogens", "PROBLEM", 74, 83], ["waste sewage sludge", "PROBLEM", 87, 106], ["soil adsorption", "TREATMENT", 127, 142], ["anaerobic digestion", "PROBLEM", 150, 169], ["biosludge", "TREATMENT", 178, 187], ["killing pathogenic microorganisms", "PROBLEM", 245, 278], ["IntroductionAD", "TREATMENT", 289, 303], ["biosludge treatment", "TREATMENT", 320, 339], ["volume reduction", "TREATMENT", 357, 373], ["biogas generation", "TREATMENT", 378, 395], ["a complex biological process", "PROBLEM", 399, 427], ["reactions", "PROBLEM", 455, 464], ["hydrolysis", "PROBLEM", 471, 481], ["acidogenesis", "PROBLEM", 483, 495], ["acetogenesis", "PROBLEM", 497, 509], ["methanogenesis", "TREATMENT", 514, 528], ["bio sludge", "PROBLEM", 558, 568], ["waste sewage sludge", "OBSERVATION", 87, 106], ["biogas generation", "OBSERVATION", 378, 395], ["bio sludge", "OBSERVATION", 558, 568]]], ["Scheme of anaerobic digestion as sewage sludge stabilization unit in WWTPs for biofertilizer production. mainly converted to biomethane or hydrogen, an emerging source of renewable energy.", [["biomethane", "CHEMICAL", 125, 135], ["hydrogen", "CHEMICAL", 139, 147], ["biomethane", "CHEMICAL", 125, 135], ["hydrogen", "CHEMICAL", 139, 147], ["biomethane", "SIMPLE_CHEMICAL", 125, 135], ["hydrogen", "SIMPLE_CHEMICAL", 139, 147], ["anaerobic digestion", "PROBLEM", 10, 29], ["sewage sludge stabilization unit", "TREATMENT", 33, 65], ["biofertilizer production", "PROBLEM", 79, 103], ["biomethane", "TREATMENT", 125, 135], ["hydrogen", "TREATMENT", 139, 147], ["anaerobic digestion", "OBSERVATION", 10, 29], ["renewable energy", "OBSERVATION", 171, 187]]], ["In many countries, the solid residue produced from AD of sewage sludge has been used as fertilizer for crop production as well as soil stabilizer for improving soil quality.", [["AD of sewage sludge", "CHEMICAL", 51, 70], ["the solid residue", "PROBLEM", 19, 36], ["sewage sludge", "TREATMENT", 57, 70], ["fertilizer", "TREATMENT", 88, 98], ["crop production", "TREATMENT", 103, 118], ["soil stabilizer", "TREATMENT", 130, 145], ["solid residue", "OBSERVATION", 23, 36]]], ["It can also be used as fish/ aquaculture food sources after vermicomposting, converting the biosolids into aquatic worms.", [["worms", "SPECIES", 115, 120]]], ["The worms mainly consist of protein and smaller fractions of fat, sugar and ash but contains low amount of heavy metals, which has a broad application potential as fish feed (Elissen et al., 2010) .", [["worms", "ANATOMY", 4, 9], ["fat", "ANATOMY", 61, 64], ["fat, sugar and ash", "CHEMICAL", 61, 79], ["sugar", "CHEMICAL", 66, 71], ["worms", "ORGANISM", 4, 9], ["fat", "TISSUE", 61, 64], ["sugar", "SIMPLE_CHEMICAL", 66, 71], ["ash", "SIMPLE_CHEMICAL", 76, 79], ["worms", "SPECIES", 4, 9], ["smaller", "OBSERVATION_MODIFIER", 40, 47], ["fractions", "OBSERVATION_MODIFIER", 48, 57], ["fat", "ANATOMY", 61, 64], ["low amount", "OBSERVATION_MODIFIER", 93, 103], ["heavy metals", "OBSERVATION_MODIFIER", 107, 119], ["broad", "OBSERVATION_MODIFIER", 133, 138]]], ["No matter for agricultural or fish/aquaculture purposes, AD is considered as the preliminary step.", [["AD", "DISEASE", 57, 59], ["agricultural or fish/aquaculture purposes", "PROBLEM", 14, 55], ["AD", "PROBLEM", 57, 59]]], ["On one hand, AD improves the biodegradability of the raw sludge and raises the organic fractions that are more available for earthworms.", [["AD", "DISEASE", 13, 15], ["the raw sludge", "PROBLEM", 49, 63], ["the organic fractions", "PROBLEM", 75, 96], ["sludge", "OBSERVATION", 57, 63]]], ["On the other land, AD, as a pretreatment for vermicomposting step, lowered the pathogen loading rate for the worms.", [["AD", "DISEASE", 19, 21], ["worms", "SPECIES", 109, 114], ["a pretreatment", "TREATMENT", 26, 40], ["vermicomposting step", "TREATMENT", 45, 65], ["the pathogen loading rate", "TREATMENT", 75, 100]]], ["Compare to fish/aquaculture food resource, the public exercises much more due caution for the agricultural use (Wan et al., 2016) .", [["fish", "ORGANISM", 11, 15], ["the public exercises", "TREATMENT", 43, 63]]], ["However, these applications of such digestate residue should be strictly regulated to ensure that it is hygienically safe.IntroductionThe relative abundances of pathogenic microorganisms including bacterium, parasite and virus had been demonstrated to significantly decline after AD of sewage sludge.", [["AD", "DISEASE", 280, 282], ["such digestate residue", "PROBLEM", 31, 53], ["pathogenic microorganisms", "PROBLEM", 161, 186], ["bacterium", "PROBLEM", 197, 206], ["parasite", "PROBLEM", 208, 216], ["virus", "PROBLEM", 221, 226], ["sewage sludge", "PROBLEM", 286, 299], ["sewage sludge", "OBSERVATION", 286, 299]]], ["Different pathogenic species might have different susceptibilities to AD, the decay of pathogens was also related to the operating conditions (Ju et al., 2016; Kearney et al., 1993a; Sahlstr\u00f6m et al., 2008) .", [["AD", "DISEASE", 70, 72], ["Different pathogenic species", "PROBLEM", 0, 28], ["different susceptibilities", "PROBLEM", 40, 66], ["pathogens", "PROBLEM", 87, 96], ["pathogenic species", "OBSERVATION", 10, 28]]], ["So far, the mechanism of pathogens deactivation has not been fully understood.", [["pathogens deactivation", "PROBLEM", 25, 47], ["pathogens", "OBSERVATION", 25, 34]]], ["Currently, extensive effort has been devoted to identifying the potential ecological and health risk of viable and infectious pathogens surviving after anaerobic stabilization of sewage sludge, while strong attention has also been given to standardize the quantification methods of viable pathogens (e.g. helminth eggs).", [["eggs", "ANATOMY", 314, 318], ["viable and infectious pathogens", "PROBLEM", 104, 135], ["anaerobic stabilization", "TREATMENT", 152, 175], ["sewage sludge", "PROBLEM", 179, 192], ["viable pathogens", "PROBLEM", 282, 298], ["infectious", "OBSERVATION_MODIFIER", 115, 125], ["sewage sludge", "OBSERVATION", 179, 192]]], ["Furthermore, with the steadily increasing antibiotic consumption, proliferation and release of ARGs-associated pathogens into the environment via biosolid discharge is of greater concern.", [["ARGs", "CHEMICAL", 95, 99], ["biosolid", "CHEMICAL", 146, 154], ["ARGs", "SIMPLE_CHEMICAL", 95, 99], ["the steadily increasing antibiotic consumption", "PROBLEM", 18, 64], ["proliferation", "PROBLEM", 66, 79], ["ARGs", "PROBLEM", 95, 99]]], ["Given such a situation, AD has gained increasing interest due to its merit of controlling ARGs, though the mechanism behind is yet clear.", [["AD", "DISEASE", 24, 26], ["ARGs", "GENE_OR_GENE_PRODUCT", 90, 94], ["clear", "OBSERVATION", 131, 136]]], ["These suggest that the life cycle of ARGs after entering into the soil environment deserves more investigations.", [["ARGs", "CHEMICAL", 37, 41], ["ARGs", "GENE_OR_GENE_PRODUCT", 37, 41]]], ["Otherwise, the digestate fertilizer as a carrier of pathogens with ARGs may pose a potential health risk to farmers during crop production, especially some specific pathogens use the soil as a transmission vector in their life cycles (Manser et al., 2015; Wang et al., 2015) .IntroductionWith its increasing sensitivity to environmental and health, digestate fertilizer has been regulated in the zero draft of ministerial outcome document \"Towards a Pollution-Free Planet\" by 2017 UN Environment Assembly in 2017.", [["digestate", "CHEMICAL", 15, 24], ["ARGs", "CHEMICAL", 67, 71], ["digestate", "CHEMICAL", 349, 358], ["digestate", "SIMPLE_CHEMICAL", 15, 24], ["ARGs", "SIMPLE_CHEMICAL", 67, 71], ["digestate", "SIMPLE_CHEMICAL", 349, 358], ["the digestate fertilizer", "TREATMENT", 11, 35], ["pathogens", "PROBLEM", 52, 61], ["ARGs", "TREATMENT", 67, 71], ["a transmission vector", "TREATMENT", 191, 212], ["its increasing sensitivity", "PROBLEM", 293, 319], ["digestate fertilizer", "TREATMENT", 349, 369], ["digestate fertilizer", "OBSERVATION", 15, 35], ["increasing", "OBSERVATION_MODIFIER", 297, 307]]], ["The EU animal by-products regulation stipulates that digestate leaving biogas or composting plants are considered acceptable only if Escherichia coli and are both below 1000/g, and Salmonella is not detectable in 5 tested samples of 25 g (Ahn et al., 2007; Commission Regulation, 2011) .", [["digestate", "CHEMICAL", 53, 62], ["digestate", "SIMPLE_CHEMICAL", 53, 62], ["Escherichia coli", "ORGANISM", 133, 149], ["Escherichia coli", "SPECIES", 133, 149], ["Escherichia coli", "SPECIES", 133, 149], ["Salmonella", "SPECIES", 181, 191], ["composting plants", "TREATMENT", 81, 98], ["Escherichia coli", "PROBLEM", 133, 149], ["Salmonella", "PROBLEM", 181, 191]]], ["In the U.S., only the sludge of Class A, i.e. containing undetectable levels of pathogens, can be used for agricultural purposes.", [["pathogens", "PROBLEM", 80, 89], ["agricultural purposes", "TEST", 107, 128], ["sludge", "OBSERVATION", 22, 28], ["pathogens", "OBSERVATION", 80, 89]]], ["However, 75% of the stabilized sewage sludge used for agriculture belonged to Class B biosolids with pathogens (Gr\u00fcbel and Suschka, 2015) .", [["the stabilized sewage sludge", "TREATMENT", 16, 44], ["pathogens", "PROBLEM", 101, 110], ["sludge", "OBSERVATION", 38, 44]]], ["For Class A biosolids, of the level of fecal coliforms as an indicator of pathogen should be strictly monitored, while the monitoring of enteric viruses, helminth ova, and Salmonella spp.", [["ova", "ANATOMY", 163, 166], ["enteric viruses", "DISEASE", 137, 152], ["helminth ova", "DISEASE", 154, 166], ["enteric viruses", "ORGANISM", 137, 152], ["helminth ova", "ORGANISM", 154, 166], ["Salmonella spp", "ORGANISM", 172, 186], ["Class A biosolids", "TREATMENT", 4, 21], ["fecal coliforms", "PROBLEM", 39, 54], ["pathogen", "PROBLEM", 74, 82], ["enteric viruses", "PROBLEM", 137, 152], ["helminth ova", "TREATMENT", 154, 166], ["Salmonella spp", "PROBLEM", 172, 186], ["fecal", "ANATOMY", 39, 44], ["coliforms", "OBSERVATION", 45, 54], ["pathogen", "OBSERVATION", 74, 82], ["enteric viruses", "ANATOMY", 137, 152]]], ["It should be stressed that even the level of indicator pathogens is below detection limit, this cannot be directly translated to the absence of potential pathogenic risk due to the occurrence of other pathogens.", [["other pathogens", "PROBLEM", 195, 210], ["pathogens", "OBSERVATION", 201, 210]]], ["So far, comprehensive survey of pathogen content and categories in AD digestate has not been undertaken.", [["AD", "DISEASE", 67, 69], ["pathogen content", "PROBLEM", 32, 48], ["categories in AD digestate", "PROBLEM", 53, 79]]], ["Moving forward, a fundamental question is how to optimize AD operation for minimizing potential pathogenic risks.", [["AD", "DISEASE", 58, 60], ["AD operation", "TREATMENT", 58, 70]]], ["Obviously, without a complete risk assessment, it is almost impossible to ensure the safe use of AD digestate.", [["AD", "DISEASE", 97, 99], ["a complete risk assessment", "TEST", 19, 45], ["AD digestate", "TREATMENT", 97, 109]]], ["Therefore, this review attempts to offer a systematic overview of pathogens profile in WWTPs, the role of AD in mitigating pathogens, the possible mechanisms of pathogen deactivation in AD, the operating conditions and the principal factors against pathogens.IntroductionMeanwhile, the potential use of digested sludge as environmentfriendly biofertilizer was also discussed.Bacterial pathogens, parasites and virusFull understanding of the bacterial pathogens profile is the crucial and primary step for the safe disposal and reuse of AD biosolid.", [["AD", "DISEASE", 106, 108], ["AD", "DISEASE", 186, 188], ["AD", "DISEASE", 536, 538], ["mitigating pathogens", "PROBLEM", 112, 132], ["pathogen deactivation", "PROBLEM", 161, 182], ["pathogens", "PROBLEM", 249, 258], ["digested sludge", "PROBLEM", 303, 318], ["Bacterial pathogens", "PROBLEM", 375, 394], ["parasites", "PROBLEM", 396, 405], ["virus", "PROBLEM", 410, 415], ["the bacterial pathogens profile", "PROBLEM", 437, 468], ["the safe disposal", "TREATMENT", 505, 522], ["AD biosolid", "TREATMENT", 536, 547], ["sludge", "OBSERVATION", 312, 318], ["pathogens", "OBSERVATION", 385, 394], ["parasites", "OBSERVATION", 396, 405], ["bacterial", "OBSERVATION_MODIFIER", 441, 450], ["pathogens", "OBSERVATION", 451, 460]]], ["With the rapid development of advanced molecular detection methods, more and more viable but nonculturable pathogens have been found in biosludge.", [["advanced molecular detection methods", "PROBLEM", 30, 66], ["nonculturable pathogens", "PROBLEM", 93, 116], ["rapid", "OBSERVATION_MODIFIER", 9, 14], ["advanced", "OBSERVATION_MODIFIER", 30, 38]]], ["As for total prokaryotic pathogenic diversity, there have been reports about accessing the phylogenetic and functional diversity with whole metagenome shotgun sequencing as well as bioinformatics analysis with MetaPhlAn (Metagenomic Phylogenetic Analysis) tool (Lu et al., 2015; Li et al., 2015) .", [["total prokaryotic pathogenic diversity", "PROBLEM", 7, 45], ["whole metagenome shotgun sequencing", "TREATMENT", 134, 169], ["bioinformatics analysis", "TEST", 181, 204], ["pathogenic diversity", "OBSERVATION", 25, 45]]], ["However, none has conducted research on the pathogenic communities with amplicon-based sequencing of marker gene which is more cost-effective.", [["communities", "ANATOMY", 55, 66], ["marker gene", "DNA", 101, 112]]], ["And 16S rRNA, such as high-throughput MiSeq sequencing, might be one more cost-effective amplicon-based sequencing methods to predict the functional capabilities of bacterial pathogenic communities after conducting bioinformatics analysis with MEGAN tool or Tax4Fun software package.", [["communities", "ANATOMY", 186, 197], ["16S rRNA", "DNA", 4, 12], ["16S rRNA", "TEST", 4, 12], ["sequencing methods", "TEST", 104, 122], ["bacterial pathogenic communities", "PROBLEM", 165, 197], ["conducting bioinformatics analysis", "TEST", 204, 238], ["MEGAN tool", "TEST", 244, 254]]], ["For the community of fungi and others pathogenic eukaryotes, highthroughput sequencing for nuclear ribosomal internal transcribed spacer (ITS) is probably a method for useful molecule identification and sensitive blast searches and sequence clustering operations for the ITS region in eukaryotes can be made by some advanced software tool such as ITSx.", [["ribosomal", "ANATOMY", 99, 108], ["nuclear", "CELLULAR_COMPONENT", 91, 98], ["nuclear ribosomal internal transcribed spacer", "DNA", 91, 136], ["ITS", "DNA", 138, 141], ["ITS region", "DNA", 271, 281], ["ITSx", "DNA", 347, 351], ["pathogenic eukaryotes", "PROBLEM", 38, 59], ["nuclear ribosomal internal transcribed spacer", "TREATMENT", 91, 136], ["useful molecule identification", "TEST", 168, 198], ["blast searches", "TEST", 213, 227], ["sequence clustering operations", "TREATMENT", 232, 262]]], ["Many of the detected pathogens, such as Aeromonas, Clostridium, Enterococcus, Corynebacterium, Klebsiella, Legionella, Mycobacterium, Salmonella, Streptococcus Vibrio and parasitic geohelminths or helminths have been reported and majority of these pathogens could cause severe morbidity or even mortality for human beings by inflicting respiratory diseases, gastroenteritis, conjunctivitis, cystitis, genital disease, skin and soft tissue infections, etc. (Table 1) .", [["respiratory", "ANATOMY", 336, 347], ["genital", "ANATOMY", 401, 408], ["skin", "ANATOMY", 418, 422], ["soft tissue", "ANATOMY", 427, 438], ["parasitic geohelminths", "DISEASE", 171, 193], ["helminths", "DISEASE", 197, 206], ["respiratory diseases", "DISEASE", 336, 356], ["gastroenteritis", "DISEASE", 358, 373], ["conjunctivitis", "DISEASE", 375, 389], ["cystitis", "DISEASE", 391, 399], ["genital disease", "DISEASE", 401, 416], ["skin and soft tissue infections", "DISEASE", 418, 449], ["Aeromonas", "ORGANISM", 40, 49], ["Clostridium, Enterococcus", "ORGANISM", 51, 76], ["Corynebacterium, Klebsiella", "ORGANISM", 78, 105], ["Legionella", "ORGANISM", 107, 117], ["Mycobacterium", "ORGANISM", 119, 132], ["Salmonella, Streptococcus Vibrio", "ORGANISM", 134, 166], ["human", "ORGANISM", 309, 314], ["genital", "ORGANISM_SUBDIVISION", 401, 408], ["skin", "ORGAN", 418, 422], ["soft tissue", "TISSUE", 427, 438], ["Streptococcus Vibrio", "SPECIES", 146, 166], ["human", "SPECIES", 309, 314], ["human", "SPECIES", 309, 314], ["the detected pathogens", "PROBLEM", 8, 30], ["Aeromonas", "PROBLEM", 40, 49], ["Clostridium", "PROBLEM", 51, 62], ["Enterococcus", "PROBLEM", 64, 76], ["Corynebacterium", "PROBLEM", 78, 93], ["Klebsiella", "PROBLEM", 95, 105], ["Legionella", "PROBLEM", 107, 117], ["Mycobacterium", "PROBLEM", 119, 132], ["Salmonella", "PROBLEM", 134, 144], ["Streptococcus Vibrio", "PROBLEM", 146, 166], ["parasitic geohelminths", "PROBLEM", 171, 193], ["these pathogens", "PROBLEM", 242, 257], ["severe morbidity", "PROBLEM", 270, 286], ["inflicting respiratory diseases", "PROBLEM", 325, 356], ["gastroenteritis", "PROBLEM", 358, 373], ["conjunctivitis", "PROBLEM", 375, 389], ["cystitis", "PROBLEM", 391, 399], ["genital disease", "PROBLEM", 401, 416], ["skin and soft tissue infections", "PROBLEM", 418, 449], ["pathogens", "OBSERVATION", 21, 30], ["respiratory diseases", "OBSERVATION", 336, 356], ["conjunctivitis", "OBSERVATION", 375, 389], ["cystitis", "OBSERVATION", 391, 399], ["genital", "ANATOMY", 401, 408], ["disease", "OBSERVATION", 409, 416], ["skin", "ANATOMY", 418, 422], ["soft tissue", "ANATOMY", 427, 438], ["infections", "OBSERVATION", 439, 449]]], ["Among the detected pathogens, Escherichia coli, Salmonella, Yersinia enterocolitica, Enterococcus were vulnerable to AD, while Campylobacter jejuni, and Streptomyces, Collinsella aerofaciens, Streptococcus salivarius and Gordonia bronchialis etc. were reported to be much more resistant to and hardly removed by AD (Ju et al., 2016; Kearney et al., 1993b; Stiborova et al., 2015) .", [["Yersinia enterocolitica", "DISEASE", 60, 83], ["AD", "DISEASE", 117, 119], ["Campylobacter jejuni", "DISEASE", 127, 147], ["AD", "DISEASE", 312, 314], ["Escherichia coli", "ORGANISM", 30, 46], ["Salmonella,", "ORGANISM", 48, 59], ["Yersinia enterocolitica", "ORGANISM", 60, 83], ["Campylobacter jejuni", "ORGANISM", 127, 147], ["Collinsella aerofaciens", "ORGANISM", 167, 190], ["Streptococcus salivarius", "ORGANISM", 192, 216], ["Gordonia bronchialis", "ORGANISM", 221, 241], ["Escherichia coli", "SPECIES", 30, 46], ["Yersinia enterocolitica", "SPECIES", 60, 83], ["Campylobacter jejuni", "SPECIES", 127, 147], ["Collinsella aerofaciens", "SPECIES", 167, 190], ["Streptococcus salivarius", "SPECIES", 192, 216], ["Gordonia bronchialis", "SPECIES", 221, 241], ["Escherichia coli", "SPECIES", 30, 46], ["Yersinia enterocolitica", "SPECIES", 60, 83], ["Campylobacter jejuni", "SPECIES", 127, 147], ["Collinsella aerofaciens", "SPECIES", 167, 190], ["Streptococcus salivarius", "SPECIES", 192, 216], ["Gordonia bronchialis", "SPECIES", 221, 241], ["the detected pathogens", "PROBLEM", 6, 28], ["Escherichia coli", "PROBLEM", 30, 46], ["Salmonella", "PROBLEM", 48, 58], ["Yersinia enterocolitica", "PROBLEM", 60, 83], ["Enterococcus", "PROBLEM", 85, 97], ["AD", "PROBLEM", 117, 119], ["Campylobacter jejuni", "PROBLEM", 127, 147], ["Streptomyces", "PROBLEM", 153, 165], ["Collinsella aerofaciens", "PROBLEM", 167, 190], ["Streptococcus salivarius", "PROBLEM", 192, 216], ["Gordonia bronchialis", "PROBLEM", 221, 241], ["pathogens", "OBSERVATION", 19, 28], ["Escherichia coli", "OBSERVATION", 30, 46], ["Yersinia enterocolitica", "OBSERVATION", 60, 83], ["Enterococcus", "OBSERVATION", 85, 97], ["Streptococcus salivarius", "OBSERVATION", 192, 216], ["Gordonia bronchialis", "OBSERVATION", 221, 241]]], ["It should also be noted that some pathogens can be enriched, and even some become emerging and reemerging after AD (Li et al., 2015) .", [["AD", "DISEASE", 112, 114], ["some pathogens", "PROBLEM", 29, 43], ["pathogens", "OBSERVATION", 34, 43]]], ["Furthermore, some spore-forming pathogens e.g. Clostridium and Bacillus species with high resistance to acute stresses can survive after mesophilic or even thermophilic anaerobic digestion, therefore creating a hygienic problem when biosolid is spread (Dixit et al., 2005; Guzm\u00e1n et al., 2007; Lloret et al., 2013) .", [["Clostridium", "ORGANISM", 47, 58], ["Bacillus species", "ORGANISM", 63, 79], ["some spore-forming pathogens", "PROBLEM", 13, 41], ["Clostridium and Bacillus species", "PROBLEM", 47, 79], ["high resistance", "PROBLEM", 85, 100], ["acute stresses", "PROBLEM", 104, 118], ["thermophilic anaerobic digestion", "PROBLEM", 156, 188], ["a hygienic problem", "PROBLEM", 209, 227], ["high resistance", "OBSERVATION_MODIFIER", 85, 100], ["anaerobic digestion", "OBSERVATION", 169, 188]]], ["For example, biosolids produced from thermophilic AD could not meet the requirements by Directive of the European Parliament and of the Council for spreading of sludge on land due to the presence of C. perfringens spores (e.g. 9.6 \u00d7 104 CFUs mL \u22121 ) (Lloret et al., 2013) .Bacterial pathogens, parasites and virusThe accumulation of viral pathogens was also observed in biosludge, and it might threaten the safety of nearby workers, while causing infectious risks associated with land application (De Serres and Lalibert\u00e9, 1997).", [["AD", "DISEASE", 50, 52], ["C. perfringens", "ORGANISM", 199, 213], ["C. perfringens", "SPECIES", 199, 213], ["C. perfringens", "SPECIES", 199, 213], ["biosolids", "TREATMENT", 13, 22], ["thermophilic AD", "PROBLEM", 37, 52], ["sludge", "PROBLEM", 161, 167], ["C. perfringens spores", "PROBLEM", 199, 220], ["CFUs mL", "TEST", 237, 244], ["Bacterial pathogens", "PROBLEM", 273, 292], ["parasites", "PROBLEM", 294, 303], ["virus", "PROBLEM", 308, 313], ["viral pathogens", "PROBLEM", 333, 348], ["sludge", "OBSERVATION", 161, 167], ["perfringens", "OBSERVATION", 202, 213], ["pathogens", "OBSERVATION", 283, 292], ["parasites", "OBSERVATION", 294, 303], ["virus", "OBSERVATION_MODIFIER", 308, 313], ["accumulation", "OBSERVATION_MODIFIER", 317, 329], ["viral pathogens", "OBSERVATION", 333, 348]]], ["As summarized in Table 1 , viruses found in biosludge generally include DNA virus (e.g. Adenovirus, Herpesvirus, Papillomavirus Bocavirus) and RNA viruses (e.g. Coronavirus, Klassevirus, Rotavirus), and some of which were classified as emerging viruses with high abundance.", [["DNA", "CELLULAR_COMPONENT", 72, 75], ["Adenovirus", "ORGANISM", 88, 98], ["Herpesvirus", "ORGANISM", 100, 111], ["Papillomavirus Bocavirus", "ORGANISM", 113, 137], ["Klassevirus, Rotavirus", "ORGANISM", 174, 196], ["viruses", "PROBLEM", 27, 34], ["DNA virus", "PROBLEM", 72, 81], ["Adenovirus", "PROBLEM", 88, 98], ["Herpesvirus", "PROBLEM", 100, 111], ["Papillomavirus Bocavirus", "PROBLEM", 113, 137], ["RNA viruses", "PROBLEM", 143, 154], ["Coronavirus", "PROBLEM", 161, 172], ["Klassevirus", "TREATMENT", 174, 185], ["Rotavirus", "PROBLEM", 187, 196], ["RNA viruses", "OBSERVATION", 143, 154]]], ["Viruses seemed closely associated with Enterococci, and they were more resistant than coliforms during AD, but less resistant than spore formers, such as Clostridia (Avery et al., 2014; Sahlstr\u00f6m, 2003) .", [["coliforms", "CHEMICAL", 86, 95], ["AD", "DISEASE", 103, 105], ["Viruses", "PROBLEM", 0, 7], ["Enterococci", "PROBLEM", 39, 50], ["Enterococci", "OBSERVATION", 39, 50], ["less resistant", "OBSERVATION_MODIFIER", 111, 125]]], ["On the other hand, DNA viruses were found to be more persistent than the sing-stranded RNA phage (Decrey and Kohn, 2017) .Bacterial pathogens, parasites and virusAlthough most of digestate-borne pathogens and their ecological impacts had been reported in the literature, it is difficult to assert which kinds of pathogen would pose higher risks to public health and which should be the primary targets of deactivation during AD.", [["AD", "DISEASE", 425, 427], ["DNA", "CELLULAR_COMPONENT", 19, 22], ["DNA viruses", "PROBLEM", 19, 30], ["Bacterial pathogens", "PROBLEM", 122, 141], ["parasites", "PROBLEM", 143, 152], ["borne pathogens", "PROBLEM", 189, 204], ["pathogen", "PROBLEM", 312, 320], ["viruses", "OBSERVATION", 23, 30], ["persistent", "OBSERVATION_MODIFIER", 53, 63], ["pathogens", "OBSERVATION", 132, 141], ["parasites", "OBSERVATION", 143, 152], ["borne pathogens", "OBSERVATION_MODIFIER", 189, 204]]], ["In this regard, it had been proposed that the stable pathogens with high occurrence frequency should be primarily targeted (e.g. Clostridium, Mycobacterium, Collinsella aerofaciens and Streptococcus Salivarius).", [["Mycobacterium", "ORGANISM", 142, 155], ["Collinsella aerofaciens", "ORGANISM", 157, 180], ["Streptococcus Salivarius", "ORGANISM", 185, 209], ["Collinsella aerofaciens", "SPECIES", 157, 180], ["Streptococcus Salivarius", "SPECIES", 185, 209], ["Collinsella aerofaciens", "SPECIES", 157, 180], ["Streptococcus Salivarius", "SPECIES", 185, 209], ["the stable pathogens", "PROBLEM", 42, 62], ["high occurrence frequency", "PROBLEM", 68, 93], ["Clostridium", "TEST", 129, 140], ["Mycobacterium", "PROBLEM", 142, 155], ["Collinsella aerofaciens", "PROBLEM", 157, 180], ["Streptococcus Salivarius", "PROBLEM", 185, 209], ["stable", "OBSERVATION_MODIFIER", 46, 52], ["pathogens", "OBSERVATION", 53, 62]]], ["Meanwhile, the enriched, and emerging-reemerging pathogens should also need to be monitored closely, including Propionibacterium acnes, Gordonia bronchialis, Eggerthella lenta, Mycobacterium bovis, Streptococcus salivarius, Collinsella aerofaciens (Ju et al., 2016; Lahiri et al., 2014; Li et al., 2015) .", [["Propionibacterium acnes", "ORGANISM", 111, 134], ["Gordonia bronchialis", "ORGANISM", 136, 156], ["Eggerthella lenta", "ORGANISM", 158, 175], ["Mycobacterium bovis", "ORGANISM", 177, 196], ["Streptococcus salivarius", "ORGANISM", 198, 222], ["Collinsella aerofaciens", "ORGANISM", 224, 247], ["Propionibacterium acnes", "SPECIES", 111, 134], ["Gordonia bronchialis", "SPECIES", 136, 156], ["Eggerthella lenta", "SPECIES", 158, 175], ["Mycobacterium bovis", "SPECIES", 177, 196], ["Streptococcus salivarius", "SPECIES", 198, 222], ["Collinsella aerofaciens", "SPECIES", 224, 247], ["Propionibacterium acnes", "SPECIES", 111, 134], ["Gordonia bronchialis", "SPECIES", 136, 156], ["Eggerthella lenta", "SPECIES", 158, 175], ["Mycobacterium bovis", "SPECIES", 177, 196], ["Streptococcus salivarius", "SPECIES", 198, 222], ["Collinsella aerofaciens", "SPECIES", 224, 247], ["Propionibacterium acnes", "PROBLEM", 111, 134], ["Gordonia bronchialis", "TEST", 136, 156], ["Eggerthella", "TEST", 158, 169], ["Mycobacterium bovis", "PROBLEM", 177, 196], ["Streptococcus salivarius", "PROBLEM", 198, 222], ["enriched", "OBSERVATION_MODIFIER", 15, 23], ["Mycobacterium bovis", "OBSERVATION", 177, 196], ["Streptococcus salivarius", "OBSERVATION", 198, 222]]], ["More importantly, the potential environmental risks associated with these infectious pathogens should be fully assessed in a holistic manner.Host of ARGsThe risk of pathogens harboring ARGs in biosludge are gaining more and more public concern.", [["ARGs", "GENE_OR_GENE_PRODUCT", 149, 153], ["ARGs", "GENE_OR_GENE_PRODUCT", 185, 189], ["ARGs", "DNA", 149, 153], ["these infectious pathogens", "PROBLEM", 68, 94], ["pathogens harboring ARGs in biosludge", "PROBLEM", 165, 202], ["infectious", "OBSERVATION", 74, 84], ["ARGs", "OBSERVATION", 149, 153], ["pathogens", "OBSERVATION_MODIFIER", 165, 174], ["harboring ARGs", "OBSERVATION", 175, 189]]], ["Bacterial pathogens can serve as a host of ARGs of multidrugs and macrolide-lincosamide-streptogramin (Ju et al., 2016) .", [["macrolide-lincosamide-streptogramin", "CHEMICAL", 66, 101], ["multidrugs", "CHEMICAL", 51, 61], ["macrolide", "CHEMICAL", 66, 75], ["lincosamide", "CHEMICAL", 76, 87], ["streptogramin", "CHEMICAL", 88, 101], ["multidrugs", "SIMPLE_CHEMICAL", 51, 61], ["macrolide-lincosamide-streptogramin", "SIMPLE_CHEMICAL", 66, 101], ["Bacterial pathogens", "PROBLEM", 0, 19], ["multidrugs", "TREATMENT", 51, 61], ["macrolide", "TREATMENT", 66, 75], ["lincosamide", "TREATMENT", 76, 87], ["streptogramin", "TREATMENT", 88, 101], ["pathogens", "OBSERVATION", 10, 19]]], ["It has been known that ARGs can proliferate and spread through mobile genetic elements, such as integron, plasmids, transposon etc., with transferrable genes encoded with pathogenicity factors (Yu et al., 2016) .", [["plasmids", "ANATOMY", 106, 114], ["ARGs", "GENE_OR_GENE_PRODUCT", 23, 27], ["mobile genetic elements", "DNA", 63, 86], ["integron", "DNA", 96, 104], ["plasmids", "DNA", 106, 114], ["transposon", "DNA", 116, 126], ["transferrable genes", "DNA", 138, 157], ["pathogenicity factors", "PROTEIN", 171, 192], ["ARGs", "PROBLEM", 23, 27], ["integron, plasmids", "TREATMENT", 96, 114]]], ["Accumulating evidence suggests that the increased antibiotic resistance in bacterial pathogenesis could be induced and facilitated by the genetic-transferring-derived virulence proteins, which interfered with the signal transduction, while failed to regulate normal cellular metabolism.", [["cellular", "ANATOMY", 266, 274], ["cellular", "CELL", 266, 274], ["virulence proteins", "PROTEIN", 167, 185], ["the increased antibiotic resistance", "PROBLEM", 36, 71], ["bacterial pathogenesis", "PROBLEM", 75, 97], ["the signal transduction", "TEST", 209, 232], ["evidence suggests", "UNCERTAINTY", 13, 30], ["increased", "OBSERVATION_MODIFIER", 40, 49], ["antibiotic resistance", "OBSERVATION", 50, 71], ["normal cellular metabolism", "OBSERVATION", 259, 285]]], ["Thermophilic AD has been adopted as a remedial mean to attenuate integrons and ARGs in sewage sludge, including tetracycline resistance genes (tetA, tetO, tetX) and integron-integrase gene (intI1) (Diehl and LaPara, 2010; Ghosh et al., 2009) .", [["AD", "DISEASE", 13, 15], ["tetracycline", "CHEMICAL", 112, 124], ["tetracycline", "CHEMICAL", 112, 124], ["ARGs", "SIMPLE_CHEMICAL", 79, 83], ["tetracycline", "SIMPLE_CHEMICAL", 112, 124], ["tetA", "GENE_OR_GENE_PRODUCT", 143, 147], ["tetO", "GENE_OR_GENE_PRODUCT", 149, 153], ["tetX", "GENE_OR_GENE_PRODUCT", 155, 159], ["integron-integrase", "GENE_OR_GENE_PRODUCT", 165, 183], ["integrons", "DNA", 65, 74], ["tetracycline resistance genes", "DNA", 112, 141], ["tetA", "DNA", 143, 147], ["tetO", "DNA", 149, 153], ["tetX", "DNA", 155, 159], ["integron", "DNA", 165, 173], ["integrase gene", "DNA", 174, 188], ["intI1", "DNA", 190, 195], ["Thermophilic AD", "PROBLEM", 0, 15], ["integrons", "PROBLEM", 65, 74], ["ARGs", "PROBLEM", 79, 83], ["sewage sludge", "PROBLEM", 87, 100], ["tetracycline resistance genes", "TREATMENT", 112, 141], ["tetA", "TREATMENT", 143, 147], ["tetO", "TREATMENT", 149, 153], ["tetX", "TREATMENT", 155, 159], ["integron-integrase gene (intI1", "TREATMENT", 165, 195], ["sewage sludge", "OBSERVATION", 87, 100]]], ["It had been reported that thermophilic treatment helped to reduce the accumulation and spread of these pathogens-associated ARGs in soil (Kang et al., 2017) .", [["ARGs", "SIMPLE_CHEMICAL", 124, 128], ["thermophilic treatment", "TREATMENT", 26, 48], ["the accumulation", "PROBLEM", 66, 82], ["these pathogens", "PROBLEM", 97, 112], ["spread", "OBSERVATION_MODIFIER", 87, 93]]], ["On the contrary, there was evidence showing that most ARGs were hardly reduced by AD.", [["AD", "DISEASE", 82, 84], ["ARGs", "GENE_OR_GENE_PRODUCT", 54, 58], ["most ARGs", "PROBLEM", 49, 58]]], ["Thus, further investigation should be urgently needed to evaluate the ARGs reduction by AD.", [["AD", "DISEASE", 88, 90], ["ARGs", "SIMPLE_CHEMICAL", 70, 74], ["further investigation", "TEST", 6, 27], ["the ARGs reduction", "TREATMENT", 66, 84]]], ["This in turn will guide the operation of AD to minimize the spread of ARGs, helping to better manage the overall risk of r digestate residue in agricultural applications.TemperatureThe abundance of pathogens in sewage sludge generally fluctuates with the process configuration and operation conditions.", [["AD", "DISEASE", 41, 43], ["ARGs", "DISEASE", 70, 74], ["the operation", "TREATMENT", 24, 37], ["AD", "TREATMENT", 41, 43], ["r digestate residue", "PROBLEM", 121, 140], ["pathogens", "PROBLEM", 198, 207], ["sewage sludge", "PROBLEM", 211, 224], ["operation conditions", "TREATMENT", 281, 301], ["digestate residue", "OBSERVATION", 123, 140], ["abundance", "OBSERVATION_MODIFIER", 185, 194], ["pathogens", "OBSERVATION_MODIFIER", 198, 207], ["sewage sludge", "OBSERVATION", 211, 224]]], ["Temperature had been considered as the primary suppressive factor of pathogens in anaerobic digested sludge (Forbis-Stokes et al., 2016) .", [["Temperature", "TEST", 0, 11], ["pathogens", "PROBLEM", 69, 78], ["anaerobic digested sludge", "PROBLEM", 82, 107], ["digested sludge", "OBSERVATION", 92, 107]]], ["In fact, lethal effect of high temperature could be primarily attributed to denaturation of inactivating enzymes or capsid protein (Pandey and Soupir, 2011) .", [["inactivating enzymes", "PROTEIN", 92, 112], ["capsid protein", "PROTEIN", 116, 130], ["high temperature", "PROBLEM", 26, 42], ["denaturation of inactivating enzymes", "PROBLEM", 76, 112], ["capsid protein", "TEST", 116, 130], ["lethal effect", "OBSERVATION_MODIFIER", 9, 22]]], ["In fact, mild thermal process operated at moderate temperature was able to inactivate a variety of enzymes, such as indigenous epectin methylesterase, glyceraldehyde-3-phosphate dehydrogenase, creatine kinase, triose phosphate isomerase, acid phosphatase, serum albumin and immunoglobulin G, Lactate dehydrogenase (Veeramuthu et al., 1998) .", [["serum", "ANATOMY", 256, 261], ["glyceraldehyde-3-phosphate", "CHEMICAL", 151, 177], ["creatine", "CHEMICAL", 193, 201], ["triose phosphate", "CHEMICAL", 210, 226], ["Lactate", "CHEMICAL", 292, 299], ["glyceraldehyde-3-phosphate", "CHEMICAL", 151, 177], ["creatine", "CHEMICAL", 193, 201], ["triose phosphate", "CHEMICAL", 210, 226], ["Lactate", "CHEMICAL", 292, 299], ["epectin methylesterase", "GENE_OR_GENE_PRODUCT", 127, 149], ["glyceraldehyde-3-phosphate dehydrogenase", "GENE_OR_GENE_PRODUCT", 151, 191], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 193, 208], ["triose phosphate isomerase", "SIMPLE_CHEMICAL", 210, 236], ["serum", "ORGANISM_SUBSTANCE", 256, 261], ["albumin", "GENE_OR_GENE_PRODUCT", 262, 269], ["immunoglobulin G", "GENE_OR_GENE_PRODUCT", 274, 290], ["Lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 292, 313], ["enzymes", "PROTEIN", 99, 106], ["indigenous epectin methylesterase", "PROTEIN", 116, 149], ["glyceraldehyde-3-phosphate dehydrogenase", "PROTEIN", 151, 191], ["creatine kinase", "PROTEIN", 193, 208], ["triose phosphate isomerase", "PROTEIN", 210, 236], ["acid phosphatase", "PROTEIN", 238, 254], ["serum albumin", "PROTEIN", 256, 269], ["immunoglobulin G", "PROTEIN", 274, 290], ["Lactate dehydrogenase", "PROTEIN", 292, 313], ["mild thermal process", "PROBLEM", 9, 29], ["moderate temperature", "PROBLEM", 42, 62], ["enzymes", "TEST", 99, 106], ["indigenous epectin methylesterase", "TREATMENT", 116, 149], ["glyceraldehyde", "TEST", 151, 165], ["phosphate dehydrogenase", "TEST", 168, 191], ["creatine kinase", "TEST", 193, 208], ["triose phosphate isomerase", "TEST", 210, 236], ["acid phosphatase", "TEST", 238, 254], ["serum albumin", "TEST", 256, 269], ["immunoglobulin G", "TEST", 274, 290], ["Lactate dehydrogenase", "TEST", 292, 313], ["mild", "OBSERVATION_MODIFIER", 9, 13], ["thermal", "OBSERVATION_MODIFIER", 14, 21], ["process", "OBSERVATION", 22, 29]]], ["Thermal conditions applied to AD could induce pathogens destruction by break-up of the gel structure and cell lysis (Arora and Kazmi, 2015) .", [["cell", "ANATOMY", 105, 109], ["AD", "DISEASE", 30, 32], ["cell", "CELL", 105, 109], ["Thermal conditions", "TREATMENT", 0, 18], ["pathogens destruction", "PROBLEM", 46, 67], ["cell lysis", "TREATMENT", 105, 115], ["pathogens", "OBSERVATION_MODIFIER", 46, 55], ["destruction", "OBSERVATION", 56, 67], ["cell lysis", "OBSERVATION", 105, 115]]], ["According to Arrhenius equation, the inactivation rate of pathogens (e.g. helminth ova and enteric viruses) at 55\u00b0C was 15-17 times higher than those at 25-37\u00b0C (Pandey and Soupir, 2011) .", [["helminth ova and enteric viruses", "DISEASE", 74, 106], ["helminth ova", "ORGANISM", 74, 86], ["Arrhenius equation", "TEST", 13, 31], ["pathogens", "PROBLEM", 58, 67], ["enteric viruses", "PROBLEM", 91, 106], ["enteric viruses", "ANATOMY", 91, 106]]], ["Thermophilic digestion could completely kill all Coli-aerogenes and Enterococcus, while viable pathogens were still detected under mesophilic conditions at a sludge retention time of 12-15 days (Iwasaki et al., 2011) .", [["Coli-aerogenes", "CHEMICAL", 49, 63], ["Enterococcus", "CHEMICAL", 68, 80], ["Coli-aerogenes", "SIMPLE_CHEMICAL", 49, 63], ["Thermophilic digestion", "PROBLEM", 0, 22], ["Enterococcus", "PROBLEM", 68, 80], ["viable pathogens", "PROBLEM", 88, 104], ["Enterococcus", "OBSERVATION", 68, 80]]], ["Similarly, the multidrug-resistant bacteria were found to survive in dairy waste after 22-day mesophilic anaerobic digestion, but they disappeared after thermophilic digestion at 55\u00b0C (Beneragama et al., 2013; Nilmini et al., 2013) .", [["the multidrug-resistant bacteria", "PROBLEM", 11, 43], ["mesophilic anaerobic digestion", "PROBLEM", 94, 124], ["thermophilic digestion", "PROBLEM", 153, 175], ["resistant bacteria", "OBSERVATION", 25, 43]]], ["The potential sulharboring and integrons-harboring pathogens (e.g. Actinomycetales and Corynebacterium) could be completely eradicated through thermophilic digestion, while 0.26% and 0.17% of which could still survive under mesophilic conditions (Sun et al., 2016) .", [["harboring pathogens", "PROBLEM", 41, 60], ["Actinomycetales", "PROBLEM", 67, 82], ["Corynebacterium", "PROBLEM", 87, 102], ["thermophilic digestion", "PROBLEM", 143, 165]]], ["Moreover, ARG subtypes showed different responses to mesophilic and thermophilic conditions.", [["ARG subtypes", "GENE_OR_GENE_PRODUCT", 10, 22], ["ARG subtypes", "TEST", 10, 22], ["mesophilic and thermophilic conditions", "PROBLEM", 53, 91], ["thermophilic conditions", "OBSERVATION", 68, 91]]], ["Metagenomic analysis further revealed the lower abundance of mobilome (e.g. integrons, insert sequences and plasmids) as well as lower horizontal gene transfer potential under thermophilic conditions compared to mesophilic conditions.", [["plasmids", "ANATOMY", 108, 116], ["mobilome", "DNA", 61, 69], ["integrons", "DNA", 76, 85], ["insert sequences", "DNA", 87, 103], ["plasmids", "DNA", 108, 116], ["Metagenomic analysis", "TEST", 0, 20], ["the lower abundance of mobilome", "PROBLEM", 38, 69], ["insert sequences and plasmids", "TREATMENT", 87, 116], ["thermophilic conditions", "TREATMENT", 176, 199], ["lower abundance", "OBSERVATION_MODIFIER", 42, 57]]], ["However, it should be realized that heat-resistant pathogens including Bacillus cereus, Erysopelotrix rhusiopathiae, Listeria monocytogene, Staphylococcus aureus, Streptococcus faecalis, Yersinia enterocolitica, C. perfringens spores etc. were hardly removed by mesophilic and thermophilic AD or composting (Elmerdahl Olsen and Errebo Larsen, 1987; Kearney et al., 1993a) .", [["spores", "ANATOMY", 227, 233], ["Staphylococcus aureus", "DISEASE", 140, 161], ["Yersinia enterocolitica", "DISEASE", 187, 210], ["AD", "DISEASE", 290, 292], ["Bacillus cereus", "ORGANISM", 71, 86], ["Erysopelotrix rhusiopathiae", "ORGANISM", 88, 115], ["Listeria monocytogene", "ORGANISM", 117, 138], ["Staphylococcus aureus", "ORGANISM", 140, 161], ["Streptococcus faecalis", "ORGANISM", 163, 185], ["Yersinia enterocolitica", "ORGANISM", 187, 210], ["C. perfringens spores", "ORGANISM", 212, 233], ["Bacillus cereus", "SPECIES", 71, 86], ["Erysopelotrix rhusiopathiae", "SPECIES", 88, 115], ["Listeria monocytogene", "SPECIES", 117, 138], ["Staphylococcus aureus", "SPECIES", 140, 161], ["Streptococcus faecalis", "SPECIES", 163, 185], ["Yersinia enterocolitica", "SPECIES", 187, 210], ["C. perfringens", "SPECIES", 212, 226], ["Bacillus cereus", "SPECIES", 71, 86], ["Erysopelotrix rhusiopathiae", "SPECIES", 88, 115], ["Listeria monocytogene", "SPECIES", 117, 138], ["Staphylococcus aureus", "SPECIES", 140, 161], ["Streptococcus faecalis", "SPECIES", 163, 185], ["Yersinia enterocolitica", "SPECIES", 187, 210], ["C. perfringens", "SPECIES", 212, 226], ["heat-resistant pathogens", "PROBLEM", 36, 60], ["Bacillus cereus", "PROBLEM", 71, 86], ["Erysopelotrix rhusiopathiae", "PROBLEM", 88, 115], ["Listeria monocytogene", "PROBLEM", 117, 138], ["Staphylococcus aureus", "PROBLEM", 140, 161], ["Streptococcus faecalis", "PROBLEM", 163, 185], ["Yersinia enterocolitica", "PROBLEM", 187, 210], ["C. perfringens spores", "PROBLEM", 212, 233], ["Bacillus cereus", "OBSERVATION", 71, 86], ["Staphylococcus aureus", "OBSERVATION", 140, 161], ["Streptococcus faecalis", "OBSERVATION", 163, 185], ["Yersinia enterocolitica", "OBSERVATION", 187, 210]]], ["Therefore, it appears that high temperature should not be always regarded as a guaranty of high ARGs removal.Ammonia concentrationThe toxicity of ammonia on pathogens is notable and ammonia sanitization was often employed as one simple and low-cost alternative to inactivate bacteria, viruses, protozoa, adenovirus, reovirus, bacteriophages and other pathogens Magri et al., 2015) .", [["Ammonia", "CHEMICAL", 109, 116], ["toxicity", "DISEASE", 134, 142], ["ammonia", "CHEMICAL", 146, 153], ["ammonia", "CHEMICAL", 182, 189], ["Ammonia", "CHEMICAL", 109, 116], ["ammonia", "CHEMICAL", 146, 153], ["ammonia", "CHEMICAL", 182, 189], ["ARGs", "SIMPLE_CHEMICAL", 96, 100], ["Ammonia", "SIMPLE_CHEMICAL", 109, 116], ["ammonia", "SIMPLE_CHEMICAL", 146, 153], ["ammonia", "SIMPLE_CHEMICAL", 182, 189], ["adenovirus", "ORGANISM", 304, 314], ["reovirus", "ORGANISM", 316, 324], ["high temperature", "PROBLEM", 27, 43], ["high ARGs removal", "TREATMENT", 91, 108], ["Ammonia concentration", "TEST", 109, 130], ["The toxicity of ammonia on pathogens", "PROBLEM", 130, 166], ["ammonia sanitization", "PROBLEM", 182, 202], ["bacteria", "PROBLEM", 275, 283], ["viruses", "PROBLEM", 285, 292], ["protozoa", "PROBLEM", 294, 302], ["adenovirus", "PROBLEM", 304, 314], ["reovirus", "PROBLEM", 316, 324], ["bacteriophages", "PROBLEM", 326, 340]]], ["Dosage should not exceed the essential amount for anaerobic microorganism in digester (Rajagopal et al., 2013; Yenig\u00fcn and Demirel, 2013) .", [["Dosage", "TREATMENT", 0, 6], ["anaerobic microorganism", "PROBLEM", 50, 73]]], ["Meanwhile, other factors, e.g. substrates, inocula, temperature, pH and acclimation periods should be controlled since they can change the effect of ammonia on pathogens by modifying the equilibrium between toxic-N (Free ammonia) and non-toxic-N fractions among nitrogen compounds (Scaglia et al., 2014) .", [["ammonia", "CHEMICAL", 149, 156], ["ammonia", "CHEMICAL", 221, 228], ["nitrogen", "CHEMICAL", 262, 270], ["ammonia", "CHEMICAL", 149, 156], ["N", "CHEMICAL", 213, 214], ["ammonia", "CHEMICAL", 221, 228], ["N", "CHEMICAL", 244, 245], ["nitrogen", "CHEMICAL", 262, 270], ["ammonia", "SIMPLE_CHEMICAL", 149, 156], ["Free ammonia", "SIMPLE_CHEMICAL", 216, 228], ["non-toxic-N fractions", "SIMPLE_CHEMICAL", 234, 255], ["nitrogen compounds", "SIMPLE_CHEMICAL", 262, 280], ["acclimation periods", "TREATMENT", 72, 91], ["ammonia on pathogens", "PROBLEM", 149, 169], ["Free ammonia", "TEST", 216, 228], ["non-toxic-N fractions", "PROBLEM", 234, 255], ["nitrogen compounds", "TREATMENT", 262, 280]]], ["Helminth eggs and Clostridium spp. spores which showed strong resistance to ammonia inactivation at ambient temperature should be inactivated with assisting techniques .Ammonia concentrationFurthermore, it has been known that ammonia can effectively deactivate bacterial pathogens by altering the intracellular/extracellular K + / NH 3 ratio and exchange reaction (Sprott and Patel, 1986) .", [["eggs", "ANATOMY", 9, 13], ["spores", "ANATOMY", 35, 41], ["intracellular", "ANATOMY", 297, 310], ["extracellular", "ANATOMY", 311, 324], ["Helminth eggs", "DISEASE", 0, 13], ["ammonia", "CHEMICAL", 76, 83], ["Ammonia", "CHEMICAL", 169, 176], ["ammonia", "CHEMICAL", 226, 233], ["K", "CHEMICAL", 325, 326], ["NH", "CHEMICAL", 331, 333], ["ammonia", "CHEMICAL", 76, 83], ["Ammonia", "CHEMICAL", 169, 176], ["ammonia", "CHEMICAL", 226, 233], ["K +", "CHEMICAL", 325, 328], ["NH 3", "CHEMICAL", 331, 335], ["Helminth eggs", "ORGANISM", 0, 13], ["Clostridium spp", "ORGANISM", 18, 33], ["ammonia", "SIMPLE_CHEMICAL", 76, 83], ["Ammonia", "SIMPLE_CHEMICAL", 169, 176], ["ammonia", "SIMPLE_CHEMICAL", 226, 233], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 297, 310], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 311, 324], ["NH 3", "GENE_OR_GENE_PRODUCT", 331, 335], ["Clostridium spp", "SPECIES", 18, 33], ["Helminth eggs", "PROBLEM", 0, 13], ["Clostridium spp", "PROBLEM", 18, 33], ["spores", "PROBLEM", 35, 41], ["strong resistance to ammonia inactivation", "PROBLEM", 55, 96], ["bacterial pathogens", "PROBLEM", 261, 280], ["the intracellular/extracellular K", "TEST", 293, 326], ["strong", "OBSERVATION_MODIFIER", 55, 61], ["resistance", "OBSERVATION", 62, 72], ["ammonia inactivation", "OBSERVATION", 76, 96]]], ["As for viruses, NH 3 may cause the loss in genome integrity, specifically, the cleavage of viral RNA in intact particles (Decrey et al., 2015) .", [["NH", "CHEMICAL", 16, 18], ["NH 3", "CHEMICAL", 16, 20], ["NH 3", "GENE_OR_GENE_PRODUCT", 16, 20], ["NH 3", "PROTEIN", 16, 20], ["viral RNA", "RNA", 91, 100], ["viruses", "PROBLEM", 7, 14], ["the loss in genome integrity", "PROBLEM", 31, 59], ["viral RNA", "PROBLEM", 91, 100], ["genome integrity", "OBSERVATION", 43, 59], ["viral RNA", "OBSERVATION", 91, 100], ["intact particles", "OBSERVATION_MODIFIER", 104, 120]]], ["As for ascaris eggs, the mechanism of ammonia inactivation remains unclear, but it is widely believed that uncharged free ammonia is able to penetrate through the cell membrane, resulting in higher intracellular pH (Pecson et al., 2007) .VFAs (volatile fatty acids) and pHHigh-concentration volatile fatty acids (VFAs) coupled with acidic pH favors deactivation and elimination of pathogens in sewage sludge.", [["cell membrane", "ANATOMY", 163, 176], ["intracellular", "ANATOMY", 198, 211], ["ammonia", "CHEMICAL", 38, 45], ["ammonia", "CHEMICAL", 122, 129], ["VFAs", "CHEMICAL", 238, 242], ["fatty acids", "CHEMICAL", 253, 264], ["pHHigh", "CHEMICAL", 270, 276], ["fatty acids", "CHEMICAL", 300, 311], ["VFAs", "CHEMICAL", 313, 317], ["ammonia", "CHEMICAL", 38, 45], ["ammonia", "CHEMICAL", 122, 129], ["VFAs", "CHEMICAL", 238, 242], ["fatty acids", "CHEMICAL", 253, 264], ["pHHigh", "CHEMICAL", 270, 276], ["fatty acids", "CHEMICAL", 300, 311], ["VFAs", "CHEMICAL", 313, 317], ["ascaris eggs", "ORGANISM", 7, 19], ["ammonia", "SIMPLE_CHEMICAL", 38, 45], ["ammonia", "SIMPLE_CHEMICAL", 122, 129], ["cell membrane", "CELLULAR_COMPONENT", 163, 176], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 198, 211], ["VFAs", "SIMPLE_CHEMICAL", 238, 242], ["volatile fatty acids", "SIMPLE_CHEMICAL", 244, 264], ["pHHigh", "SIMPLE_CHEMICAL", 270, 276], ["volatile fatty acids", "SIMPLE_CHEMICAL", 291, 311], ["VFAs", "SIMPLE_CHEMICAL", 313, 317], ["ascaris eggs", "PROBLEM", 7, 19], ["ammonia inactivation", "PROBLEM", 38, 58], ["uncharged free ammonia", "PROBLEM", 107, 129], ["higher intracellular pH", "PROBLEM", 191, 214], ["VFAs", "TEST", 238, 242], ["volatile fatty acids", "TEST", 244, 264], ["pHHigh", "TEST", 270, 276], ["concentration volatile fatty acids", "TEST", 277, 311], ["VFAs", "TEST", 313, 317], ["acidic pH", "PROBLEM", 332, 341], ["pathogens", "PROBLEM", 381, 390], ["sewage sludge", "PROBLEM", 394, 407], ["ammonia inactivation", "OBSERVATION", 38, 58], ["cell membrane", "OBSERVATION", 163, 176], ["higher", "OBSERVATION_MODIFIER", 191, 197], ["intracellular pH", "OBSERVATION", 198, 214], ["pathogens", "OBSERVATION_MODIFIER", 381, 390], ["sewage sludge", "OBSERVATION", 394, 407]]], ["For example, VFAs produced at the acedogenic stage of AD could effectively inactivate Escherichia coli, Salmonella typhimurium, or even Clostridium spp.", [["VFAs", "CHEMICAL", 13, 17], ["AD", "DISEASE", 54, 56], ["VFAs", "SIMPLE_CHEMICAL", 13, 17], ["Escherichia coli", "ORGANISM", 86, 102], ["Salmonella typhimurium", "ORGANISM", 104, 126], ["Clostridium spp", "ORGANISM", 136, 151], ["Escherichia coli", "SPECIES", 86, 102], ["Salmonella typhimurium", "SPECIES", 104, 126], ["Escherichia coli", "SPECIES", 86, 102], ["Salmonella typhimurium", "SPECIES", 104, 126], ["Clostridium spp", "SPECIES", 136, 151], ["VFAs", "TEST", 13, 17], ["AD", "PROBLEM", 54, 56], ["Escherichia coli", "PROBLEM", 86, 102], ["Salmonella typhimurium", "PROBLEM", 104, 126], ["Clostridium spp", "PROBLEM", 136, 151], ["Escherichia coli", "OBSERVATION", 86, 102]]], ["In contrast, VFAs were ineffective in deactivating the Ralstonia solanacearum, a soil-born pathogen, while Bacteriophages MS2 was found to be insensitive to pH at 50\u00b0C (Chen et al., 2016) .", [["VFAs", "CHEMICAL", 13, 17], ["VFAs", "CHEMICAL", 13, 17], ["VFAs", "SIMPLE_CHEMICAL", 13, 17], ["Ralstonia solanacearum", "ORGANISM", 55, 77], ["Ralstonia solanacearum", "SPECIES", 55, 77], ["Ralstonia solanacearum", "SPECIES", 55, 77], ["VFAs", "TEST", 13, 17], ["the Ralstonia solanacearum", "PROBLEM", 51, 77], ["a soil-born pathogen", "PROBLEM", 79, 99], ["Bacteriophages MS2", "TEST", 107, 125], ["pH", "TEST", 157, 159], ["Ralstonia solanacearum", "OBSERVATION", 55, 77]]], ["Enterococci and Enterobacteriaceae which are the ubiquitous and potentially opportunistic intestine pathogens could survive and proliferate under stressed conditions due to their high tolerance to solution pH (Fisher and Phillips, 2009 ).", [["intestine", "ANATOMY", 90, 99], ["Enterococci", "ORGANISM_SUBSTANCE", 0, 11], ["intestine", "ORGAN", 90, 99], ["Enterococci", "PROBLEM", 0, 11], ["Enterobacteriaceae", "PROBLEM", 16, 34], ["opportunistic intestine pathogens", "PROBLEM", 76, 109], ["Enterobacteriaceae", "OBSERVATION", 16, 34], ["opportunistic", "OBSERVATION_MODIFIER", 76, 89]]], ["However, it is not practical to adjust or control the level of VFAs or pH in anaerobic digester for deactivation of pathogen because such control would adversely impact on the overall performance of AD, or even caused the operation failure.", [["AD", "DISEASE", 199, 201], ["VFAs", "SIMPLE_CHEMICAL", 63, 67], ["pH in anaerobic digester", "PROBLEM", 71, 95], ["pathogen", "PROBLEM", 116, 124], ["the operation failure", "PROBLEM", 218, 239], ["operation failure", "OBSERVATION", 222, 239]]], ["Currently, significant reduction of fecal coliform, polio virus, ascaris egg and other pathogens had been reported in both twostage and two-phase AD (Leite et al., 2016; Wahidunnabi and Eskicioglu, 2014; Wan et al., 2018) .VFAs (volatile fatty acids) and pHIt should be noted that the underlying mechanism VFAs-promoted deactivation of pathogens had not yet been reported.", [["fecal coliform", "DISEASE", 36, 50], ["AD", "DISEASE", 146, 148], ["VFAs", "CHEMICAL", 223, 227], ["fatty acids", "CHEMICAL", 238, 249], ["VFAs", "CHEMICAL", 306, 310], ["VFAs", "CHEMICAL", 223, 227], ["fatty acids", "CHEMICAL", 238, 249], ["fecal coliform", "PATHOLOGICAL_FORMATION", 36, 50], ["polio virus", "ORGANISM", 52, 63], ["ascaris egg", "ORGANISM", 65, 76], ["VFAs", "SIMPLE_CHEMICAL", 223, 227], ["volatile fatty acids", "SIMPLE_CHEMICAL", 229, 249], ["pHIt", "SIMPLE_CHEMICAL", 255, 259], ["VFAs", "SIMPLE_CHEMICAL", 306, 310], ["polio virus", "SPECIES", 52, 63], ["polio virus", "SPECIES", 52, 63], ["fecal coliform", "PROBLEM", 36, 50], ["polio virus", "PROBLEM", 52, 63], ["ascaris egg", "PROBLEM", 65, 76], ["other pathogens", "PROBLEM", 81, 96], ["VFAs (volatile fatty acids", "TEST", 223, 249], ["the underlying mechanism VFAs", "PROBLEM", 281, 310], ["pathogens", "PROBLEM", 336, 345], ["significant", "OBSERVATION_MODIFIER", 11, 22], ["reduction", "OBSERVATION_MODIFIER", 23, 32], ["fecal coliform", "OBSERVATION", 36, 50], ["polio virus", "OBSERVATION", 52, 63], ["ascaris egg", "OBSERVATION", 65, 76], ["pathogens", "OBSERVATION", 87, 96]]], ["According the findings from research of bacterial pathogens in gastrointestinal tract microbiota, high-concentration short chain VFAs and low pH generated during anaerobic hydrolysis and acidogenesis could likely exert adverse effects on electron transfer and proton translocation, leading to pathogen deactivation.", [["gastrointestinal tract", "ANATOMY", 63, 85], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 63, 85], ["microbiota", "PATHOLOGICAL_FORMATION", 86, 96], ["VFAs", "SIMPLE_CHEMICAL", 129, 133], ["electron", "SIMPLE_CHEMICAL", 238, 246], ["proton", "SIMPLE_CHEMICAL", 260, 266], ["bacterial pathogens in gastrointestinal tract microbiota", "PROBLEM", 40, 96], ["high-concentration short chain VFAs", "PROBLEM", 98, 133], ["low pH", "PROBLEM", 138, 144], ["anaerobic hydrolysis", "TREATMENT", 162, 182], ["acidogenesis", "PROBLEM", 187, 199], ["electron transfer", "TREATMENT", 238, 255], ["proton translocation", "TREATMENT", 260, 280], ["pathogen deactivation", "PROBLEM", 293, 314], ["bacterial", "OBSERVATION_MODIFIER", 40, 49], ["pathogens", "OBSERVATION", 50, 59], ["gastrointestinal tract", "ANATOMY", 63, 85], ["high", "OBSERVATION_MODIFIER", 98, 102], ["low pH", "OBSERVATION_MODIFIER", 138, 144], ["pathogen deactivation", "OBSERVATION", 293, 314]]], ["However, some VFAs at low concentration (e.g. Salmonella Typhimurium, enterohemorrhagic Escherichia coli) were found to stimulate virulence gene expression, leading to systemic infection (Vogt et al., 2015) .Solid retention time (SRT)Prolonged sludge retention time (SRT) in AD offers an alternative for enhancing deactivation of 90% of pathogenic species (e.g. Yersinia enterocolitica) could be deactivated by AD at the SRT of 18.2 d (defined as T90) (Kearney et al., 1993a) , while total coliforms could be reduced to below detection limit at the SRT longer than 15 days in AD (Coelho et al., 2011; Iranpour and Cox, 2007) .", [["VFAs", "CHEMICAL", 14, 18], ["systemic infection", "DISEASE", 168, 186], ["AD", "DISEASE", 275, 277], ["Yersinia enterocolitica", "DISEASE", 362, 385], ["AD", "DISEASE", 411, 413], ["AD", "DISEASE", 576, 578], ["VFAs", "GENE_OR_GENE_PRODUCT", 14, 18], ["Salmonella Typhimurium", "ORGANISM", 46, 68], ["enterohemorrhagic Escherichia coli", "ORGANISM", 70, 104], ["Yersinia enterocolitica", "ORGANISM", 362, 385], ["Salmonella Typhimurium", "SPECIES", 46, 68], ["enterohemorrhagic", "SPECIES", 70, 87], ["Escherichia coli", "SPECIES", 88, 104], ["Yersinia enterocolitica", "SPECIES", 362, 385], ["Salmonella Typhimurium", "SPECIES", 46, 68], ["Escherichia coli", "SPECIES", 88, 104], ["Yersinia enterocolitica", "SPECIES", 362, 385], ["some VFAs at low concentration", "PROBLEM", 9, 39], ["Salmonella Typhimurium", "PROBLEM", 46, 68], ["enterohemorrhagic Escherichia coli", "PROBLEM", 70, 104], ["systemic infection", "PROBLEM", 168, 186], ["Solid retention time", "PROBLEM", 208, 228], ["Prolonged sludge retention", "PROBLEM", 234, 260], ["enhancing deactivation", "PROBLEM", 304, 326], ["pathogenic species", "PROBLEM", 337, 355], ["Yersinia enterocolitica", "PROBLEM", 362, 385], ["the SRT", "TEST", 417, 424], ["total coliforms", "PROBLEM", 484, 499], ["Escherichia coli", "OBSERVATION", 88, 104], ["systemic", "OBSERVATION_MODIFIER", 168, 176], ["infection", "OBSERVATION", 177, 186], ["retention", "OBSERVATION_MODIFIER", 214, 223], ["pathogenic species", "OBSERVATION", 337, 355]]], ["The similar phenomenon was also observed for Escherichia coli and Salmonella spp. which could be removed at a minimum SRT of 15 days (Forster-Carneiro et al., 2010) .", [["Escherichia coli", "ORGANISM", 45, 61], ["Salmonella spp", "ORGANISM", 66, 80], ["Escherichia coli", "SPECIES", 45, 61], ["Escherichia coli", "SPECIES", 45, 61], ["The similar phenomenon", "PROBLEM", 0, 22], ["Escherichia coli", "PROBLEM", 45, 61], ["Salmonella spp", "PROBLEM", 66, 80], ["Salmonella spp", "OBSERVATION", 66, 80]]], ["However, some pathogens could still survive even at a prolonged SRT, e.g. 90% of deactivation of Campylobacter jejuni required an SRT as long as 438.6 day which was far beyond the operational range of SRT for AD (Kearney et al., 1993b) .", [["Campylobacter jejuni", "DISEASE", 97, 117], ["AD", "DISEASE", 209, 211], ["Campylobacter jejuni", "ORGANISM", 97, 117], ["Campylobacter jejuni", "SPECIES", 97, 117], ["Campylobacter jejuni", "SPECIES", 97, 117], ["some pathogens", "PROBLEM", 9, 23], ["a prolonged SRT", "PROBLEM", 52, 67], ["Campylobacter jejuni", "PROBLEM", 97, 117], ["AD", "PROBLEM", 209, 211], ["Campylobacter jejuni", "OBSERVATION", 97, 117]]], ["Table 2 summarizes the effect of temperature, SRT, ammonia, VFAs and pH on the removal efficiency of pathogens in AD.", [["ammonia", "CHEMICAL", 51, 58], ["VFAs", "CHEMICAL", 60, 64], ["AD", "DISEASE", 114, 116], ["ammonia", "CHEMICAL", 51, 58], ["VFAs", "CHEMICAL", 60, 64], ["ammonia", "SIMPLE_CHEMICAL", 51, 58], ["VFAs", "SIMPLE_CHEMICAL", 60, 64], ["temperature", "TEST", 33, 44], ["SRT", "TEST", 46, 49], ["ammonia", "TEST", 51, 58], ["VFAs", "TEST", 60, 64], ["the removal efficiency", "TREATMENT", 75, 97], ["pathogens", "PROBLEM", 101, 110]]], ["It can be concluded that there is no single factor that has broad-spectrum antipathogen effect.", [["single factor", "PROBLEM", 37, 50], ["broad-spectrum antipathogen effect", "PROBLEM", 60, 94], ["no", "UNCERTAINTY", 34, 36]]], ["Thermal condition maintained for the AD could kill more species of pathogens in comparison.", [["AD", "DISEASE", 37, 39], ["Thermal condition", "PROBLEM", 0, 17]]], ["In addition to the factors discussed above, many other factors, such as nutrients availability, embryonated status, operation modes of AD etc., can also affect the growth and accumulation of pathogens.", [["AD", "DISEASE", 135, 137], ["pathogens", "PROBLEM", 191, 200], ["pathogens", "OBSERVATION", 191, 200]]], ["For example, Campylobacter jejuni can use amino acids and vitamins that are not used by other bacteria, hence creating a favorable living environment to counter-count deactivation stress, while Salmonella typhimurium, Listeria monocytogenes and Yersinia enterocolitica need to compete with other bacterial species for carbohydrates.", [["Campylobacter jejuni", "DISEASE", 13, 33], ["amino acids", "CHEMICAL", 42, 53], ["Yersinia enterocolitica", "DISEASE", 245, 268], ["amino acids", "CHEMICAL", 42, 53], ["vitamins", "CHEMICAL", 58, 66], ["carbohydrates", "CHEMICAL", 318, 331], ["Campylobacter jejuni", "ORGANISM", 13, 33], ["amino acids", "AMINO_ACID", 42, 53], ["vitamins", "SIMPLE_CHEMICAL", 58, 66], ["Salmonella typhimurium", "ORGANISM", 194, 216], ["Listeria monocytogenes", "ORGANISM", 218, 240], ["Yersinia enterocolitica", "ORGANISM", 245, 268], ["carbohydrates", "SIMPLE_CHEMICAL", 318, 331], ["Campylobacter jejuni", "SPECIES", 13, 33], ["Salmonella typhimurium", "SPECIES", 194, 216], ["Listeria monocytogenes", "SPECIES", 218, 240], ["Yersinia enterocolitica", "SPECIES", 245, 268], ["Campylobacter jejuni", "SPECIES", 13, 33], ["Salmonella typhimurium", "SPECIES", 194, 216], ["Listeria monocytogenes", "SPECIES", 218, 240], ["Yersinia enterocolitica", "SPECIES", 245, 268], ["Campylobacter jejuni", "PROBLEM", 13, 33], ["amino acids", "TREATMENT", 42, 53], ["vitamins", "TREATMENT", 58, 66], ["other bacteria", "PROBLEM", 88, 102], ["count deactivation stress", "PROBLEM", 161, 186], ["Salmonella typhimurium", "PROBLEM", 194, 216], ["Listeria monocytogenes", "PROBLEM", 218, 240], ["Yersinia enterocolitica", "PROBLEM", 245, 268], ["other bacterial species", "PROBLEM", 290, 313], ["Campylobacter jejuni", "OBSERVATION", 13, 33]]], ["In addition, embryonated or dominant ova showed different viabilities when exposed to AD, e.g. about 35% of fully developed Ascaris suum ova still remained viable after 16-day AD against 65% for unembryonated ova (Manser et al., 2015) .", [["ova", "ANATOMY", 37, 40], ["ova", "ANATOMY", 209, 212], ["AD", "DISEASE", 86, 88], ["AD", "DISEASE", 176, 178], ["Ascaris suum", "ORGANISM", 124, 136], ["ova", "ORGANISM", 137, 140], ["Ascaris suum", "SPECIES", 124, 136], ["Ascaris suum", "SPECIES", 124, 136], ["embryonated or dominant ova", "PROBLEM", 13, 40], ["different viabilities", "PROBLEM", 48, 69], ["Ascaris suum ova", "PROBLEM", 124, 140]]], ["Batch or continuous operation modes of AD may also influence pathogenic profile in sewage sludge (Narula et al., 2011) .", [["AD", "DISEASE", 39, 41], ["Batch", "TREATMENT", 0, 5], ["continuous operation modes", "TREATMENT", 9, 35], ["sewage sludge", "PROBLEM", 83, 96], ["sewage sludge", "OBSERVATION", 83, 96]]], ["Enteropathogenic Escherichia coli and Salmonella Typhimurium were reported to have the lower T90 values in batch anaerobic digestion than those in semi-continuous or fullcontinuous operations (Kearney et al., 1993a) .", [["Escherichia coli", "ORGANISM", 17, 33], ["Salmonella Typhimurium", "ORGANISM", 38, 60], ["Escherichia coli", "SPECIES", 17, 33], ["Salmonella Typhimurium", "SPECIES", 38, 60], ["Escherichia coli", "SPECIES", 17, 33], ["Salmonella Typhimurium", "SPECIES", 38, 60], ["Enteropathogenic Escherichia coli", "PROBLEM", 0, 33], ["Salmonella Typhimurium", "PROBLEM", 38, 60], ["the lower T90 values", "PROBLEM", 83, 103], ["batch anaerobic digestion", "PROBLEM", 107, 132], ["fullcontinuous operations", "TREATMENT", 166, 191], ["Escherichia coli", "OBSERVATION", 17, 33], ["Salmonella Typhimurium", "OBSERVATION", 38, 60], ["lower T90", "OBSERVATION_MODIFIER", 87, 96], ["anaerobic digestion", "OBSERVATION", 113, 132]]], ["To survive or infect host, pathogens have to compete each other or with anaerobic bacteria for nutrients and microsites (Vogt et al., 2015) , whereas some compounds in AD had been known to protect pathogens from deactivation (Pandey and Soupir, 2011) .Other factorsCorrelation between bacterial community succession and pathogenic population in AD had been established (Luo et al., 2017) .", [["community", "ANATOMY", 295, 304], ["AD", "DISEASE", 168, 170], ["AD", "DISEASE", 345, 347], ["pathogens", "PROBLEM", 27, 36], ["anaerobic bacteria", "PROBLEM", 72, 90], ["Other factors", "PROBLEM", 252, 265], ["bacterial community succession", "TREATMENT", 285, 315], ["pathogenic population", "PROBLEM", 320, 341]]], ["As both total organics and nitrogen in sewage sludge were reduced substantially during AD, this in turn led to the shift in the archaea and bacteria communities, including pathogens.", [["communities", "ANATOMY", 149, 160], ["nitrogen", "CHEMICAL", 27, 35], ["AD", "DISEASE", 87, 89], ["nitrogen", "CHEMICAL", 27, 35], ["organics", "SIMPLE_CHEMICAL", 14, 22], ["nitrogen", "SIMPLE_CHEMICAL", 27, 35], ["both total organics", "TREATMENT", 3, 22], ["nitrogen in sewage sludge", "TREATMENT", 27, 52], ["the archaea and bacteria communities", "PROBLEM", 124, 160], ["pathogens", "PROBLEM", 172, 181], ["sewage sludge", "OBSERVATION", 39, 52], ["archaea", "OBSERVATION", 128, 135], ["bacteria", "OBSERVATION_MODIFIER", 140, 148]]], ["In general, less diversified microbial community was observed after AD of sewage sludge (Ennouri et al., 2016) .", [["community", "ANATOMY", 39, 48], ["less", "OBSERVATION_MODIFIER", 12, 16], ["diversified", "OBSERVATION_MODIFIER", 17, 28], ["microbial", "OBSERVATION_MODIFIER", 29, 38]]], ["For example, Firmicutes (e.g. Bacilli and Clostridia as representative order) and Actinobacteria (e.g. Actinomycetales as typical member) were found to be the dominant phyla in raw sludge, while their abundances declined during the digestion, along with the enrichment of Bacteroidetes.", [["Firmicutes (e.g. Bacilli and Clostridia", "PROBLEM", 13, 52], ["Actinobacteria", "PROBLEM", 82, 96], ["the dominant phyla in raw sludge", "PROBLEM", 155, 187], ["the digestion", "PROBLEM", 228, 241], ["Bacteroidetes", "PROBLEM", 272, 285], ["Firmicutes", "OBSERVATION", 13, 23], ["dominant", "OBSERVATION_MODIFIER", 159, 167], ["phyla", "OBSERVATION", 168, 173], ["raw sludge", "OBSERVATION", 177, 187], ["Bacteroidetes", "OBSERVATION", 272, 285]]], ["It was also found that the microbial diversity was further lowered when AD was turned from mesophilic to thermophilic operation with notable shifts towards the higher number of thermotolerant taxa and lower abundances of Bacteroidetes and Proteobacteria (Sun et al., 2016; Stiborova et al., 2015) .", [["AD", "DISEASE", 72, 74], ["the microbial diversity", "PROBLEM", 23, 46], ["thermophilic operation", "TREATMENT", 105, 127], ["notable shifts", "PROBLEM", 133, 147], ["Bacteroidetes", "PROBLEM", 221, 234], ["Proteobacteria", "PROBLEM", 239, 253], ["microbial", "OBSERVATION_MODIFIER", 27, 36], ["diversity", "OBSERVATION", 37, 46]]], ["It is worth to note that Bacteroidetes and Proteobacteria had been considered as potential pathogens that harbored ARGs, while Actinomycetales, Bacilli Corynebacterium were known as sul and integron carrier (Sun et al., 2017) .", [["ARGs", "GENE_OR_GENE_PRODUCT", 115, 119], ["Bacteroidetes", "PROBLEM", 25, 38], ["Proteobacteria", "PROBLEM", 43, 57], ["potential pathogens", "PROBLEM", 81, 100], ["harbored ARGs", "PROBLEM", 106, 119], ["Actinomycetales", "PROBLEM", 127, 142], ["Bacilli Corynebacterium", "PROBLEM", 144, 167]]], ["Other operating conditions, such as SRT, VFA, ammonia as discussed above can also influence the community structure.", [["VFA", "CHEMICAL", 41, 44], ["ammonia", "CHEMICAL", 46, 53], ["VFA", "CHEMICAL", 41, 44], ["ammonia", "CHEMICAL", 46, 53], ["VFA", "SIMPLE_CHEMICAL", 41, 44], ["ammonia", "SIMPLE_CHEMICAL", 46, 53], ["Other operating conditions", "PROBLEM", 0, 26], ["VFA", "TEST", 41, 44]]], ["After shifting of operation conditions of AD, positive or negative correlations were observed between bacterial pathogens or between pathogens and integrase genes or ARGs, indicating that the bacterial community shift was one of the key drivers of variation in survival or death of antidrug-resistant pathogens during AD (Sun et al., 2016; Jang et al., 2019) .Other factorsFor a practical AD system, environmental factors are often correlated and have intertwined effect on the outcome (Decrey and Kohn, 2017; Kumar et al., 1999) .", [["community", "ANATOMY", 202, 211], ["AD", "DISEASE", 42, 44], ["death", "DISEASE", 273, 278], ["antidrug", "CHEMICAL", 282, 290], ["AD", "DISEASE", 318, 320], ["AD", "DISEASE", 389, 391], ["ARGs", "GENE_OR_GENE_PRODUCT", 166, 170], ["integrase genes", "DNA", 147, 162], ["AD", "PROBLEM", 42, 44], ["bacterial pathogens", "PROBLEM", 102, 121], ["pathogens", "PROBLEM", 133, 142], ["ARGs", "PROBLEM", 166, 170], ["the bacterial community shift", "PROBLEM", 188, 217], ["antidrug-resistant pathogens", "PROBLEM", 282, 310], ["Other factors", "PROBLEM", 360, 373]]], ["For example, temperature can act directly or indirectly on pathogens by enhancing the toxicity of ammonia and VFAs.", [["toxicity", "DISEASE", 86, 94], ["ammonia", "CHEMICAL", 98, 105], ["ammonia", "CHEMICAL", 98, 105], ["VFAs", "CHEMICAL", 110, 114], ["ammonia", "SIMPLE_CHEMICAL", 98, 105], ["VFAs", "SIMPLE_CHEMICAL", 110, 114], ["VFAs", "TEST", 110, 114]]], ["And pH effects are not significant itself but cannot be separated from both temperature and ammonia concentration (Pecson et al., 2007) .", [["ammonia", "CHEMICAL", 92, 99], ["ammonia", "CHEMICAL", 92, 99], ["ammonia", "SIMPLE_CHEMICAL", 92, 99], ["pH effects", "PROBLEM", 4, 14], ["pH effects", "OBSERVATION", 4, 14]]], ["Slight change in temperature, ammonia, VFA and SRT would shape distinct bacterial community succession.", [["community", "ANATOMY", 82, 91], ["ammonia", "CHEMICAL", 30, 37], ["VFA", "CHEMICAL", 39, 42], ["ammonia", "CHEMICAL", 30, 37], ["VFA", "CHEMICAL", 39, 42], ["ammonia", "SIMPLE_CHEMICAL", 30, 37], ["VFA", "SIMPLE_CHEMICAL", 39, 42], ["Slight change in temperature", "PROBLEM", 0, 28], ["ammonia", "TEST", 30, 37], ["VFA", "TEST", 39, 42], ["SRT", "TREATMENT", 47, 50], ["change", "OBSERVATION_MODIFIER", 7, 13], ["temperature", "OBSERVATION_MODIFIER", 17, 28], ["distinct", "OBSERVATION_MODIFIER", 63, 71], ["bacterial community succession", "OBSERVATION", 72, 102]]], ["Thus, the overall hygienic performance of AD should be assessed and optimized based on these parameters on the integrity.Models, engineering designs and technological aspectsMathematical modeling of anaerobic digestion is useful for improving digester performance.", [["AD", "DISEASE", 42, 44], ["anaerobic digestion", "PROBLEM", 199, 218], ["anaerobic digestion", "OBSERVATION", 199, 218]]], ["The IWA Anaerobic Digestion Model No. 1 has widely used for describing and predicting AD performance under various scenarios.", [["AD", "DISEASE", 86, 88], ["IWA", "PROTEIN", 4, 7]]], ["In this model, the degradation process is described by Monod kinetics, while the disintegration and hydrolysis of sludge is supposed to follow first order kinetics.", [["the degradation process", "PROBLEM", 15, 38], ["hydrolysis of sludge", "TREATMENT", 100, 120], ["sludge", "OBSERVATION", 114, 120]]], ["As such, it has been debated the rational of using simple first order kinetic for highly complicated sophisticated AD.", [["AD", "DISEASE", 115, 117]]], ["In addition, the model takes into account seven bacterial groups, but does not distinguish among them, therefore undermining the predictive power of the models.", [["bacterial groups", "OBSERVATION", 48, 64]]], ["So far, pathogens or ARGs removal has not yet considered in the models for AD.", [["AD", "DISEASE", 75, 77], ["ARGs", "SIMPLE_CHEMICAL", 21, 25], ["pathogens", "PROBLEM", 8, 17], ["ARGs removal", "TREATMENT", 21, 33], ["AD", "PROBLEM", 75, 77]]], ["As a step forward, pathogenic variables should be included in AD optimization and automation (Appels et al., 2011) .Models, engineering designs and technological aspectsIn fact, AD as mature technology has been extensively applied for treating sewage sludge with the aims for volume reduction and biogas generation.", [["AD", "DISEASE", 62, 64], ["AD", "DISEASE", 178, 180], ["pathogenic variables", "PROBLEM", 19, 39], ["sewage sludge", "PROBLEM", 244, 257], ["volume reduction", "TREATMENT", 276, 292], ["biogas generation", "TREATMENT", 297, 314], ["sludge", "OBSERVATION", 251, 257], ["biogas generation", "OBSERVATION", 297, 314]]], ["However, as elucidated above, the issues associated with pathogens, to some extent, might be overlooked.", [["pathogens", "PROBLEM", 57, 66]]], ["The current design and operation are primarily driven by maximizing biogas production, while going forward, the engineering trade-off should be considered by including pathogen-associated environmental risks.", [["operation", "TREATMENT", 23, 32]]], ["So far, various engineering designs, such as two-stage AD, two-phase AD, codigestion, membraned enhanced AD with different configurations etc. have been explored.", [["AD", "DISEASE", 55, 57], ["AD", "DISEASE", 69, 71], ["AD", "DISEASE", 105, 107], ["codigestion", "TREATMENT", 73, 84]]], ["In sanitary engineering practice, a robust AD project for biosludge treatment that not only fulfills the bio-energy generating functions but also produce clean biosolids requires comprehensive technological measures, including: (a) Reception and inspection area; (b) Mixer equipment; (c) Comminuting drums that screen the raw sludge; (d) Separation of liquid from the digestate and the pumps. (e) Heating equipment; (f) Sufficient volume and long retention time; (g) Biogas combustion or utilization device (for heat, power, or fuel) and the necessary safety precautions.", [["AD", "DISEASE", 43, 45], ["biosludge treatment", "TREATMENT", 58, 77], ["Comminuting drums", "PROBLEM", 288, 305], ["the raw sludge", "PROBLEM", 318, 332], ["the pumps", "TREATMENT", 382, 391], ["Sufficient volume and long retention time", "TREATMENT", 420, 461], ["Biogas combustion", "TREATMENT", 467, 484], ["utilization device", "TREATMENT", 488, 506], ["sludge", "OBSERVATION", 326, 332]]], ["With the development of novel pretreatment or post-treatment to enhance pathogens removal, more work needs to been done to identify optimized Table 2 Influence of main factors on the removal efficiency of some typical pathogens.Genus/speciesTemperature NH 3 VFA SRT Unrestricted parametersMesophilic ThermophilicClostridium perfringens \u00d7 \u4e44 \u4e44 Kearney et al., 1993a; Lloret et al., 2013; Orzi et al., 2015; Sahlstr\u00f6m, 2003 ) Clostridium difficile \u4e44 Bacillus cereus \u4e44 \u4e44 (Govasmark et al., 2011; Kearney et al., 1993a ) Campylobacter jejuni 438.6d \u221a/\u00d7 (Kearney et al., 1993a; Wagner et al., 2008) Forster-Carneiro et al., 2010; Lloret et al., 2013; Orzi et al., 2015; Sahlstr\u00f6m, 2003 Forster-Carneiro et al., 2010; Lloret et al., 2013; Orzi et al., 2015; Sahlstr\u00f6m, 2003 5.", [["VFA", "CHEMICAL", 258, 261], ["Clostridium difficile", "DISEASE", 423, 444], ["NH 3 VFA", "CHEMICAL", 253, 261], ["Clostridium difficile", "ORGANISM", 423, 444], ["Bacillus cereus", "ORGANISM", 447, 462], ["Campylobacter jejuni", "ORGANISM", 516, 536], ["ThermophilicClostridium perfringens", "SPECIES", 300, 335], ["Clostridium difficile", "SPECIES", 423, 444], ["Bacillus cereus", "SPECIES", 447, 462], ["Campylobacter jejuni", "SPECIES", 516, 536], ["Clostridium difficile", "SPECIES", 423, 444], ["Bacillus cereus \u4e44 \u4e44 (Govasmark et al., 2011; Kearney et al., 1993a", "SPECIES", 447, 513], ["Campylobacter jejuni", "SPECIES", 516, 536], ["novel pretreatment", "TREATMENT", 24, 42], ["treatment", "TREATMENT", 51, 60], ["pathogens removal", "TREATMENT", 72, 89], ["the removal efficiency", "TREATMENT", 179, 201], ["some typical pathogens", "PROBLEM", 205, 227], ["Sahlstr\u00f6m", "TEST", 405, 414], ["Clostridium difficile", "TEST", 423, 444], ["Bacillus cereus", "TEST", 447, 462], ["Campylobacter jejuni", "TEST", 516, 536], ["some typical", "OBSERVATION_MODIFIER", 205, 217], ["pathogens", "OBSERVATION", 218, 227]]], ["Is AD reliable for sludge pathogens control: challenges for the potential use of digested sludge?Mesophilic ThermophilicUp to now, many large municipalities worldwide have been or are considering options for optimizing and upgrading AD in WWTPs to make biosolids more \"RELIABE\" for land application.", [["AD", "DISEASE", 3, 5], ["AD", "DISEASE", 233, 235], ["sludge pathogens control", "TREATMENT", 19, 43], ["digested sludge", "PROBLEM", 81, 96], ["Mesophilic ThermophilicUp", "TREATMENT", 97, 122], ["sludge", "OBSERVATION", 90, 96], ["large", "OBSERVATION_MODIFIER", 136, 141], ["municipalities", "OBSERVATION", 142, 156]]], ["Improved techniques have been developed for AD to enhance the removal efficiency of pathogens by employing pretreatment and post-treatment.", [["AD", "DISEASE", 44, 46], ["AD", "PROBLEM", 44, 46], ["the removal efficiency", "TREATMENT", 58, 80], ["pathogens", "PROBLEM", 84, 93]]], ["Thermal or electrical-thermal pre-treatment is believed to induce hydrolysis of sludge by breaking the gel structure and cell lysis, which involved pathogens destruction as well (Ennouri et al., 2016; Daneshmand et al., 2012) .", [["cell", "ANATOMY", 121, 125], ["cell", "CELL", 121, 125], ["electrical-thermal pre-treatment", "TREATMENT", 11, 43], ["hydrolysis of sludge", "PROBLEM", 66, 86], ["breaking the gel structure", "PROBLEM", 90, 116], ["cell lysis", "TREATMENT", 121, 131], ["pathogens destruction", "PROBLEM", 148, 169], ["sludge", "OBSERVATION", 80, 86], ["cell lysis", "OBSERVATION", 121, 131], ["pathogens", "OBSERVATION_MODIFIER", 148, 157], ["destruction", "OBSERVATION", 158, 169]]], ["Low frequency pretreatment of ultrasound prior to thermophilic AD was also found to achieve significant logarithmic removal of fecal coliforms, somatic coliphages and other pathogens in sludge.", [["fecal coliforms", "ANATOMY", 127, 142], ["somatic coliphages", "ANATOMY", 144, 162], ["AD", "DISEASE", 63, 65], ["somatic coliphages", "DISEASE", 144, 162], ["ultrasound", "TEST", 30, 40], ["thermophilic AD", "PROBLEM", 50, 65], ["significant logarithmic removal", "TREATMENT", 92, 123], ["fecal coliforms", "PROBLEM", 127, 142], ["somatic coliphages", "PROBLEM", 144, 162], ["other pathogens in sludge", "PROBLEM", 167, 192], ["significant", "OBSERVATION_MODIFIER", 92, 103], ["logarithmic removal", "OBSERVATION", 104, 123], ["fecal coliforms", "OBSERVATION", 127, 142], ["somatic coliphages", "OBSERVATION", 144, 162], ["pathogens", "OBSERVATION_MODIFIER", 173, 182], ["sludge", "OBSERVATION", 186, 192]]], ["Ultrasound generated the shear stress induced by cavitation while high temperature led to denaturation and loss of function of enzymes, nucleic acids, organelles and other cellular structures (Neumann et al., 2018) .", [["organelles", "ANATOMY", 151, 161], ["cellular structures", "ANATOMY", 172, 191], ["nucleic acids", "CHEMICAL", 136, 149], ["nucleic acids", "SIMPLE_CHEMICAL", 136, 149], ["organelles", "CELLULAR_COMPONENT", 151, 161], ["cellular structures", "CELLULAR_COMPONENT", 172, 191], ["enzymes", "PROTEIN", 127, 134], ["Ultrasound", "TEST", 0, 10], ["the shear stress", "TEST", 21, 37], ["cavitation", "PROBLEM", 49, 59], ["high temperature", "PROBLEM", 66, 82], ["denaturation", "PROBLEM", 90, 102], ["loss of function of enzymes", "PROBLEM", 107, 134], ["nucleic acids", "TEST", 136, 149], ["cavitation", "OBSERVATION", 49, 59]]], ["Microwave irradiation, UV, or nanoparticle were also reported to successfully improve the AD performance, achieving higher inactivation rate of fecal coliforms than single AD (Hong et al., 2006; Neto et al., 2006; Miller et al., 2013) .", [["fecal coliforms", "ANATOMY", 144, 159], ["UV", "CHEMICAL", 23, 25], ["AD", "DISEASE", 90, 92], ["fecal coliforms", "DISEASE", 144, 159], ["AD", "DISEASE", 172, 174], ["Microwave irradiation", "TREATMENT", 0, 21], ["UV", "TREATMENT", 23, 25], ["fecal coliforms", "PROBLEM", 144, 159], ["fecal coliforms", "OBSERVATION", 144, 159]]], ["The biotechnological development was less reported to integrate with AD compared to physiochemical technologies.", [["AD", "DISEASE", 69, 71]]], ["One notable example is anaerobic digestion pasteurization latrine system developed by researchers in North Carolina of the Statesa self-contained and energy neutral on-site sanitation systemusing the biogas generated from the sludge to pasteurize the digestate at 65-75\u00b0C to produce a safe fertilizer (Forbis-Stokes et al., 2016) .", [["digestate", "SIMPLE_CHEMICAL", 251, 260], ["anaerobic digestion pasteurization latrine system", "PROBLEM", 23, 72], ["the biogas", "TREATMENT", 196, 206], ["the sludge", "PROBLEM", 222, 232], ["a safe fertilizer", "TREATMENT", 283, 300], ["anaerobic digestion", "OBSERVATION", 23, 42], ["sludge", "OBSERVATION", 226, 232]]], ["It was essentially the integrated AD with thermal treatment via technical modifications.", [["AD", "DISEASE", 34, 36], ["thermal treatment", "TREATMENT", 42, 59], ["technical modifications", "TREATMENT", 64, 87]]], ["From my standpoint, modern biosystem developed with AD as a solution to the problem should be built based on the psychological differences between the pathogens and normal anaerobes or predation by higher trophic level in the food chain.", [["AD", "DISEASE", 52, 54], ["a solution", "TREATMENT", 58, 68], ["the pathogens", "PROBLEM", 147, 160], ["anaerobes", "OBSERVATION", 172, 181]]], ["But the mild conditions maintained for anaerobes in pure-biosystem might not thoroughly eradicate the pathogens to the required level.", [["the mild conditions", "PROBLEM", 4, 23], ["anaerobes", "PROBLEM", 39, 48], ["mild", "OBSERVATION_MODIFIER", 8, 12]]], ["Therefore, physiochemical methods were preferred to integrate with AD.", [["AD", "DISEASE", 67, 69], ["physiochemical methods", "TREATMENT", 11, 33]]], ["And the biological-based digestion and physiochemical-based sanitation were generally separated in two compartments/steps so that the harsh conditions in sanitation stage would not have fatal or harmful effect on the anaerobes and other functional organisms in AD.Mesophilic ThermophilicAD with assisted techniques has been tested to achieve good performance.", [["AD", "DISEASE", 261, 263], ["ThermophilicAD", "CHEMICAL", 275, 289], ["physiochemical-based sanitation", "TREATMENT", 39, 70], ["the harsh conditions", "PROBLEM", 130, 150], ["the anaerobes", "PROBLEM", 213, 226], ["Mesophilic ThermophilicAD", "TREATMENT", 264, 289], ["assisted techniques", "TREATMENT", 295, 314]]], ["However, is it really reasonable to declare that AD is \"RELIABE\" or NOT after narrowly focusing on the research of pathogen deactivation within a digester or a reactor?", [["AD", "DISEASE", 49, 51], ["pathogen deactivation", "PROBLEM", 115, 136], ["a reactor", "PROBLEM", 158, 167]]], ["In fact, the outbreak of infectious diseases caused by digestate residue is an extremely complicated event since the disseminating procedures involved a complex matrix of sub-procedures and factors, e.g. levels of pathogens in the sludges, particular combination of chemicals, usage rate at farmland, sun exposure, climate, infection routes and host susceptibility etc. Some pathogenic microbes are easily deactivated via AD, but may be regenerated during the subsequent transmission.", [["infectious diseases", "DISEASE", 25, 44], ["digestate", "CHEMICAL", 55, 64], ["infection", "DISEASE", 324, 333], ["AD", "DISEASE", 422, 424], ["matrix", "CELLULAR_COMPONENT", 161, 167], ["infectious diseases", "PROBLEM", 25, 44], ["digestate residue", "PROBLEM", 55, 72], ["the disseminating procedures", "TREATMENT", 113, 141], ["sub-procedures", "TREATMENT", 171, 185], ["pathogens", "PROBLEM", 214, 223], ["the sludges", "PROBLEM", 227, 238], ["infection", "PROBLEM", 324, 333], ["Some pathogenic microbes", "PROBLEM", 370, 394], ["infectious", "OBSERVATION", 25, 35], ["digestate residue", "OBSERVATION", 55, 72], ["sludges", "OBSERVATION", 231, 238], ["infection", "OBSERVATION", 324, 333], ["pathogenic", "OBSERVATION_MODIFIER", 375, 385], ["microbes", "OBSERVATION", 386, 394]]], ["On the other hand, some pathogenic microbes, though existed in digestate, could not be removed after exposed to sunlight or plants during fertilization.", [["some pathogenic microbes", "PROBLEM", 19, 43], ["pathogenic", "OBSERVATION_MODIFIER", 24, 34], ["microbes", "OBSERVATION", 35, 43]]], ["Meanwhile, antagonistic microbes and antimicrobial substances also need to be taken into account (Cao et al., 2013) .", [["antagonistic microbes", "TREATMENT", 11, 32], ["antimicrobial substances", "TREATMENT", 37, 61]]], ["As shown in Fig. 2 , even though AD may deactivate a wide range of pathogens, while meeting both EU legislated requirement and U.S. Class A standard for solid residue, pathogens still could be detected in surface water after use of digestates on land (REF).", [["AD", "DISEASE", 33, 35], ["pathogens", "PROBLEM", 67, 76], ["solid residue", "PROBLEM", 153, 166], ["pathogens", "PROBLEM", 168, 177], ["Fig", "OBSERVATION", 12, 15], ["pathogens", "OBSERVATION", 67, 76]]], ["Therefore, there is a concern associated with the use of digestates for agricultural purpose.Mesophilic ThermophilicAD can be considered as hygienically reliable only if the subsequent pathogenic migration process is also tracked.", [["ThermophilicAD", "CHEMICAL", 104, 118], ["digestates", "TREATMENT", 57, 67], ["Mesophilic ThermophilicAD", "PROBLEM", 93, 118], ["the subsequent pathogenic migration process", "PROBLEM", 170, 213], ["pathogenic", "OBSERVATION_MODIFIER", 185, 195], ["migration", "OBSERVATION", 196, 205]]], ["Quantitative microbial risk assessment (QMRA) combined with AD is an advisable solution.", [["AD", "DISEASE", 60, 62], ["Quantitative microbial risk assessment", "TEST", 0, 38], ["an advisable solution", "TREATMENT", 66, 87]]], ["The QMRA approach is recommended for AD under different sensitive conditions, including temperature, SRT, concentration of free ammonia, pH, VFA, etc. Pathogens species discharged determine whether it is necessary to undertake risk assessment and the extent of mitigation.", [["AD", "DISEASE", 37, 39], ["ammonia", "CHEMICAL", 128, 135], ["VFA", "CHEMICAL", 141, 144], ["ammonia", "CHEMICAL", 128, 135], ["VFA", "CHEMICAL", 141, 144], ["ammonia", "SIMPLE_CHEMICAL", 128, 135], ["VFA", "SIMPLE_CHEMICAL", 141, 144], ["The QMRA approach", "TREATMENT", 0, 17], ["temperature", "TEST", 88, 99], ["free ammonia", "TEST", 123, 135], ["pH", "TEST", 137, 139], ["VFA", "TEST", 141, 144], ["Pathogens species", "PROBLEM", 151, 168], ["risk assessment", "TEST", 227, 242]]], ["After exposure assessment, the risk can be characterized based on quantitative dose response models, which have been or will be developed for the species/subspecies of the pathogens identified.", [["exposure assessment", "TEST", 6, 25], ["quantitative dose response models", "TEST", 66, 99], ["the species", "PROBLEM", 142, 153], ["the pathogens", "PROBLEM", 168, 181]]], ["Finally, the infection risk associated with AD digestate can be assessed more precisely by expressing in annual probability of infection and disability-adjusted life years.", [["infection", "DISEASE", 13, 22], ["AD", "DISEASE", 44, 46], ["infection", "DISEASE", 127, 136], ["disability", "DISEASE", 141, 151], ["the infection risk", "PROBLEM", 9, 27], ["AD digestate", "PROBLEM", 44, 56], ["infection", "PROBLEM", 127, 136], ["infection", "OBSERVATION", 13, 22], ["infection", "OBSERVATION", 127, 136]]], ["Now it seems that enrichment of dose response models is top priority for the digestate-relevant pathogens, since the value of parameters in dose response models are varied with different pathogenic microorganisms (Xiao et al., 2018) .", [["dose response models", "TREATMENT", 32, 52], ["the digestate", "PROBLEM", 73, 86], ["relevant pathogens", "PROBLEM", 87, 105], ["dose response models", "TEST", 140, 160], ["different pathogenic microorganisms", "PROBLEM", 177, 212], ["pathogens", "OBSERVATION", 96, 105]]], ["Sometimes, aerosol transport models for pathogen doses are needed for the receptors downwind of land application sites.", [["aerosol transport models", "TREATMENT", 11, 35], ["pathogen doses", "TREATMENT", 40, 54], ["land application sites", "TREATMENT", 96, 118]]], ["Studies of relevant infection outbreaks and epidemiological investigations for digestaterelevant are also highly required.", [["infection", "DISEASE", 20, 29], ["relevant infection outbreaks", "PROBLEM", 11, 39], ["epidemiological investigations", "TEST", 44, 74], ["digestaterelevant", "PROBLEM", 79, 96], ["relevant", "OBSERVATION_MODIFIER", 11, 19], ["infection", "OBSERVATION", 20, 29]]], ["With more complete and accurate models, QMRA is helpful to develop more appropriate AD management strategies, on a physiological hygienical level to evaluate whether an AD of certain SRT, temperature etc. is reasonable and reliable.", [["AD", "DISEASE", 84, 86], ["AD", "DISEASE", 169, 171], ["appropriate AD management strategies", "TREATMENT", 72, 108], ["a physiological hygienical level", "TEST", 113, 145]]], ["This is also helpful for risk assessors and environmental regulators to make policy and engineering decisions (Fig. 3) .Concluding remarksThis review sheds light into the role of AD in deactivating sludgeassociated pathogens.", [["AD", "DISEASE", 179, 181], ["AD", "GENE_OR_GENE_PRODUCT", 179, 181], ["deactivating sludgeassociated pathogens", "PROBLEM", 185, 224], ["pathogens", "OBSERVATION", 215, 224]]], ["Variety of pathogens, including bacterium, parasites, virus and pathogenic host of ARGs has been successfully deactivated by AD.", [["AD", "DISEASE", 125, 127], ["ARGs", "GENE_OR_GENE_PRODUCT", 83, 87], ["pathogens", "PROBLEM", 11, 20], ["bacterium", "PROBLEM", 32, 41], ["parasites", "PROBLEM", 43, 52], ["virus", "PROBLEM", 54, 59], ["pathogenic host of ARGs", "PROBLEM", 64, 87], ["pathogens", "OBSERVATION", 11, 20]]], ["The inactivation mechanism could be attributed to many forms of cytopathy, such as enzyme denaturation, intracellular/ extracellular ion content alteration, viral RNA cleavage, bacterial community succession, etc., at given temperature, ammonia concentration, VFAs content, pH value, SRT, etc. And AD hygienic performance can be optimized by setting these parameters at reasonable range.", [["intracellular", "ANATOMY", 104, 117], ["extracellular", "ANATOMY", 119, 132], ["community", "ANATOMY", 187, 196], ["cytopathy", "DISEASE", 64, 73], ["ammonia", "CHEMICAL", 237, 244], ["ammonia", "CHEMICAL", 237, 244], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 104, 117], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 119, 132], ["ammonia", "SIMPLE_CHEMICAL", 237, 244], ["VFAs", "SIMPLE_CHEMICAL", 260, 264], ["The inactivation mechanism", "PROBLEM", 0, 26], ["cytopathy", "PROBLEM", 64, 73], ["enzyme denaturation", "PROBLEM", 83, 102], ["intracellular/ extracellular ion content alteration", "PROBLEM", 104, 155], ["viral RNA cleavage", "PROBLEM", 157, 175], ["ammonia concentration", "TEST", 237, 258], ["VFAs content", "TEST", 260, 272], ["pH value", "TEST", 274, 282], ["SRT", "PROBLEM", 284, 287], ["cytopathy", "OBSERVATION", 64, 73], ["ion content", "OBSERVATION", 133, 144], ["viral RNA cleavage", "OBSERVATION", 157, 175]]], ["Moving forward, in order to be available for agricultural purposes, the digestate residue discharged from AD should inevitably be evaluated and assessed by looking into the integrated ecological and epidemiology system.", [["AD", "DISEASE", 106, 108], ["agricultural purposes", "TREATMENT", 45, 66], ["the digestate residue", "PROBLEM", 68, 89]]], ["It appears that future study should look into: 1) There is a need to reveal the diversity and property of more pathogens within digestate, since whole genome sequences of many species have not been obtained and relevant primer have not been designed.Concluding remarks2) Scientific credibility for the restrictions on crop and access to application sites even for Class A biosolids should be reviewed since regrowth of pathogens occur or host of ARGs proliferate; 3) Virus and the ones harboring ARGs should be tracked and more fully described.", [["ARGs", "GENE_OR_GENE_PRODUCT", 446, 450], ["Virus", "ORGANISM", 467, 472], ["ARGs", "GENE_OR_GENE_PRODUCT", 496, 500], ["future study", "TEST", 16, 28], ["the diversity", "PROBLEM", 76, 89], ["more pathogens within digestate", "PROBLEM", 106, 137], ["whole genome sequences", "TEST", 145, 167], ["many species", "PROBLEM", 171, 183], ["crop and access to application sites", "TREATMENT", 318, 354], ["Class A biosolids", "TREATMENT", 364, 381], ["pathogens", "PROBLEM", 419, 428], ["ARGs proliferate", "PROBLEM", 446, 462], ["Virus", "PROBLEM", 467, 472], ["the ones harboring ARGs", "PROBLEM", 477, 500]]], ["Relationships between resistant-pathogen concentrations and fecal indicators should also be identified.", [["fecal", "ORGANISM_SUBSTANCE", 60, 65], ["Relationships between resistant-pathogen concentrations", "PROBLEM", 0, 55], ["fecal indicators", "PROBLEM", 60, 76], ["resistant", "OBSERVATION_MODIFIER", 22, 31], ["pathogen concentrations", "OBSERVATION", 32, 55], ["fecal indicators", "OBSERVATION_MODIFIER", 60, 76]]], ["4) Better quantification of human exposure routes to pathogens is recommended.", [["human", "ORGANISM", 28, 33], ["human", "SPECIES", 28, 33], ["human", "SPECIES", 28, 33], ["pathogens", "PROBLEM", 53, 62]]], ["Prospective epidemiological studies are indispensable, with dose response models probably required to conduct a comprehensive risk assessment on a quantitative level.", [["Prospective epidemiological studies", "TEST", 0, 35], ["a comprehensive risk assessment", "TEST", 110, 141]]], ["In brief, it is required to conduct a comprehensive and system life cycle analysis about pathogens' fate-originally from activated sludge bed, digester, composting handling, exposure on farmland to host characteristics.", [["pathogens' fate", "PROBLEM", 89, 104], ["activated sludge bed", "PROBLEM", 121, 141], ["sludge", "OBSERVATION", 131, 137], ["host characteristics", "OBSERVATION_MODIFIER", 198, 218]]], ["5) Incorporating pathogens and ARGs removal into the present anaerobic digestion models is needed.Concluding remarksFinally, pathogen attenuation at the source WWTPs is the basic principle in the science of sewage sludge management.", [["ARGs", "SIMPLE_CHEMICAL", 31, 35], ["Incorporating pathogens", "PROBLEM", 3, 26], ["ARGs removal", "TREATMENT", 31, 43], ["the present anaerobic digestion models", "TREATMENT", 49, 87], ["pathogen attenuation", "PROBLEM", 125, 145], ["sewage sludge management", "TREATMENT", 207, 231], ["pathogen", "OBSERVATION_MODIFIER", 125, 133], ["attenuation", "OBSERVATION_MODIFIER", 134, 145], ["sewage sludge management", "OBSERVATION", 207, 231]]], ["AD process should be operated and maintained with strictly monitoring pathogens of low content, low removal rate and low potential risks for the public health.", [["AD", "DISEASE", 0, 2], ["low content", "PROBLEM", 83, 94], ["low removal rate", "TREATMENT", 96, 112], ["low content", "OBSERVATION_MODIFIER", 83, 94]]], ["Only AD that converts sewage sludge to qualified biofertilizer is a robust biological process gaining acceptance within the scientific community and public domain.", [["AD", "DISEASE", 5, 7], ["sewage sludge", "OBSERVATION", 22, 35]]]], "PMC7162193": [["IntroductionViruses, even the largest ones, are minute compared with host cells and cannot encode all the proteins required for their replication because of limitations in their coding capacity.", [["cells", "ANATOMY", 74, 79], ["host cells", "CELL", 69, 79], ["host cells", "CELL_TYPE", 69, 79], ["IntroductionViruses", "TEST", 0, 19], ["their replication", "TREATMENT", 128, 145], ["largest", "OBSERVATION_MODIFIER", 30, 37]]], ["For this reason, viruses rely on the utilization of host cell proteins and cellular structures to facilitate their own replicative processes.", [["cell", "ANATOMY", 57, 61], ["cellular structures", "ANATOMY", 75, 94], ["host cell", "CELL", 52, 61], ["cellular structures", "CELLULAR_COMPONENT", 75, 94], ["host cell proteins", "PROTEIN", 52, 70], ["viruses", "PROBLEM", 17, 24], ["host cell proteins", "TREATMENT", 52, 70], ["host cell proteins", "OBSERVATION", 52, 70]]], ["Most DNA viruses have evolved the ability to replicate in the host nucleus (with the exception of poxviruses) and to exploit nuclear compartments.", [["nucleus", "ANATOMY", 67, 74], ["nuclear compartments", "ANATOMY", 125, 145], ["DNA", "CELLULAR_COMPONENT", 5, 8], ["nucleus", "CELLULAR_COMPONENT", 67, 74], ["Most DNA viruses", "PROBLEM", 0, 16], ["poxviruses", "PROBLEM", 98, 108], ["viruses", "OBSERVATION", 9, 16], ["host nucleus", "ANATOMY", 62, 74]]], ["On the other hand, many RNA viruses are thought to replicate only in the cytoplasm.", [["cytoplasm", "ANATOMY", 73, 82], ["cytoplasm", "ORGANISM_SUBSTANCE", 73, 82], ["many RNA viruses", "PROBLEM", 19, 35], ["RNA viruses", "OBSERVATION", 24, 35], ["cytoplasm", "OBSERVATION", 73, 82]]], ["However, it has become increasingly apparent that many RNA as well as DNA viruses use nuclear compartments or components for their replication.", [["nuclear compartments", "ANATOMY", 86, 106], ["DNA", "CELLULAR_COMPONENT", 70, 73], ["many RNA", "PROBLEM", 50, 58], ["DNA viruses", "PROBLEM", 70, 81]]], ["The nucleus provides the machinery for viral DNA and RNA polymerization, processing and stabilization, and it also is stocked with essential factors for viral egress and maturation.", [["nucleus", "ANATOMY", 4, 11], ["nucleus", "CELLULAR_COMPONENT", 4, 11], ["DNA", "CELLULAR_COMPONENT", 45, 48], ["the machinery", "TREATMENT", 21, 34], ["viral DNA", "PROBLEM", 39, 48], ["RNA polymerization", "TREATMENT", 53, 71], ["stabilization", "TREATMENT", 88, 101], ["viral egress", "PROBLEM", 153, 165], ["nucleus", "ANATOMY_MODIFIER", 4, 11], ["viral DNA", "OBSERVATION", 39, 48], ["RNA polymerization", "OBSERVATION", 53, 71]]], ["At the same time, the nucleus is the most important organelle, which contains the cell's genetic material and several subnuclear structures that ensure normal cell function.", [["nucleus", "ANATOMY", 22, 29], ["organelle", "ANATOMY", 52, 61], ["cell", "ANATOMY", 82, 86], ["subnuclear structures", "ANATOMY", 118, 139], ["cell", "ANATOMY", 159, 163], ["nucleus", "CELLULAR_COMPONENT", 22, 29], ["organelle", "CELLULAR_COMPONENT", 52, 61], ["cell", "CELL", 82, 86], ["subnuclear structures", "CELLULAR_COMPONENT", 118, 139], ["cell", "CELL", 159, 163], ["nucleus", "ANATOMY", 22, 29], ["most important", "OBSERVATION_MODIFIER", 37, 51], ["cell's genetic material", "OBSERVATION", 82, 105], ["several", "OBSERVATION_MODIFIER", 110, 117], ["subnuclear", "OBSERVATION_MODIFIER", 118, 128], ["normal cell function", "OBSERVATION", 152, 172]]], ["Therefore, the usurpation of the nucleus by viruses constitutes an enormous stress for the cell that may lead to a profound disturbance of physiological functions.IntroductionRecent research based on cellular imaging techniques is beginning to increase our understanding of the mechanisms that viruses use to hijack and alter the host cell nucleus.", [["nucleus", "ANATOMY", 33, 40], ["cell", "ANATOMY", 91, 95], ["cellular", "ANATOMY", 200, 208], ["cell nucleus", "ANATOMY", 335, 347], ["nucleus", "CELLULAR_COMPONENT", 33, 40], ["cell", "CELL", 91, 95], ["cellular", "CELL", 200, 208], ["cell nucleus", "CELLULAR_COMPONENT", 335, 347], ["an enormous stress", "PROBLEM", 64, 82], ["the cell", "PROBLEM", 87, 95], ["a profound disturbance of physiological functions", "PROBLEM", 113, 162], ["cellular imaging techniques", "TEST", 200, 227], ["nucleus", "ANATOMY", 33, 40], ["viruses", "OBSERVATION", 44, 51], ["enormous", "OBSERVATION_MODIFIER", 67, 75], ["stress", "OBSERVATION", 76, 82], ["profound", "OBSERVATION_MODIFIER", 115, 123], ["disturbance", "OBSERVATION", 124, 135], ["physiological functions", "OBSERVATION", 139, 162], ["host cell nucleus", "OBSERVATION", 330, 347]]], ["In this article, we will review recent advances on how several viruses change the nucleus for their own needs.Nucleolus ::: Nuclear structure: nucleolus and promyelocytic leukaemia nuclear bodyDetailed analysis of the nucleolus by electron microscopy indicated that this subnuclear structure can be subdivided into three regions formed by the association of macromolecules that comprise fibrillar centres, surrounded by dense fibrillar components, which in turn are bordered by granular components (Scheer and Hock, 1999).", [["nucleus", "ANATOMY", 82, 89], ["Nuclear", "ANATOMY", 124, 131], ["nucleolus", "ANATOMY", 143, 152], ["promyelocytic leukaemia nuclear body", "ANATOMY", 157, 193], ["nucleolus", "ANATOMY", 218, 227], ["subnuclear", "ANATOMY", 271, 281], ["fibrillar centres", "ANATOMY", 387, 404], ["fibrillar components", "ANATOMY", 426, 446], ["promyelocytic leukaemia", "DISEASE", 157, 180], ["nucleus", "CELLULAR_COMPONENT", 82, 89], ["Nuclear", "CELLULAR_COMPONENT", 124, 131], ["nucleolus", "CELLULAR_COMPONENT", 143, 152], ["promyelocytic leukaemia", "CANCER", 157, 180], ["nucleolus", "CELLULAR_COMPONENT", 218, 227], ["fibrillar components", "CELLULAR_COMPONENT", 426, 446], ["granular components", "CELLULAR_COMPONENT", 478, 497], ["nucleolus and promyelocytic leukaemia", "PROBLEM", 143, 180], ["Detailed analysis", "TEST", 193, 210], ["electron microscopy", "TEST", 231, 250], ["this subnuclear structure", "PROBLEM", 266, 291], ["dense fibrillar components", "PROBLEM", 420, 446], ["nucleolus", "OBSERVATION", 143, 152], ["promyelocytic leukaemia", "OBSERVATION", 157, 180], ["body", "ANATOMY_MODIFIER", 189, 193], ["subnuclear structure", "OBSERVATION", 271, 291], ["macromolecules", "OBSERVATION", 358, 372], ["fibrillar centres", "OBSERVATION", 387, 404], ["dense", "OBSERVATION_MODIFIER", 420, 425], ["fibrillar components", "OBSERVATION", 426, 446], ["bordered", "OBSERVATION_MODIFIER", 466, 474], ["granular", "OBSERVATION_MODIFIER", 478, 486], ["components", "OBSERVATION_MODIFIER", 487, 497]]], ["For many years the classical view of these components focused ontheir crucial role for the biogenesis of ribosomal subunits, but proteomic analysis of human nucleoli showed the presence of about 4500 nucleolar proteins with different functions, thus revealing the multifunctional nature of the nucleolus (Ahmad et al., 2009).", [["ribosomal", "ANATOMY", 105, 114], ["nucleoli", "ANATOMY", 157, 165], ["nucleolar", "ANATOMY", 200, 209], ["nucleolus", "ANATOMY", 294, 303], ["ribosomal", "CELLULAR_COMPONENT", 105, 114], ["human", "ORGANISM", 151, 156], ["nucleoli", "CELLULAR_COMPONENT", 157, 165], ["nucleolus", "CELLULAR_COMPONENT", 294, 303], ["ribosomal subunits", "PROTEIN", 105, 123], ["4500 nucleolar proteins", "PROTEIN", 195, 218], ["human", "SPECIES", 151, 156], ["human", "SPECIES", 151, 156], ["ribosomal subunits", "PROBLEM", 105, 123], ["proteomic analysis", "TEST", 129, 147], ["human nucleoli", "PROBLEM", 151, 165]]], ["Nucleolin, fibrillarin and B23 (nucleophosmin) are three major proteins that represent approximately 20% of the total nucleolar protein content and that are highly conserved in structure and function within eukaryotes (Dumbar et al., 1989; Tollervey et al., 1993; Allain et al., 2000).Nucleolus ::: Nuclear structure: nucleolus and promyelocytic leukaemia nuclear bodyThe main function of nucleolin is to facilitate the first cleavage step of rRNA.", [["nucleolar", "ANATOMY", 118, 127], ["Nuclear", "ANATOMY", 299, 306], ["nucleolus", "ANATOMY", 318, 327], ["promyelocytic leukaemia nuclear body", "ANATOMY", 332, 368], ["promyelocytic leukaemia", "DISEASE", 332, 355], ["Nucleolin", "GENE_OR_GENE_PRODUCT", 0, 9], ["fibrillarin", "GENE_OR_GENE_PRODUCT", 11, 22], ["B23", "GENE_OR_GENE_PRODUCT", 27, 30], ["nucleophosmin", "GENE_OR_GENE_PRODUCT", 32, 45], ["nucleolar", "CELLULAR_COMPONENT", 118, 127], ["Nuclear", "CELLULAR_COMPONENT", 299, 306], ["nucleolus", "CELLULAR_COMPONENT", 318, 327], ["promyelocytic leukaemia", "CANCER", 332, 355], ["nucleolin", "GENE_OR_GENE_PRODUCT", 389, 398], ["rRNA", "CELLULAR_COMPONENT", 443, 447], ["Nucleolin", "PROTEIN", 0, 9], ["fibrillarin", "PROTEIN", 11, 22], ["B23", "PROTEIN", 27, 30], ["nucleophosmin", "PROTEIN", 32, 45], ["nucleolar protein", "PROTEIN", 118, 135], ["nucleolin", "PROTEIN", 389, 398], ["rRNA", "RNA", 443, 447], ["Nucleolin", "TREATMENT", 0, 9], ["fibrillarin", "TREATMENT", 11, 22], ["B23 (nucleophosmin", "TREATMENT", 27, 45], ["the total nucleolar protein content", "TEST", 108, 143], ["nucleolus and promyelocytic leukaemia", "PROBLEM", 318, 355], ["nucleolin", "TREATMENT", 389, 398], ["fibrillarin", "OBSERVATION", 11, 22], ["approximately", "OBSERVATION_MODIFIER", 87, 100], ["20%", "OBSERVATION_MODIFIER", 101, 104], ["nucleolar protein content", "OBSERVATION", 118, 143], ["nucleolus", "OBSERVATION", 318, 327], ["promyelocytic leukaemia", "OBSERVATION", 332, 355], ["body", "ANATOMY_MODIFIER", 364, 368], ["main", "OBSERVATION_MODIFIER", 372, 376], ["nucleolin", "OBSERVATION", 389, 398]]], ["Nucleolin also functions as a chaperon for correct folding in pre\u2010rRNA processing.", [["Nucleolin", "GENE_OR_GENE_PRODUCT", 0, 9], ["pre\u2010rRNA", "GENE_OR_GENE_PRODUCT", 62, 70], ["Nucleolin", "PROTEIN", 0, 9]]], ["Fibrillarin is involved in post\u2010transcriptional processes, such as pre\u2010rRNA processing, pre\u2010rRNA methylation and ribosome assembly.", [["ribosome", "ANATOMY", 113, 121], ["Fibrillarin", "CHEMICAL", 0, 11], ["Fibrillarin", "GENE_OR_GENE_PRODUCT", 0, 11], ["pre\u2010rRNA", "GENE_OR_GENE_PRODUCT", 67, 75], ["pre\u2010rRNA", "GENE_OR_GENE_PRODUCT", 88, 96], ["ribosome", "CELLULAR_COMPONENT", 113, 121], ["Fibrillarin", "PROTEIN", 0, 11], ["Fibrillarin", "PROBLEM", 0, 11]]], ["B23 is widely distributed among different species.", [["B23", "GENE_OR_GENE_PRODUCT", 0, 3], ["B23", "PROTEIN", 0, 3], ["B23", "PROBLEM", 0, 3], ["widely", "OBSERVATION_MODIFIER", 7, 13], ["distributed", "OBSERVATION_MODIFIER", 14, 25], ["different species", "OBSERVATION", 32, 49]]], ["It has two isoforms (B23.1 and B23.2) that have multiple functions.", [["B23.1", "GENE_OR_GENE_PRODUCT", 21, 26], ["B23.2", "GENE_OR_GENE_PRODUCT", 31, 36], ["B23.1", "PROTEIN", 21, 26], ["B23.2", "PROTEIN", 31, 36], ["two", "OBSERVATION_MODIFIER", 7, 10], ["isoforms", "OBSERVATION_MODIFIER", 11, 19], ["multiple", "OBSERVATION_MODIFIER", 48, 56], ["functions", "OBSERVATION", 57, 66]]], ["They have been implicated in ribosome assembly (Dumbar et al., 1989), nucleocytoplasmic shuttling (Li et al., 1996) and regulation of transcription of rDNA (Okuwaki et al., 2001).PML NB ::: Nuclear structure: nucleolus and promyelocytic leukaemia nuclear bodyAs for several other subnuclear structures, PML NBs were originally observed through electron microscopy in the early 1960s, which revealed the presence of spheric nuclear bodies (0.2\u20131.0 \u00b5m in diameter) in most cell types and many tissues (de The\u2032et al., 1960).", [["ribosome", "ANATOMY", 29, 37], ["nucleolus", "ANATOMY", 209, 218], ["promyelocytic leukaemia nuclear body", "ANATOMY", 223, 259], ["subnuclear structures", "ANATOMY", 280, 301], ["PML NBs", "ANATOMY", 303, 310], ["nuclear bodies", "ANATOMY", 423, 437], ["cell", "ANATOMY", 471, 475], ["tissues", "ANATOMY", 491, 498], ["promyelocytic leukaemia", "DISEASE", 223, 246], ["ribosome", "CELLULAR_COMPONENT", 29, 37], ["rDNA", "CELLULAR_COMPONENT", 151, 155], ["PML NB", "CANCER", 179, 185], ["Nuclear", "CELLULAR_COMPONENT", 190, 197], ["nucleolus", "CELLULAR_COMPONENT", 209, 218], ["promyelocytic leukaemia", "CANCER", 223, 246], ["subnuclear structures", "CELLULAR_COMPONENT", 280, 301], ["PML NBs", "GENE_OR_GENE_PRODUCT", 303, 310], ["cell", "CELL", 471, 475], ["tissues", "TISSUE", 491, 498], ["rDNA", "DNA", 151, 155], ["nucleolus", "PROBLEM", 209, 218], ["promyelocytic leukaemia", "PROBLEM", 223, 246], ["PML NBs", "TEST", 303, 310], ["electron microscopy", "TEST", 344, 363], ["spheric nuclear bodies", "PROBLEM", 415, 437], ["nucleolus", "OBSERVATION", 209, 218], ["promyelocytic leukaemia", "OBSERVATION", 223, 246], ["body", "ANATOMY_MODIFIER", 255, 259], ["PML NBs", "OBSERVATION", 303, 310], ["spheric", "OBSERVATION_MODIFIER", 415, 422], ["nuclear bodies", "OBSERVATION", 423, 437], ["most cell types", "OBSERVATION", 466, 481], ["many", "OBSERVATION_MODIFIER", 486, 490], ["tissues", "OBSERVATION", 491, 498]]], ["The frequency of PML NBs depends on cell type and condition, varying from 3 to 30 per cell (Ascoli and Maul, 1991).", [["PML NBs", "ANATOMY", 17, 24], ["cell", "ANATOMY", 36, 40], ["cell", "ANATOMY", 86, 90], ["PML", "GENE_OR_GENE_PRODUCT", 17, 20], ["cell", "CELL", 36, 40], ["cell", "CELL", 86, 90], ["PML NBs", "PROBLEM", 17, 24], ["PML NBs", "OBSERVATION", 17, 24], ["cell type", "OBSERVATION", 36, 45]]], ["Several studies have shown that PML NBs are dynamic, macromolecular structures that represent accumulations of multiple cellular proteins, whose only common known feature is their ability to be SUMOylated (Bernardi and Pandolfi, 2007).", [["PML NBs", "ANATOMY", 32, 39], ["cellular", "ANATOMY", 120, 128], ["PML NBs", "GENE_OR_GENE_PRODUCT", 32, 39], ["cellular", "CELL", 120, 128], ["cellular proteins", "PROTEIN", 120, 137], ["Several studies", "TEST", 0, 15], ["PML NBs", "PROBLEM", 32, 39], ["multiple cellular proteins", "PROBLEM", 111, 137], ["PML NBs", "OBSERVATION", 32, 39], ["dynamic", "OBSERVATION_MODIFIER", 44, 51], ["macromolecular structures", "OBSERVATION", 53, 78], ["accumulations", "OBSERVATION_MODIFIER", 94, 107], ["multiple", "OBSERVATION_MODIFIER", 111, 119], ["cellular proteins", "OBSERVATION", 120, 137]]], ["Probably the most important components of PML NBs are Sp100, hDaxx and PML.", [["PML NBs", "ANATOMY", 42, 49], ["PML NBs", "GENE_OR_GENE_PRODUCT", 42, 49], ["Sp100", "GENE_OR_GENE_PRODUCT", 54, 59], ["hDaxx", "GENE_OR_GENE_PRODUCT", 61, 66], ["PML", "GENE_OR_GENE_PRODUCT", 71, 74], ["Sp100", "PROTEIN", 54, 59], ["hDaxx", "PROTEIN", 61, 66], ["PML", "PROTEIN", 71, 74], ["PML NBs", "TEST", 42, 49], ["PML", "PROBLEM", 71, 74], ["PML NBs", "OBSERVATION", 42, 49]]], ["These proteins have several isoforms and motifs, such as SUMOylation sites (PML, hDaxx and Sp100), a RING finger motif (PML), SUMO\u2010interacting motifs (PML, hDaxx and Sp100) and a SAND domain (Sp100) that are involved in PML formation and functionality (Fig. 2).PML NB ::: Nuclear structure: nucleolus and promyelocytic leukaemia nuclear bodyThe previous decade of extensive studies implicated PML NBs in stress response (Maul et al., 1995), gene regulation (Zhong et al., 2000), oncogenesis (Salomoni and Pandolfi, 2002), cell senescence (Bischof et al., 2002), DNA damage repair (Dellaire and Bazett\u2010Jones, 2004), apoptosis (Takahashi et al., 2004) as well as in antiviral defence mechanisms (Everett and Chelbi\u2010Alix, 2007).Nucleolar proteins ::: Hijacking the nucleolusThe multifunctional nature of many nucleolar proteins may explain the usurpation and incorporation of these proteins into replication and translation complexes formed by RNA as well as DNA viruses.", [["PML", "ANATOMY", 220, 223], ["nucleolus", "ANATOMY", 291, 300], ["promyelocytic leukaemia nuclear body", "ANATOMY", 305, 341], ["PML NBs", "ANATOMY", 393, 400], ["cell", "ANATOMY", 522, 526], ["Nucleolar", "ANATOMY", 725, 734], ["nucleolus", "ANATOMY", 762, 771], ["nucleolar", "ANATOMY", 806, 815], ["promyelocytic leukaemia", "DISEASE", 305, 328], ["DNA damage", "DISEASE", 562, 572], ["PML", "GENE_OR_GENE_PRODUCT", 76, 79], ["hDaxx", "GENE_OR_GENE_PRODUCT", 81, 86], ["Sp100", "GENE_OR_GENE_PRODUCT", 91, 96], ["PML", "GENE_OR_GENE_PRODUCT", 120, 123], ["SUMO", "GENE_OR_GENE_PRODUCT", 126, 130], ["PML", "GENE_OR_GENE_PRODUCT", 151, 154], ["hDaxx", "GENE_OR_GENE_PRODUCT", 156, 161], ["Sp100", "GENE_OR_GENE_PRODUCT", 166, 171], ["Sp100", "GENE_OR_GENE_PRODUCT", 192, 197], ["PML", "GENE_OR_GENE_PRODUCT", 220, 223], ["PML NB", "CANCER", 261, 267], ["Nuclear", "CELLULAR_COMPONENT", 272, 279], ["nucleolus", "CELLULAR_COMPONENT", 291, 300], ["promyelocytic leukaemia", "CANCER", 305, 328], ["PML NBs", "GENE_OR_GENE_PRODUCT", 393, 400], ["cell", "CELL", 522, 526], ["DNA", "CELLULAR_COMPONENT", 562, 565], ["Nucleolar", "CELLULAR_COMPONENT", 725, 734], ["nucleolus", "CELLULAR_COMPONENT", 762, 771], ["nucleolar", "CELLULAR_COMPONENT", 806, 815], ["DNA", "CELLULAR_COMPONENT", 956, 959], ["SUMOylation sites", "PROTEIN", 57, 74], ["PML", "PROTEIN", 76, 79], ["hDaxx", "PROTEIN", 81, 86], ["Sp100", "PROTEIN", 91, 96], ["RING finger motif", "PROTEIN", 101, 118], ["PML", "PROTEIN", 120, 123], ["SUMO\u2010interacting motifs", "PROTEIN", 126, 149], ["PML", "PROTEIN", 151, 154], ["hDaxx", "PROTEIN", 156, 161], ["Sp100", "PROTEIN", 166, 171], ["SAND domain", "DNA", 179, 190], ["Sp100", "PROTEIN", 192, 197], ["Nucleolar proteins", "PROTEIN", 725, 743], ["nucleolar proteins", "PROTEIN", 806, 824], ["replication and translation complexes", "PROTEIN", 893, 930], ["several isoforms and motifs", "PROBLEM", 20, 47], ["SUMOylation sites", "PROBLEM", 57, 74], ["PML", "PROBLEM", 76, 79], ["hDaxx", "TREATMENT", 81, 86], ["a RING finger motif (PML", "TREATMENT", 99, 123], ["SUMO\u2010interacting motifs", "PROBLEM", 126, 149], ["PML", "PROBLEM", 151, 154], ["hDaxx", "TEST", 156, 161], ["a SAND domain", "TEST", 177, 190], ["nucleolus", "PROBLEM", 291, 300], ["promyelocytic leukaemia", "PROBLEM", 305, 328], ["extensive studies", "TEST", 364, 381], ["PML NBs", "PROBLEM", 393, 400], ["oncogenesis (Salomoni and Pandolfi", "TREATMENT", 479, 513], ["cell senescence", "PROBLEM", 522, 537], ["DNA damage repair", "TREATMENT", 562, 579], ["apoptosis", "PROBLEM", 615, 624], ["many nucleolar proteins", "PROBLEM", 801, 824], ["these proteins into replication", "PROBLEM", 873, 904], ["DNA viruses", "PROBLEM", 956, 967], ["PML", "OBSERVATION", 220, 223], ["nucleolus", "OBSERVATION", 291, 300], ["promyelocytic leukaemia", "OBSERVATION", 305, 328], ["body", "ANATOMY_MODIFIER", 337, 341], ["PML NBs", "OBSERVATION", 393, 400], ["damage repair", "OBSERVATION", 566, 579], ["nucleolar proteins", "OBSERVATION", 806, 824]]], ["The best example for this is the interaction between picornaviruses and nucleolin followed by blocking of nuclear import pathways (Gustin and Sarnow, 2002).", [["nuclear", "ANATOMY", 106, 113], ["picornaviruses", "ORGANISM", 53, 67], ["nucleolin", "GENE_OR_GENE_PRODUCT", 72, 81], ["nuclear", "CELLULAR_COMPONENT", 106, 113], ["nucleolin", "PROTEIN", 72, 81], ["picornaviruses", "TREATMENT", 53, 67], ["nucleolin", "TREATMENT", 72, 81]]], ["These dramatic changes in the nuclear pore complex result in an accumulation of nucleolin in the cytoplasm of infected cells.", [["nuclear pore", "ANATOMY", 30, 42], ["cytoplasm", "ANATOMY", 97, 106], ["cells", "ANATOMY", 119, 124], ["nuclear", "CELLULAR_COMPONENT", 30, 37], ["nucleolin", "GENE_OR_GENE_PRODUCT", 80, 89], ["cytoplasm", "ORGANISM_SUBSTANCE", 97, 106], ["cells", "CELL", 119, 124], ["nuclear pore complex", "PROTEIN", 30, 50], ["nucleolin", "PROTEIN", 80, 89], ["infected cells", "CELL_TYPE", 110, 124], ["These dramatic changes", "PROBLEM", 0, 22], ["an accumulation of nucleolin", "PROBLEM", 61, 89], ["infected cells", "PROBLEM", 110, 124], ["dramatic", "OBSERVATION_MODIFIER", 6, 14], ["nuclear pore", "OBSERVATION_MODIFIER", 30, 42], ["accumulation of nucleolin", "OBSERVATION", 64, 89], ["cytoplasm", "OBSERVATION_MODIFIER", 97, 106], ["infected cells", "OBSERVATION", 110, 124]]], ["After accumulation, nucleolin interacts with the 5\u2032 non\u2010coding region of the poliovirus genome known as internal ribosome entry site (IRES).", [["ribosome", "ANATOMY", 113, 121], ["nucleolin", "GENE_OR_GENE_PRODUCT", 20, 29], ["nucleolin", "PROTEIN", 20, 29], ["5\u2032 non\u2010coding region", "DNA", 49, 69], ["poliovirus genome", "DNA", 77, 94], ["internal ribosome entry site", "DNA", 104, 132], ["IRES", "DNA", 134, 138], ["nucleolin interacts", "PROBLEM", 20, 39], ["the poliovirus genome", "PROBLEM", 73, 94], ["nucleolin interacts", "OBSERVATION", 20, 39], ["poliovirus genome", "OBSERVATION", 77, 94], ["internal", "OBSERVATION_MODIFIER", 104, 112], ["ribosome entry", "OBSERVATION", 113, 127]]], ["IRESes are RNA structural elements that function in the binding of ribosomes to the mRNA and initiate translation of mRNA in a cap\u2010independent manner (Hellen and Sarnow, 2001), and therefore nucleolin interaction with the IRES element stimulates IRES\u2010dependent translation (Izumi et al., 2001).", [["IRESes", "GENE_OR_GENE_PRODUCT", 0, 6], ["ribosomes", "CELLULAR_COMPONENT", 67, 76], ["nucleolin", "GENE_OR_GENE_PRODUCT", 191, 200], ["IRESes", "PROTEIN", 0, 6], ["RNA structural elements", "DNA", 11, 34], ["ribosomes", "RNA", 67, 76], ["mRNA", "RNA", 84, 88], ["mRNA", "RNA", 117, 121], ["nucleolin", "PROTEIN", 191, 200], ["IRES element", "DNA", 222, 234], ["IRES", "DNA", 246, 250]]], ["Nucleolin can also interact with the poliovirus 3\u2032 non\u2010coding region, which is implicated in the regulation of negative\u2010strand RNA synthesis (Waggoner and Sarnow, 1998).", [["Nucleolin", "CHEMICAL", 0, 9], ["Nucleolin", "GENE_OR_GENE_PRODUCT", 0, 9], ["Nucleolin", "PROTEIN", 0, 9], ["poliovirus 3\u2032 non\u2010coding region", "DNA", 37, 68], ["negative\u2010strand RNA", "RNA", 111, 130], ["Nucleolin", "TREATMENT", 0, 9], ["poliovirus", "OBSERVATION", 37, 47]]], ["Moreover, interaction of picornaviruses with the nucleolar proteins not only facilitates viral replication but also leads to the shutdown of host cell transcription.", [["nucleolar", "ANATOMY", 49, 58], ["cell", "ANATOMY", 146, 150], ["picornaviruses", "ORGANISM", 25, 39], ["nucleolar", "CELLULAR_COMPONENT", 49, 58], ["host cell", "CELL", 141, 150], ["nucleolar proteins", "PROTEIN", 49, 67], ["picornaviruses", "PROBLEM", 25, 39], ["the nucleolar proteins", "TREATMENT", 45, 67], ["viral replication", "TREATMENT", 89, 106], ["host cell transcription", "TREATMENT", 141, 164], ["picornaviruses", "OBSERVATION", 25, 39], ["host cell transcription", "OBSERVATION", 141, 164]]], ["Aminev and co\u2010authors showed that encephalomyocarditis virus proteins 2A and 3BCD localize in the nucleoli and inhibit cellular mRNA transcription but not rRNA transcription (Aminev et al., 2003).", [["nucleoli", "ANATOMY", 98, 106], ["cellular", "ANATOMY", 119, 127], ["Aminev", "CHEMICAL", 0, 6], ["encephalomyocarditis virus", "ORGANISM", 34, 60], ["2A", "GENE_OR_GENE_PRODUCT", 70, 72], ["3BCD", "GENE_OR_GENE_PRODUCT", 77, 81], ["nucleoli", "CELLULAR_COMPONENT", 98, 106], ["cellular", "CELL", 119, 127], ["rRNA", "CELLULAR_COMPONENT", 155, 159], ["encephalomyocarditis virus proteins 2A", "PROTEIN", 34, 72], ["3BCD", "PROTEIN", 77, 81], ["encephalomyocarditis virus", "SPECIES", 34, 60], ["encephalomyocarditis virus", "SPECIES", 34, 60], ["Aminev", "TREATMENT", 0, 6], ["co\u2010authors", "TEST", 11, 21], ["encephalomyocarditis virus proteins 2A", "PROBLEM", 34, 72], ["cellular mRNA transcription", "TREATMENT", 119, 146], ["encephalomyocarditis", "OBSERVATION", 34, 54], ["nucleoli", "ANATOMY", 98, 106], ["cellular mRNA", "OBSERVATION", 119, 132]]], ["Another study done by Aminev showed that human rhinovirus 3C protease precursors also localize in the nucleoli of infected cells and inhibit cellular RNA transcription through proteolytic mechanisms (Amineva et al., 2004).", [["nucleoli", "ANATOMY", 102, 110], ["cells", "ANATOMY", 123, 128], ["cellular", "ANATOMY", 141, 149], ["human", "ORGANISM", 41, 46], ["rhinovirus 3C", "ORGANISM", 47, 60], ["nucleoli", "CELLULAR_COMPONENT", 102, 110], ["cells", "CELL", 123, 128], ["cellular", "CELL", 141, 149], ["human rhinovirus 3C protease precursors", "PROTEIN", 41, 80], ["infected cells", "CELL_TYPE", 114, 128], ["human", "SPECIES", 41, 46], ["human rhinovirus", "SPECIES", 41, 57], ["Another study", "TEST", 0, 13], ["human rhinovirus 3C protease precursors", "TREATMENT", 41, 80], ["infected cells", "PROBLEM", 114, 128], ["cellular RNA transcription", "TREATMENT", 141, 167], ["infected cells", "OBSERVATION", 114, 128], ["cellular RNA transcription", "OBSERVATION", 141, 167]]], ["Virus\u2010induced shutdown of the host\u2010cell transcription may inhibit intracellular defence mechanisms and may free the translational machinery for viral replication.Nucleolar proteins ::: Hijacking the nucleolusOther RNA viruses that replicate and assemble in the cytoplasm also induce nucleolar response in the host cell as viruses alter nucleolar protein content.", [["host\u2010cell", "ANATOMY", 30, 39], ["intracellular", "ANATOMY", 66, 79], ["Nucleolar", "ANATOMY", 162, 171], ["nucleolus", "ANATOMY", 199, 208], ["cytoplasm", "ANATOMY", 261, 270], ["nucleolar", "ANATOMY", 283, 292], ["cell", "ANATOMY", 314, 318], ["nucleolar", "ANATOMY", 336, 345], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 66, 79], ["Nucleolar", "CELLULAR_COMPONENT", 162, 171], ["nucleolus", "CELLULAR_COMPONENT", 199, 208], ["cytoplasm", "ORGANISM_SUBSTANCE", 261, 270], ["nucleolar", "CELLULAR_COMPONENT", 283, 292], ["host cell", "CELL", 309, 318], ["nucleolar", "CELLULAR_COMPONENT", 336, 345], ["Nucleolar proteins", "PROTEIN", 162, 180], ["the host\u2010cell transcription", "TREATMENT", 26, 53], ["intracellular defence mechanisms", "PROBLEM", 66, 98], ["viral replication", "TREATMENT", 144, 161], ["Hijacking the nucleolusOther RNA viruses", "PROBLEM", 185, 225], ["nucleolar response", "PROBLEM", 283, 301], ["nucleolusOther", "OBSERVATION", 199, 213], ["RNA viruses", "OBSERVATION", 214, 225], ["nucleolar response", "OBSERVATION", 283, 301], ["host cell", "OBSERVATION", 309, 318], ["nucleolar protein content", "OBSERVATION", 336, 361]]], ["Quantitative proteomics was used to take an overview of the protein changes in epithelial cells infected with human respiratory syncytial virus.", [["epithelial cells", "ANATOMY", 79, 95], ["respiratory syncytial virus", "DISEASE", 116, 143], ["epithelial cells", "CELL", 79, 95], ["human", "ORGANISM", 110, 115], ["respiratory syncytial virus", "ORGANISM", 116, 143], ["epithelial cells", "CELL_TYPE", 79, 95], ["human", "SPECIES", 110, 115], ["respiratory syncytial virus", "SPECIES", 116, 143], ["human respiratory syncytial virus", "SPECIES", 110, 143], ["Quantitative proteomics", "TREATMENT", 0, 23], ["the protein changes", "PROBLEM", 56, 75], ["epithelial cells", "PROBLEM", 79, 95], ["human respiratory syncytial virus", "PROBLEM", 110, 143], ["epithelial cells", "OBSERVATION", 79, 95], ["syncytial virus", "OBSERVATION", 128, 143]]], ["In addition to the alterations in mitochondrial and nuclear pore complex proteins content, Hiscox and co\u2010authors described depletion of nucleolin and B23 in human respiratory syncytial virus\u2010infected cells (Munday et al., 2010).", [["mitochondrial", "ANATOMY", 34, 47], ["nuclear pore", "ANATOMY", 52, 64], ["respiratory syncytial virus\u2010infected cells", "ANATOMY", 163, 205], ["respiratory syncytial virus\u2010infected", "DISEASE", 163, 199], ["mitochondrial", "CELLULAR_COMPONENT", 34, 47], ["nuclear", "CELLULAR_COMPONENT", 52, 59], ["nucleolin", "GENE_OR_GENE_PRODUCT", 136, 145], ["B23", "GENE_OR_GENE_PRODUCT", 150, 153], ["human", "ORGANISM", 157, 162], ["respiratory syncytial virus\u2010infected cells", "CELL", 163, 205], ["nuclear pore complex proteins", "PROTEIN", 52, 81], ["nucleolin", "PROTEIN", 136, 145], ["B23", "PROTEIN", 150, 153], ["human respiratory syncytial virus\u2010infected cells", "CELL_TYPE", 157, 205], ["human", "SPECIES", 157, 162], ["human", "SPECIES", 157, 162], ["the alterations in mitochondrial and nuclear pore complex proteins content", "PROBLEM", 15, 89], ["Hiscox", "TREATMENT", 91, 97], ["co\u2010authors", "TREATMENT", 102, 112], ["nucleolin and B23", "TREATMENT", 136, 153], ["respiratory syncytial", "ANATOMY", 163, 184]]], ["Similarly, high throughput proteomics was used to analyse protein content of Vero cells infected with the coronavirus infectious bronchitis virus (IBV) and protein content of 293\u2010T cells infected with influenza A virus.", [["Vero cells", "ANATOMY", 77, 87], ["293\u2010T cells", "ANATOMY", 175, 186], ["infectious bronchitis", "DISEASE", 118, 139], ["influenza A virus", "DISEASE", 201, 218], ["Vero cells", "CELL", 77, 87], ["coronavirus infectious bronchitis virus", "ORGANISM", 106, 145], ["IBV", "ORGANISM", 147, 150], ["293\u2010T cells", "CELL", 175, 186], ["influenza A virus", "ORGANISM", 201, 218], ["Vero cells", "CELL_LINE", 77, 87], ["293\u2010T cells", "CELL_LINE", 175, 186], ["coronavirus infectious bronchitis virus", "SPECIES", 106, 145], ["influenza A virus", "SPECIES", 201, 218], ["coronavirus infectious bronchitis virus", "SPECIES", 106, 145], ["IBV", "SPECIES", 147, 150], ["influenza A virus", "SPECIES", 201, 218], ["high throughput proteomics", "PROBLEM", 11, 37], ["Vero cells", "PROBLEM", 77, 87], ["the coronavirus infectious bronchitis virus", "PROBLEM", 102, 145], ["protein content", "TEST", 156, 171], ["influenza A virus", "PROBLEM", 201, 218], ["high", "OBSERVATION_MODIFIER", 11, 15], ["Vero cells", "OBSERVATION", 77, 87], ["coronavirus", "OBSERVATION_MODIFIER", 106, 117]]], ["Proteomic analyses revealed that global nucleolar proteome change did not occur in influenza A virus and IBV infected cells, and only a subset of nucleolar proteins changed in abundance (2010a, 2010b).Nucleolar proteins ::: Hijacking the nucleolusSome DNA viruses, including herpesviruses, papillomaviruses and adenoviruses can also interact with the nucleolus.", [["nucleolar", "ANATOMY", 40, 49], ["cells", "ANATOMY", 118, 123], ["nucleolar", "ANATOMY", 146, 155], ["Nucleolar", "ANATOMY", 201, 210], ["nucleolus", "ANATOMY", 238, 247], ["nucleolus", "ANATOMY", 351, 360], ["nucleolar", "CELLULAR_COMPONENT", 40, 49], ["influenza A virus", "ORGANISM", 83, 100], ["IBV", "ORGANISM", 105, 108], ["cells", "CELL", 118, 123], ["nucleolar", "CELLULAR_COMPONENT", 146, 155], ["Nucleolar", "CELLULAR_COMPONENT", 201, 210], ["nucleolus", "CELLULAR_COMPONENT", 238, 247], ["DNA", "CELLULAR_COMPONENT", 252, 255], ["papillomaviruses", "ORGANISM", 290, 306], ["adenoviruses", "ORGANISM", 311, 323], ["nucleolus", "CELLULAR_COMPONENT", 351, 360], ["IBV infected cells", "CELL_TYPE", 105, 123], ["nucleolar proteins", "PROTEIN", 146, 164], ["Nucleolar proteins", "PROTEIN", 201, 219], ["influenza A virus", "SPECIES", 83, 100], ["influenza A virus", "SPECIES", 83, 100], ["IBV", "SPECIES", 105, 108], ["Proteomic analyses", "TEST", 0, 18], ["global nucleolar proteome change", "PROBLEM", 33, 65], ["influenza A virus", "PROBLEM", 83, 100], ["IBV infected cells", "PROBLEM", 105, 123], ["nucleolar proteins", "PROBLEM", 146, 164], ["DNA viruses", "PROBLEM", 252, 263], ["herpesviruses", "PROBLEM", 275, 288], ["papillomaviruses", "PROBLEM", 290, 306], ["adenoviruses", "TREATMENT", 311, 323], ["global", "OBSERVATION_MODIFIER", 33, 39], ["nucleolar proteome", "OBSERVATION", 40, 58], ["infected cells", "OBSERVATION", 109, 123], ["nucleolar proteins changed", "OBSERVATION", 146, 172], ["nucleolusSome", "OBSERVATION", 238, 251], ["DNA viruses", "OBSERVATION", 252, 263]]], ["For example, several nucleolar proteins are relocalized during herpes simplex virus 1 (HSV\u20101) infection.", [["nucleolar", "ANATOMY", 21, 30], ["herpes simplex virus 1 (HSV\u20101) infection", "DISEASE", 63, 103], ["nucleolar", "CELLULAR_COMPONENT", 21, 30], ["herpes simplex virus 1", "ORGANISM", 63, 85], ["HSV\u20101", "ORGANISM", 87, 92], ["nucleolar proteins", "PROTEIN", 21, 39], ["herpes simplex virus 1", "SPECIES", 63, 85], ["HSV\u20101", "SPECIES", 87, 92], ["herpes simplex virus 1", "SPECIES", 63, 85], ["HSV\u20101", "SPECIES", 87, 92], ["several nucleolar proteins", "PROBLEM", 13, 39], ["herpes simplex virus", "PROBLEM", 63, 83], ["infection", "PROBLEM", 94, 103], ["several", "OBSERVATION_MODIFIER", 13, 20], ["nucleolar proteins", "OBSERVATION", 21, 39], ["infection", "OBSERVATION", 94, 103]]], ["Nucleolin and B23 are dispersed throughout the nucleus in a manner dependent on expression of the viral protein UL24 (Lymberopoulos and Pearson, 2007; Calle et al., 2008; Lymberopoulos et al., 2011).", [["nucleus", "ANATOMY", 47, 54], ["Nucleolin", "GENE_OR_GENE_PRODUCT", 0, 9], ["B23", "GENE_OR_GENE_PRODUCT", 14, 17], ["nucleus", "CELLULAR_COMPONENT", 47, 54], ["UL24", "GENE_OR_GENE_PRODUCT", 112, 116], ["Nucleolin", "PROTEIN", 0, 9], ["B23", "PROTEIN", 14, 17], ["viral protein UL24", "PROTEIN", 98, 116], ["Nucleolin and B23", "TREATMENT", 0, 17], ["nucleus", "OBSERVATION_MODIFIER", 47, 54]]], ["Unlike nucleolin and B23, fibrillarin is redistributed in spots throughout the nucleus during infection in a manner independent of UL24 (Lymberopoulos and Pearson, 2007).Nucleolar proteins ::: Hijacking the nucleolusInteraction between adenoviruses and the nucleolus is another well\u2010studied example.", [["nucleus", "ANATOMY", 79, 86], ["Nucleolar", "ANATOMY", 170, 179], ["nucleolus", "ANATOMY", 207, 216], ["nucleolus", "ANATOMY", 257, 266], ["infection", "DISEASE", 94, 103], ["nucleolin", "GENE_OR_GENE_PRODUCT", 7, 16], ["B23", "GENE_OR_GENE_PRODUCT", 21, 24], ["fibrillarin", "GENE_OR_GENE_PRODUCT", 26, 37], ["nucleus", "CELLULAR_COMPONENT", 79, 86], ["UL24", "GENE_OR_GENE_PRODUCT", 131, 135], ["Nucleolar", "CELLULAR_COMPONENT", 170, 179], ["nucleolus", "CELLULAR_COMPONENT", 207, 216], ["adenoviruses", "ORGANISM", 236, 248], ["nucleolus", "CELLULAR_COMPONENT", 257, 266], ["nucleolin", "PROTEIN", 7, 16], ["B23", "PROTEIN", 21, 24], ["fibrillarin", "PROTEIN", 26, 37], ["Nucleolar proteins", "PROTEIN", 170, 188], ["B23", "TREATMENT", 21, 24], ["fibrillarin", "PROBLEM", 26, 37], ["infection", "PROBLEM", 94, 103], ["nucleolin", "OBSERVATION", 7, 16], ["fibrillarin", "OBSERVATION", 26, 37], ["redistributed", "OBSERVATION_MODIFIER", 41, 54], ["spots", "OBSERVATION_MODIFIER", 58, 63], ["nucleus", "ANATOMY", 79, 86], ["infection", "OBSERVATION", 94, 103], ["nucleolusInteraction", "OBSERVATION", 207, 227]]], ["It has been shown that adenoviruses inhibit the synthesis, processing and exit of the 18S and 28S species of rRNA (Castiglia and Flint, 1983) and disrupt the nucleolus at late time of infection (Walton et al., 1989).", [["nucleolus", "ANATOMY", 158, 167], ["infection", "DISEASE", 184, 193], ["adenoviruses", "ORGANISM", 23, 35], ["18S", "CELLULAR_COMPONENT", 86, 89], ["rRNA", "CELLULAR_COMPONENT", 109, 113], ["nucleolus", "CELLULAR_COMPONENT", 158, 167], ["18S and 28S species", "DNA", 86, 105], ["rRNA", "DNA", 109, 113], ["adenoviruses", "PROBLEM", 23, 35], ["the synthesis", "PROBLEM", 44, 57], ["the 18S", "TEST", 82, 89], ["28S species of rRNA", "PROBLEM", 94, 113], ["the nucleolus", "PROBLEM", 154, 167], ["infection", "PROBLEM", 184, 193], ["adenoviruses", "OBSERVATION", 23, 35], ["nucleolus", "ANATOMY", 158, 167], ["infection", "OBSERVATION", 184, 193]]], ["More recent studies done by Matthews and colleagues showed that the adenovirus core protein V is delivered to the nucleus and is associated with the nucleolus, leading to the mass relocation of nucleolin to the cytoplasm (Matthews and Russell, 1998; Matthews, 2001).", [["nucleus", "ANATOMY", 114, 121], ["nucleolus", "ANATOMY", 149, 158], ["cytoplasm", "ANATOMY", 211, 220], ["adenovirus core protein V", "GENE_OR_GENE_PRODUCT", 68, 93], ["nucleus", "CELLULAR_COMPONENT", 114, 121], ["nucleolus", "CELLULAR_COMPONENT", 149, 158], ["nucleolin", "GENE_OR_GENE_PRODUCT", 194, 203], ["cytoplasm", "ORGANISM_SUBSTANCE", 211, 220], ["adenovirus core protein V", "PROTEIN", 68, 93], ["nucleolin", "PROTEIN", 194, 203], ["recent studies", "TEST", 5, 19], ["the adenovirus core protein V", "PROBLEM", 64, 93], ["the nucleolus", "PROBLEM", 145, 158], ["the mass relocation of nucleolin", "PROBLEM", 171, 203], ["nucleus", "ANATOMY", 114, 121], ["nucleolus", "OBSERVATION", 149, 158], ["mass", "OBSERVATION", 175, 179]]], ["Examination of the adenoviral genome revealed potential binding sites for nucleolin.", [["adenoviral", "ORGANISM", 19, 29], ["nucleolin", "GENE_OR_GENE_PRODUCT", 74, 83], ["adenoviral genome", "DNA", 19, 36], ["nucleolin", "PROTEIN", 74, 83], ["Examination of the adenoviral genome", "TEST", 0, 36], ["potential binding sites", "PROBLEM", 46, 69], ["nucleolin", "PROBLEM", 74, 83], ["binding sites", "OBSERVATION", 56, 69]]], ["Thus, nucleolin may interfere with adenoviral replication via its ability to bind and repress transcription (Yang et al., 1994).", [["nucleolin", "GENE_OR_GENE_PRODUCT", 6, 15], ["adenoviral", "ORGANISM", 35, 45], ["nucleolin", "PROTEIN", 6, 15], ["nucleolin", "TREATMENT", 6, 15], ["adenoviral replication", "TREATMENT", 35, 57]]], ["Therefore, adenovirus\u2010induced displacement of nucleolin appears to constitute an important step towards the antagonization of host obstacles.", [["nucleolin", "GENE_OR_GENE_PRODUCT", 46, 55], ["nucleolin", "PROTEIN", 46, 55], ["adenovirus\u2010induced displacement of nucleolin", "PROBLEM", 11, 55], ["nucleolin", "OBSERVATION", 46, 55]]], ["It has also been shown that B23.1, B23.2 and UBF (upstream binding factor) interact with viral proteins in replication centres and stimulate adenovirus DNA replication independently (Okuwaki et al., 2001; Lawrence et al., 2006; Hindley et al., 2007).", [["B23.1", "GENE_OR_GENE_PRODUCT", 28, 33], ["B23.2", "GENE_OR_GENE_PRODUCT", 35, 40], ["UBF", "GENE_OR_GENE_PRODUCT", 45, 48], ["upstream binding factor", "GENE_OR_GENE_PRODUCT", 50, 73], ["adenovirus", "ORGANISM", 141, 151], ["DNA", "CELLULAR_COMPONENT", 152, 155], ["B23.1", "PROTEIN", 28, 33], ["B23.2", "PROTEIN", 35, 40], ["UBF", "PROTEIN", 45, 48], ["upstream binding factor", "PROTEIN", 50, 73], ["viral proteins", "PROTEIN", 89, 103], ["adenovirus", "SPECIES", 141, 151], ["B23.1", "TEST", 28, 33], ["UBF (upstream binding factor", "PROBLEM", 45, 73], ["viral proteins in replication centres", "TREATMENT", 89, 126]]], ["And finally, proteomic analyses identified quantitative changes in 351 proteins of the nucleolus during adenovirus infection, finally corroborating that the nucleolus is extensively targeted and modified by adenoviruses (Lam et al., 2010).Localization of RNA virus proteins to the nucleolus: is there a benefit? ::: Hijacking the nucleolusIt has been shown that many capsid and RNA\u2010binding proteins, including influenza virus nucleoprotein (Dimmock, 1969), Newcastle disease virus matrix protein (Peeples et al., 1992), dengue virus core protein (Wang et al., 2002) or coronavirus nucleocapsid protein (Dove et al., 2006) localize to the nucleolus, and for many years these localizations seemed only phenomenological without any known consequence for cells or viruses.", [["nucleolus", "ANATOMY", 87, 96], ["nucleolus", "ANATOMY", 157, 166], ["nucleolus", "ANATOMY", 281, 290], ["nucleolus", "ANATOMY", 330, 339], ["nucleolus", "ANATOMY", 638, 647], ["cells", "ANATOMY", 751, 756], ["adenovirus infection", "DISEASE", 104, 124], ["Newcastle disease", "DISEASE", 457, 474], ["dengue", "DISEASE", 520, 526], ["nucleolus", "CELLULAR_COMPONENT", 87, 96], ["adenovirus", "ORGANISM", 104, 114], ["nucleolus", "CELLULAR_COMPONENT", 157, 166], ["adenoviruses", "ORGANISM", 207, 219], ["nucleolus", "CELLULAR_COMPONENT", 281, 290], ["nucleolus", "CELLULAR_COMPONENT", 330, 339], ["RNA\u2010binding proteins", "GENE_OR_GENE_PRODUCT", 378, 398], ["influenza virus nucleoprotein", "ORGANISM", 410, 439], ["Newcastle disease virus matrix protein", "GENE_OR_GENE_PRODUCT", 457, 495], ["dengue virus", "ORGANISM", 520, 532], ["coronavirus nucleocapsid", "ORGANISM", 569, 593], ["nucleolus", "CELLULAR_COMPONENT", 638, 647], ["cells", "CELL", 751, 756], ["351 proteins", "PROTEIN", 67, 79], ["RNA virus proteins", "PROTEIN", 255, 273], ["capsid and RNA\u2010binding proteins", "PROTEIN", 367, 398], ["Newcastle disease virus matrix protein", "PROTEIN", 457, 495], ["dengue virus core protein", "PROTEIN", 520, 545], ["coronavirus nucleocapsid protein", "PROTEIN", 569, 601], ["influenza virus", "SPECIES", 410, 425], ["dengue virus", "SPECIES", 520, 532], ["coronavirus nucleocapsid", "SPECIES", 569, 593], ["adenovirus", "SPECIES", 104, 114], ["Newcastle disease virus", "SPECIES", 457, 480], ["dengue virus", "SPECIES", 520, 532], ["proteomic analyses", "TEST", 13, 31], ["quantitative changes", "PROBLEM", 43, 63], ["the nucleolus", "PROBLEM", 83, 96], ["adenovirus infection", "PROBLEM", 104, 124], ["RNA virus proteins", "PROBLEM", 255, 273], ["many capsid and RNA\u2010binding proteins", "PROBLEM", 362, 398], ["influenza virus nucleoprotein", "PROBLEM", 410, 439], ["Newcastle disease virus matrix protein", "TEST", 457, 495], ["Peeples et al.", "TEST", 497, 511], ["dengue virus core protein", "TEST", 520, 545], ["coronavirus nucleocapsid protein", "PROBLEM", 569, 601], ["cells", "PROBLEM", 751, 756], ["viruses", "PROBLEM", 760, 767], ["nucleolus", "ANATOMY", 87, 96], ["adenovirus infection", "OBSERVATION", 104, 124], ["RNA virus", "OBSERVATION", 255, 264], ["nucleolus", "OBSERVATION", 330, 339], ["many", "OBSERVATION_MODIFIER", 362, 366], ["capsid", "OBSERVATION", 367, 373], ["nucleolus", "ANATOMY", 638, 647], ["viruses", "OBSERVATION", 760, 767]]], ["It was speculated that viral (particularly RNA viral) proteins might accumulate at the nucleolus as a result of diffusion through the nuclear pore complex and association with the nuclear compartments that have high RNA content, and therefore within the nucleolus because it is transcriptionally active.", [["nucleolus", "ANATOMY", 87, 96], ["nuclear pore", "ANATOMY", 134, 146], ["nuclear compartments", "ANATOMY", 180, 200], ["nucleolus", "ANATOMY", 254, 263], ["nucleolus", "CELLULAR_COMPONENT", 87, 96], ["nuclear", "CELLULAR_COMPONENT", 134, 141], ["nuclear", "CELLULAR_COMPONENT", 180, 187], ["nucleolus", "CELLULAR_COMPONENT", 254, 263], ["RNA viral) proteins", "PROTEIN", 43, 62], ["nuclear pore complex", "PROTEIN", 134, 154], ["viral (particularly RNA viral) proteins", "PROBLEM", 23, 62], ["high RNA content", "PROBLEM", 211, 227], ["viral", "OBSERVATION", 23, 28], ["nuclear pore", "OBSERVATION_MODIFIER", 134, 146], ["high RNA content", "OBSERVATION", 211, 227], ["transcriptionally", "OBSERVATION_MODIFIER", 278, 295], ["active", "OBSERVATION_MODIFIER", 296, 302]]], ["Although the characterization of viral life cycles determined the accumulation of several specific viral proteins within the nucleolus, until recently there was huge gap in our knowledge about the consequences.Localization of RNA virus proteins to the nucleolus: is there a benefit? ::: Hijacking the nucleolusAt present, it is apparent that nucleolar localization of viral proteins may disrupt the nucleolus and may lead to serious consequences for the cell (Matthews and Olson, 2006).", [["nucleolus", "ANATOMY", 125, 134], ["nucleolus", "ANATOMY", 252, 261], ["nucleolus", "ANATOMY", 301, 310], ["nucleolar", "ANATOMY", 342, 351], ["nucleolus", "ANATOMY", 399, 408], ["cell", "ANATOMY", 454, 458], ["nucleolus", "CELLULAR_COMPONENT", 125, 134], ["nucleolus", "CELLULAR_COMPONENT", 252, 261], ["nucleolus", "CELLULAR_COMPONENT", 301, 310], ["nucleolar", "CELLULAR_COMPONENT", 342, 351], ["nucleolus", "CELLULAR_COMPONENT", 399, 408], ["cell", "CELL", 454, 458], ["viral proteins", "PROTEIN", 99, 113], ["RNA virus proteins", "PROTEIN", 226, 244], ["viral proteins", "PROTEIN", 368, 382], ["viral life cycles", "TREATMENT", 33, 50], ["several specific viral proteins within the nucleolus", "PROBLEM", 82, 134], ["huge gap", "PROBLEM", 161, 169], ["RNA virus proteins", "PROBLEM", 226, 244], ["viral proteins", "PROBLEM", 368, 382], ["several", "OBSERVATION_MODIFIER", 82, 89], ["viral proteins", "OBSERVATION", 99, 113], ["RNA virus", "OBSERVATION", 226, 235], ["nucleolus", "OBSERVATION", 301, 310], ["viral proteins", "OBSERVATION", 368, 382]]], ["For example, the HIV\u20101 Rev protein localizes to the dense fibrillar component and is able to alter the nucleolar architecture, which in turn may lead to a dysregulation of the cell cycle and of cytokinesis (Miyazaki et al., 1996; Cannavo et al., 2001).", [["fibrillar", "ANATOMY", 58, 67], ["nucleolar", "ANATOMY", 103, 112], ["cell", "ANATOMY", 176, 180], ["HIV\u20101", "ORGANISM", 17, 22], ["Rev", "GENE_OR_GENE_PRODUCT", 23, 26], ["nucleolar", "CELLULAR_COMPONENT", 103, 112], ["cell", "CELL", 176, 180], ["HIV\u20101 Rev protein", "PROTEIN", 17, 34], ["dense fibrillar component", "PROTEIN", 52, 77], ["HIV", "SPECIES", 17, 20], ["HIV\u20101", "SPECIES", 17, 22], ["Rev protein", "TEST", 23, 34], ["the dense fibrillar component", "PROBLEM", 48, 77], ["a dysregulation of the cell cycle", "PROBLEM", 153, 186], ["cytokinesis", "PROBLEM", 194, 205], ["dense", "OBSERVATION_MODIFIER", 52, 57], ["fibrillar component", "OBSERVATION", 58, 77], ["nucleolar architecture", "OBSERVATION", 103, 125], ["cell cycle", "OBSERVATION", 176, 186]]], ["Similarly, IBV proteins interact with nucleolar proteins and cause damage to the nucleolus and failure of cytokinesis (Wurm et al., 2001; Dove et al., 2006).Localization of RNA virus proteins to the nucleolus: is there a benefit? ::: Hijacking the nucleolusOn the other hand, the localization of viral proteins to the nucleolus seems a prerequisite for replication of some viruses.", [["nucleolar", "ANATOMY", 38, 47], ["nucleolus", "ANATOMY", 81, 90], ["nucleolus", "ANATOMY", 199, 208], ["nucleolus", "ANATOMY", 318, 327], ["IBV", "ORGANISM", 11, 14], ["nucleolar", "CELLULAR_COMPONENT", 38, 47], ["nucleolus", "CELLULAR_COMPONENT", 81, 90], ["nucleolus", "CELLULAR_COMPONENT", 199, 208], ["nucleolus", "CELLULAR_COMPONENT", 318, 327], ["IBV proteins", "PROTEIN", 11, 23], ["nucleolar proteins", "PROTEIN", 38, 56], ["RNA virus proteins", "PROTEIN", 173, 191], ["viral proteins", "PROTEIN", 296, 310], ["IBV", "SPECIES", 11, 14], ["IBV proteins", "PROBLEM", 11, 23], ["nucleolar proteins", "PROBLEM", 38, 56], ["damage to the nucleolus", "PROBLEM", 67, 90], ["failure of cytokinesis", "PROBLEM", 95, 117], ["RNA virus proteins", "PROBLEM", 173, 191], ["viral proteins", "PROBLEM", 296, 310], ["some viruses", "PROBLEM", 368, 380], ["nucleolar proteins", "OBSERVATION", 38, 56], ["nucleolus", "ANATOMY", 81, 90], ["failure", "OBSERVATION_MODIFIER", 95, 102], ["cytokinesis", "OBSERVATION_MODIFIER", 106, 117], ["RNA virus", "OBSERVATION", 173, 182], ["viral proteins", "OBSERVATION", 296, 310], ["viruses", "OBSERVATION", 373, 380]]], ["For example, it has been shown that the nucleolar localization of HIV\u20101 regulatory proteins, Rev and Tat, serves an important role in virus life cycle.", [["nucleolar", "ANATOMY", 40, 49], ["nucleolar", "CELLULAR_COMPONENT", 40, 49], ["HIV\u20101", "GENE_OR_GENE_PRODUCT", 66, 71], ["Rev", "GENE_OR_GENE_PRODUCT", 93, 96], ["Tat", "GENE_OR_GENE_PRODUCT", 101, 104], ["HIV\u20101 regulatory proteins", "PROTEIN", 66, 91], ["Rev", "PROTEIN", 93, 96], ["Tat", "PROTEIN", 101, 104], ["HIV\u20101", "SPECIES", 66, 71]]], ["The function of Rev is to bind HIV RNA and assist the transportation of spliced and unspliced RNA to the cytoplasm, and therefore it is likely that the nucleolus plays a critical role in HIV\u20101 RNA export (Michienzi et al., 2000).", [["cytoplasm", "ANATOMY", 105, 114], ["nucleolus", "ANATOMY", 152, 161], ["Rev", "GENE_OR_GENE_PRODUCT", 16, 19], ["cytoplasm", "ORGANISM_SUBSTANCE", 105, 114], ["nucleolus", "CELLULAR_COMPONENT", 152, 161], ["HIV\u20101", "ORGANISM", 187, 192], ["Rev", "PROTEIN", 16, 19], ["HIV RNA", "RNA", 31, 38], ["spliced and unspliced RNA", "RNA", 72, 97], ["HIV", "SPECIES", 187, 190], ["HIV", "SPECIES", 31, 34], ["HIV\u20101", "SPECIES", 187, 192], ["is likely", "UNCERTAINTY", 133, 142]]], ["The Tat is a key regulator of HIV\u20101 replication, and studies strongly suggest that the nucleolus is implicated in the regulation of Tat activity and consequently in HIV\u20101 replication (Wei et al., 1998; Michienzi et al., 2002).Localization of RNA virus proteins to the nucleolus: is there a benefit? ::: Hijacking the nucleolusSeveral other studies also showed that viral proteins may accumulate at the nucleolus and this phenomenon is important for viral life cycle (Tijms et al., 2002; Kim et al., 2007; Pei et al., 2008).", [["nucleolus", "ANATOMY", 87, 96], ["nucleolus", "ANATOMY", 268, 277], ["nucleolus", "ANATOMY", 317, 326], ["nucleolus", "ANATOMY", 402, 411], ["Tat", "GENE_OR_GENE_PRODUCT", 4, 7], ["HIV\u20101", "ORGANISM", 30, 35], ["nucleolus", "CELLULAR_COMPONENT", 87, 96], ["Tat", "GENE_OR_GENE_PRODUCT", 132, 135], ["HIV\u20101", "ORGANISM", 165, 170], ["nucleolus", "CELLULAR_COMPONENT", 268, 277], ["nucleolus", "CELLULAR_COMPONENT", 317, 326], ["nucleolus", "CELLULAR_COMPONENT", 402, 411], ["Tat", "PROTEIN", 4, 7], ["Tat", "PROTEIN", 132, 135], ["RNA virus proteins", "PROTEIN", 242, 260], ["viral proteins", "PROTEIN", 365, 379], ["HIV", "SPECIES", 30, 33], ["HIV", "SPECIES", 165, 168], ["HIV\u20101", "SPECIES", 30, 35], ["HIV\u20101", "SPECIES", 165, 170], ["studies", "TEST", 53, 60], ["RNA virus proteins", "PROBLEM", 242, 260], ["other studies", "TEST", 334, 347], ["viral proteins", "PROBLEM", 365, 379], ["RNA virus", "OBSERVATION", 242, 251], ["viral proteins", "OBSERVATION", 365, 379]]], ["However, the precise role of the nucleolus in viral pathogenesis remains poorly understood and further investigations will be necessary to shed light on the all aspects of interaction between nucleolus and viral proteins.DNA viruses ::: Overcoming the PML NBsIt was shown that the parental genomes of herpes simplex virus type 1 (HSV\u20101), human cytomegalovirus (HCMV) and adenovirus are closely associated with PML NBs (Ishov and Maul, 1996).", [["nucleolus", "ANATOMY", 33, 42], ["nucleolus", "ANATOMY", 192, 201], ["PML NBs", "ANATOMY", 252, 259], ["PML NBs", "ANATOMY", 410, 417], ["herpes simplex virus", "DISEASE", 301, 321], ["human cytomegalovirus (HCMV)", "DISEASE", 338, 366], ["nucleolus", "CELLULAR_COMPONENT", 33, 42], ["nucleolus", "CELLULAR_COMPONENT", 192, 201], ["DNA", "CELLULAR_COMPONENT", 221, 224], ["PML", "GENE_OR_GENE_PRODUCT", 252, 255], ["herpes simplex virus type 1", "ORGANISM", 301, 328], ["HSV\u20101", "ORGANISM", 330, 335], ["human cytomegalovirus", "ORGANISM", 338, 359], ["HCMV", "ORGANISM", 361, 365], ["adenovirus", "ORGANISM", 371, 381], ["viral proteins", "PROTEIN", 206, 220], ["herpes simplex virus type 1", "SPECIES", 301, 328], ["HSV\u20101", "SPECIES", 330, 335], ["human", "SPECIES", 338, 343], ["cytomegalovirus", "SPECIES", 344, 359], ["herpes simplex virus type 1", "SPECIES", 301, 328], ["HSV\u20101", "SPECIES", 330, 335], ["human cytomegalovirus", "SPECIES", 338, 359], ["HCMV", "SPECIES", 361, 365], ["adenovirus", "SPECIES", 371, 381], ["further investigations", "TEST", 95, 117], ["nucleolus and viral proteins", "PROBLEM", 192, 220], ["the PML NBs", "TEST", 248, 259], ["herpes simplex virus type", "PROBLEM", 301, 326], ["HSV", "TEST", 330, 333], ["human cytomegalovirus (HCMV", "PROBLEM", 338, 365], ["adenovirus", "PROBLEM", 371, 381], ["nucleolus", "OBSERVATION", 33, 42], ["viral", "OBSERVATION", 46, 51], ["viral proteins", "OBSERVATION", 206, 220], ["viruses", "OBSERVATION", 225, 232], ["PML NBs", "OBSERVATION", 252, 259], ["cytomegalovirus", "OBSERVATION", 344, 359]]], ["The consequences of association were unclear for many years, but recent studies revealed the importance of this event for intrinsic defence against DNA viruses (Everett, 2006).", [["DNA", "CELLULAR_COMPONENT", 148, 151], ["recent studies", "TEST", 65, 79], ["DNA viruses", "PROBLEM", 148, 159]]], ["In turn, DNA viruses, especially herpesviruses, counteract this intracellular defence by modifying PML NBs.DNA viruses ::: Overcoming the PML NBsHerpes simplex virus 1 was the first virus to be shown to disrupt PML NBs early during infection.", [["intracellular", "ANATOMY", 64, 77], ["PML NBs", "ANATOMY", 99, 106], ["PML NBs", "ANATOMY", 211, 218], ["Herpes simplex virus", "DISEASE", 145, 165], ["infection", "DISEASE", 232, 241], ["DNA", "CELLULAR_COMPONENT", 9, 12], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 64, 77], ["PML NBs", "GENE_OR_GENE_PRODUCT", 99, 106], ["DNA", "CELLULAR_COMPONENT", 107, 110], ["PML NBs", "ORGANISM", 138, 145], ["Herpes simplex virus 1", "ORGANISM", 145, 167], ["PML NBs", "GENE_OR_GENE_PRODUCT", 211, 218], ["Herpes simplex virus", "SPECIES", 145, 165], ["Herpes simplex virus 1", "SPECIES", 145, 167], ["DNA viruses", "PROBLEM", 9, 20], ["herpesviruses", "PROBLEM", 33, 46], ["DNA viruses", "PROBLEM", 107, 118], ["the PML NBsHerpes simplex virus", "PROBLEM", 134, 165], ["the first virus", "PROBLEM", 172, 187], ["PML NBs", "PROBLEM", 211, 218], ["infection", "PROBLEM", 232, 241], ["DNA viruses", "OBSERVATION", 9, 20], ["PML NBs", "OBSERVATION", 99, 106], ["viruses", "OBSERVATION", 111, 118], ["PML", "OBSERVATION", 138, 141], ["Herpes", "OBSERVATION_MODIFIER", 145, 151], ["simplex virus", "OBSERVATION", 152, 165], ["PML", "OBSERVATION", 211, 214], ["infection", "OBSERVATION", 232, 241]]], ["The observation that HSV\u20101 affects PML NBs, whereas an ICP0\u2010deficient mutant does not, led to the identification of the importance of ICP0 for this effect (Maul et al., 1993; Everett and Maul, 1994).", [["PML NBs", "ANATOMY", 35, 42], ["HSV\u20101", "ORGANISM", 21, 26], ["PML NBs", "GENE_OR_GENE_PRODUCT", 35, 42], ["ICP0", "GENE_OR_GENE_PRODUCT", 55, 59], ["ICP0", "GENE_OR_GENE_PRODUCT", 134, 138], ["ICP0", "PROTEIN", 55, 59], ["ICP0", "PROTEIN", 134, 138], ["HSV\u20101", "SPECIES", 21, 26], ["The observation", "TEST", 0, 15], ["HSV", "TEST", 21, 24], ["PML NBs", "PROBLEM", 35, 42], ["ICP0", "TREATMENT", 134, 138]]], ["The ICP0 protein contains a RING finger domain with ubiquitin E3 ligase activity, which induces the degradation of PML, leading to the release of other proteins of PML NBs (Parkinson and Everett, 2000).", [["PML NBs", "ANATOMY", 164, 171], ["ICP0", "GENE_OR_GENE_PRODUCT", 4, 8], ["PML", "GENE_OR_GENE_PRODUCT", 115, 118], ["PML NBs", "GENE_OR_GENE_PRODUCT", 164, 171], ["ICP0 protein", "PROTEIN", 4, 16], ["RING finger domain", "PROTEIN", 28, 46], ["ubiquitin E3 ligase", "PROTEIN", 52, 71], ["PML", "PROTEIN", 115, 118], ["The ICP0 protein", "TEST", 0, 16], ["a RING finger domain", "PROBLEM", 26, 46], ["ubiquitin E3 ligase activity", "PROBLEM", 52, 80], ["the degradation of PML", "PROBLEM", 96, 118], ["PML NBs", "PROBLEM", 164, 171], ["ICP0 protein", "OBSERVATION", 4, 16], ["RING finger", "OBSERVATION", 28, 39], ["ubiquitin E3", "OBSERVATION", 52, 64], ["ligase activity", "OBSERVATION", 65, 80], ["PML", "OBSERVATION", 115, 118], ["PML NBs", "OBSERVATION", 164, 171]]], ["Proteins with similar, ND10\u2010modifying functions have been identified for other herpesviruses, including human cytomegalovirus (pp71 and IE1) and Epstein\u2010Barr virus (EBNA LP).", [["ND10", "GENE_OR_GENE_PRODUCT", 23, 27], ["herpesviruses", "ORGANISM", 79, 92], ["human", "ORGANISM", 104, 109], ["cytomegalovirus", "ORGANISM", 110, 125], ["pp71", "GENE_OR_GENE_PRODUCT", 127, 131], ["IE1", "GENE_OR_GENE_PRODUCT", 136, 139], ["Epstein\u2010Barr virus", "ORGANISM", 145, 163], ["EBNA", "ORGANISM", 165, 169], ["LP", "ORGANISM", 170, 172], ["ND10", "PROTEIN", 23, 27], ["IE1", "PROTEIN", 136, 139], ["human", "SPECIES", 104, 109], ["human cytomegalovirus", "SPECIES", 104, 125], ["Epstein\u2010Barr virus", "SPECIES", 145, 163], ["Proteins", "TEST", 0, 8], ["other herpesviruses", "PROBLEM", 73, 92], ["human cytomegalovirus", "PROBLEM", 104, 125], ["IE1", "TEST", 136, 139], ["Epstein\u2010Barr virus", "PROBLEM", 145, 163], ["EBNA LP", "TEST", 165, 172], ["cytomegalovirus", "OBSERVATION", 110, 125], ["Barr virus", "OBSERVATION", 153, 163]]], ["The cytomegalovirus structural protein pp71 accumulates at PML NBs and is able to induce the proteasomal degradation of hDaxx (Saffert and Kalejta, 2006).", [["PML NBs", "ANATOMY", 59, 66], ["proteasomal", "ANATOMY", 93, 104], ["cytomegalovirus", "ORGANISM", 4, 19], ["pp71", "GENE_OR_GENE_PRODUCT", 39, 43], ["hDaxx", "GENE_OR_GENE_PRODUCT", 120, 125], ["cytomegalovirus structural protein", "PROTEIN", 4, 38], ["pp71", "PROTEIN", 39, 43], ["hDaxx", "PROTEIN", 120, 125], ["The cytomegalovirus structural protein", "TEST", 0, 38], ["cytomegalovirus", "OBSERVATION", 4, 19], ["protein pp71", "OBSERVATION", 31, 43], ["PML NBs", "OBSERVATION", 59, 66]]], ["Thus, pp71 can antagonize the cellular repression of immediate early gene expression.", [["cellular", "ANATOMY", 30, 38], ["pp71", "CHEMICAL", 6, 10], ["pp71", "GENE_OR_GENE_PRODUCT", 6, 10], ["cellular", "CELL", 30, 38], ["pp71", "PROTEIN", 6, 10], ["gene expression", "OBSERVATION", 69, 84]]], ["Consequently, the IE72 protein is synthesized, which then localizes to PML NBs and dissociates them through an abrogation of PML SUMOylation (Kang et al., 2006).", [["PML NBs", "ANATOMY", 71, 78], ["IE72", "GENE_OR_GENE_PRODUCT", 18, 22], ["PML NBs", "GENE_OR_GENE_PRODUCT", 71, 78], ["PML", "GENE_OR_GENE_PRODUCT", 125, 128], ["IE72 protein", "PROTEIN", 18, 30], ["PML", "PROTEIN", 125, 128], ["the IE72 protein", "TEST", 14, 30], ["PML NBs", "PROBLEM", 71, 78], ["PML SUMOylation", "TREATMENT", 125, 140], ["PML NBs", "OBSERVATION", 71, 78], ["PML SUMOylation", "OBSERVATION", 125, 140]]], ["In case of Epstein\u2010Barr virus, EBNA LP dislocates Sp100 from PML NB, leading to an alteration of this nuclear body (Ling et al., 2005).DNA viruses ::: Overcoming the PML NBsInfection with human adenovirus type 5 (Ad5) results in a repartition of PML NBs into elongated tracks during the early hours of infection (Doucas et al., 1996).", [["PML NB", "ANATOMY", 61, 67], ["nuclear body", "ANATOMY", 102, 114], ["PML NBs", "ANATOMY", 246, 253], ["infection", "DISEASE", 302, 311], ["Epstein\u2010Barr virus", "ORGANISM", 11, 29], ["EBNA", "GENE_OR_GENE_PRODUCT", 31, 35], ["Sp100", "GENE_OR_GENE_PRODUCT", 50, 55], ["PML NB", "CANCER", 61, 67], ["DNA", "CELLULAR_COMPONENT", 135, 138], ["PML", "GENE_OR_GENE_PRODUCT", 166, 169], ["human adenovirus type 5", "ORGANISM", 188, 211], ["Ad5", "ORGANISM", 213, 216], ["PML NBs", "GENE_OR_GENE_PRODUCT", 246, 253], ["EBNA LP", "PROTEIN", 31, 38], ["Sp100", "PROTEIN", 50, 55], ["human", "SPECIES", 188, 193], ["Epstein\u2010Barr virus", "SPECIES", 11, 29], ["human adenovirus type 5", "SPECIES", 188, 211], ["Ad5", "SPECIES", 213, 216], ["Epstein\u2010Barr virus", "PROBLEM", 11, 29], ["EBNA LP", "TEST", 31, 38], ["PML NB", "PROBLEM", 61, 67], ["the PML NBsInfection", "PROBLEM", 162, 182], ["human adenovirus type 5 (Ad5", "TREATMENT", 188, 216], ["PML NBs", "PROBLEM", 246, 253], ["elongated tracks", "PROBLEM", 259, 275], ["infection", "PROBLEM", 302, 311], ["Barr virus", "OBSERVATION", 19, 29], ["PML NB", "OBSERVATION", 61, 67], ["alteration", "OBSERVATION", 83, 93], ["body", "ANATOMY", 110, 114], ["viruses", "OBSERVATION", 139, 146], ["PML", "OBSERVATION", 166, 169], ["PML NBs", "OBSERVATION", 246, 253], ["elongated", "OBSERVATION_MODIFIER", 259, 268], ["tracks", "OBSERVATION_MODIFIER", 269, 275], ["infection", "OBSERVATION", 302, 311]]], ["By screening a variety of Ad5 mutants, viral E4 ORF3 early protein was identified as key protein that induces the rearrangement of PML NBs into track\u2010like structures.", [["PML NBs", "ANATOMY", 131, 138], ["track\u2010like structures", "ANATOMY", 144, 165], ["Ad5", "ORGANISM", 26, 29], ["E4", "GENE_OR_GENE_PRODUCT", 45, 47], ["PML NBs", "GENE_OR_GENE_PRODUCT", 131, 138], ["Ad5 mutants", "PROTEIN", 26, 37], ["viral E4 ORF3 early protein", "PROTEIN", 39, 66], ["Ad5", "SPECIES", 26, 29], ["E4", "SPECIES", 45, 47], ["Ad5 mutants", "TREATMENT", 26, 37], ["viral E4 ORF3 early protein", "TEST", 39, 66], ["PML NBs", "OBSERVATION", 131, 138]]], ["Until recently the significance of E4 ORF3\u2010induced PML NBs track formation was obscure.", [["PML NBs", "ANATOMY", 51, 58], ["E4", "GENE_OR_GENE_PRODUCT", 35, 37], ["PML", "GENE_OR_GENE_PRODUCT", 51, 54], ["E4 ORF3", "DNA", 35, 42], ["E4", "SPECIES", 35, 37], ["E4 ORF3", "PROBLEM", 35, 42]]], ["Recent studies by Ullman and colleagues showed that the replication of an E4 ORF3 deletion virus is restricted in cells that are pretreated with IFN\u2010\u03b1 or IFN\u2010\u03b3, thus revealing the role of E4 ORF3 in viral counteraction against IFN\u2010induced antiviral response (Ullman et al., 2007).", [["cells", "ANATOMY", 114, 119], ["IFN", "CHEMICAL", 227, 230], ["E4", "GENE_OR_GENE_PRODUCT", 74, 76], ["cells", "CELL", 114, 119], ["IFN\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 145, 150], ["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 154, 159], ["E4 ORF3", "GENE_OR_GENE_PRODUCT", 188, 195], ["E4 ORF3 deletion", "DNA", 74, 90], ["IFN\u2010\u03b1", "PROTEIN", 145, 150], ["IFN\u2010\u03b3", "PROTEIN", 154, 159], ["E4 ORF3", "DNA", 188, 195], ["IFN", "PROTEIN", 227, 230], ["E4", "SPECIES", 74, 76], ["E4", "SPECIES", 188, 190], ["Recent studies", "TEST", 0, 14], ["an E4 ORF3 deletion virus", "PROBLEM", 71, 96], ["E4 ORF3", "TREATMENT", 188, 195], ["IFN", "PROBLEM", 227, 230], ["viral counteraction", "OBSERVATION", 199, 218]]], ["The exact mechanism by which E4 ORF3 helps Ad5 to overcome PML NBs is still unclear.", [["PML NBs", "ANATOMY", 59, 66], ["E4", "GENE_OR_GENE_PRODUCT", 29, 31], ["Ad5", "ORGANISM", 43, 46], ["PML NBs", "GENE_OR_GENE_PRODUCT", 59, 66], ["E4 ORF3", "PROTEIN", 29, 36], ["Ad5", "SPECIES", 43, 46], ["E4 ORF3", "TREATMENT", 29, 36], ["PML NBs", "PROBLEM", 59, 66]]], ["Instead, it was reported that another Ad5 protein, E1B\u201055K, may induce the degradation of hDaxx by a proteasome\u2010dependent pathway, thus antagonizing the antiviral activity of PML NBs (Schreiner et al., 2010).", [["PML NBs", "ANATOMY", 175, 182], ["Ad5", "ORGANISM", 38, 41], ["E1B\u201055K", "GENE_OR_GENE_PRODUCT", 51, 58], ["hDaxx", "GENE_OR_GENE_PRODUCT", 90, 95], ["PML NBs", "GENE_OR_GENE_PRODUCT", 175, 182], ["Ad5 protein", "PROTEIN", 38, 49], ["E1B\u201055K", "PROTEIN", 51, 58], ["hDaxx", "PROTEIN", 90, 95], ["proteasome", "PROTEIN", 101, 111], ["Ad5", "SPECIES", 38, 41], ["another Ad5 protein", "TEST", 30, 49], ["hDaxx", "TREATMENT", 90, 95], ["a proteasome\u2010dependent pathway", "TREATMENT", 99, 129]]], ["This finding demonstrates that E4 ORF3 is most probably not the only adenoviral protein involved in viral countermeasures against ND10, and further studies may reveal additional proteins like E1B\u201055K.RNA viruses ::: Overcoming the PML NBsExamination of the functional role of PML in vivo demonstrated that fibroblasts derived from PML \u2212/\u2212 mice are much more sensitive to some RNA viruses, such as rhabdoviruses vesicular stomatitis and rabies virus, and the arenavirus lymphocytic choriomeningitis virus.", [["fibroblasts", "ANATOMY", 306, 317], ["vesicular stomatitis", "DISEASE", 411, 431], ["rabies virus", "DISEASE", 436, 448], ["arenavirus lymphocytic choriomeningitis virus", "DISEASE", 458, 503], ["E4", "GENE_OR_GENE_PRODUCT", 31, 33], ["adenoviral", "ORGANISM", 69, 79], ["ND10", "GENE_OR_GENE_PRODUCT", 130, 134], ["E1B", "GENE_OR_GENE_PRODUCT", 192, 195], ["55K", "GENE_OR_GENE_PRODUCT", 196, 199], ["PML", "GENE_OR_GENE_PRODUCT", 231, 234], ["PML", "GENE_OR_GENE_PRODUCT", 276, 279], ["fibroblasts", "CELL", 306, 317], ["PML", "GENE_OR_GENE_PRODUCT", 331, 334], ["rhabdoviruses vesicular stomatitis", "ORGANISM", 397, 431], ["rabies virus", "ORGANISM", 436, 448], ["arenavirus lymphocytic choriomeningitis virus", "ORGANISM", 458, 503], ["E4 ORF3", "DNA", 31, 38], ["adenoviral protein", "PROTEIN", 69, 87], ["ND10", "PROTEIN", 130, 134], ["E1B", "PROTEIN", 192, 195], ["55K", "PROTEIN", 196, 199], ["PML", "PROTEIN", 276, 279], ["fibroblasts", "CELL_TYPE", 306, 317], ["mice", "SPECIES", 339, 343], ["rabies virus", "SPECIES", 436, 448], ["arenavirus lymphocytic choriomeningitis virus", "SPECIES", 458, 503], ["E4", "SPECIES", 31, 33], ["mice", "SPECIES", 339, 343], ["rabies virus", "SPECIES", 436, 448], ["arenavirus lymphocytic choriomeningitis virus", "SPECIES", 458, 503], ["E4 ORF3", "PROBLEM", 31, 38], ["viral countermeasures", "TREATMENT", 100, 121], ["ND10", "PROBLEM", 130, 134], ["further studies", "TEST", 140, 155], ["additional proteins like E1B", "PROBLEM", 167, 195], ["PML", "PROBLEM", 276, 279], ["fibroblasts", "PROBLEM", 306, 317], ["PML", "PROBLEM", 331, 334], ["some RNA viruses", "PROBLEM", 371, 387], ["rhabdoviruses vesicular stomatitis", "PROBLEM", 397, 431], ["rabies virus", "PROBLEM", 436, 448], ["the arenavirus lymphocytic choriomeningitis virus", "PROBLEM", 454, 503], ["most probably not", "UNCERTAINTY", 42, 59], ["viruses", "OBSERVATION", 204, 211], ["PML", "OBSERVATION", 231, 234], ["PML", "OBSERVATION", 276, 279], ["RNA viruses", "OBSERVATION", 376, 387], ["vesicular stomatitis", "OBSERVATION", 411, 431], ["rabies virus", "OBSERVATION", 436, 448], ["arenavirus lymphocytic", "OBSERVATION", 458, 480], ["choriomeningitis virus", "OBSERVATION", 481, 503]]], ["This and several other findings implicate PML in an intrinsic antiviral response of the cell that targets not only DNA but also RNA viruses (Djavani et al., 2001; Bonilla et al., 2002; Blondel et al., 2010).", [["cell", "ANATOMY", 88, 92], ["PML", "GENE_OR_GENE_PRODUCT", 42, 45], ["cell", "CELL", 88, 92], ["DNA", "CELLULAR_COMPONENT", 115, 118], ["PML", "PROTEIN", 42, 45], ["PML", "PROBLEM", 42, 45], ["PML", "OBSERVATION", 42, 45], ["antiviral response", "OBSERVATION", 62, 80]]], ["Like DNA viruses, RNA viruses have evolved different ways to impair the cellular antiviral response.", [["cellular", "ANATOMY", 72, 80], ["DNA", "CELLULAR_COMPONENT", 5, 8], ["RNA viruses", "ORGANISM", 18, 29], ["cellular", "CELL", 72, 80], ["DNA viruses", "PROBLEM", 5, 16], ["RNA viruses", "PROBLEM", 18, 29], ["DNA viruses", "OBSERVATION", 5, 16], ["RNA viruses", "OBSERVATION", 18, 29], ["cellular antiviral response", "OBSERVATION", 72, 99]]], ["For example, the lymphocytic choriomeningitis virus RING finger protein Z with an unknown function targets and redistributes PML to the cytoplasm (Borden et al., 1998).", [["PML", "ANATOMY", 125, 128], ["cytoplasm", "ANATOMY", 136, 145], ["lymphocytic choriomeningitis virus", "ORGANISM", 17, 51], ["RING finger protein Z", "GENE_OR_GENE_PRODUCT", 52, 73], ["PML", "GENE_OR_GENE_PRODUCT", 125, 128], ["cytoplasm", "ORGANISM_SUBSTANCE", 136, 145], ["lymphocytic choriomeningitis virus RING finger protein Z", "PROTEIN", 17, 73], ["PML", "PROTEIN", 125, 128], ["lymphocytic choriomeningitis virus", "SPECIES", 17, 51], ["lymphocytic choriomeningitis virus", "SPECIES", 17, 51], ["the lymphocytic choriomeningitis virus RING finger protein Z", "PROBLEM", 13, 73], ["redistributes PML", "PROBLEM", 111, 128], ["lymphocytic choriomeningitis", "OBSERVATION", 17, 45], ["function targets", "OBSERVATION", 90, 106], ["redistributes PML", "OBSERVATION", 111, 128], ["cytoplasm", "OBSERVATION_MODIFIER", 136, 145]]], ["Rabies virus phosphoprotein P and four other amino\u2010terminally truncated products (P2, P3, P4 and P5) are involved in virus\u2010induced reorganization of PML NBs (Blondel et al., 2002).", [["PML NBs", "ANATOMY", 149, 156], ["Rabies virus", "ORGANISM", 0, 12], ["P4", "GENE_OR_GENE_PRODUCT", 90, 92], ["P5", "GENE_OR_GENE_PRODUCT", 97, 99], ["PML", "GENE_OR_GENE_PRODUCT", 149, 152], ["Rabies virus phosphoprotein P", "PROTEIN", 0, 29], ["amino\u2010terminally truncated products", "PROTEIN", 45, 80], ["P2", "PROTEIN", 82, 84], ["P3", "PROTEIN", 86, 88], ["P4", "PROTEIN", 90, 92], ["P5", "PROTEIN", 97, 99], ["Rabies virus", "SPECIES", 0, 12], ["Rabies virus", "SPECIES", 0, 12], ["Rabies virus phosphoprotein P", "TREATMENT", 0, 29], ["four other amino\u2010terminally truncated products", "TREATMENT", 34, 80], ["P2, P3, P4 and P5", "TREATMENT", 82, 99], ["PML NBs", "OBSERVATION", 149, 156]]], ["Encephalomyocarditis virus 3C protease co\u2010localizes with PML within nuclear bodies and induces the degradation of PML in a proteasome\u2010 and SUMO\u2010dependent manner (El McHichi et al., 2010).", [["nuclear bodies", "ANATOMY", 68, 82], ["Encephalomyocarditis", "DISEASE", 0, 20], ["Encephalomyocarditis virus 3C", "ORGANISM", 0, 29], ["PML", "GENE_OR_GENE_PRODUCT", 57, 60], ["nuclear bodies", "CELLULAR_COMPONENT", 68, 82], ["PML", "GENE_OR_GENE_PRODUCT", 114, 117], ["SUMO", "GENE_OR_GENE_PRODUCT", 139, 143], ["Encephalomyocarditis virus 3C protease", "PROTEIN", 0, 38], ["PML", "PROTEIN", 57, 60], ["PML", "PROTEIN", 114, 117], ["SUMO", "PROTEIN", 139, 143], ["Encephalomyocarditis virus 3C", "SPECIES", 0, 29], ["Encephalomyocarditis virus", "PROBLEM", 0, 26], ["3C protease co\u2010localizes", "TREATMENT", 27, 51], ["PML within nuclear bodies", "PROBLEM", 57, 82], ["the degradation of PML", "PROBLEM", 95, 117], ["PML", "OBSERVATION", 57, 60], ["nuclear bodies", "OBSERVATION_MODIFIER", 68, 82], ["PML", "OBSERVATION", 114, 117]]], ["Within the family of retroviruses human T\u2010cell leukaemia virus type 1 encodes the Tax oncoprotein that has been demonstrated to alter the localization of a PML NB\u2010associated protein known as Int\u20106 (Desbois et al., 1996).", [["T\u2010cell leukaemia", "DISEASE", 40, 56], ["retroviruses", "ORGANISM", 21, 33], ["human T\u2010cell leukaemia virus type 1", "ORGANISM", 34, 69], ["Tax", "GENE_OR_GENE_PRODUCT", 82, 85], ["PML NB\u2010", "GENE_OR_GENE_PRODUCT", 156, 163], ["Int\u20106", "GENE_OR_GENE_PRODUCT", 191, 196], ["Tax oncoprotein", "PROTEIN", 82, 97], ["PML NB\u2010associated protein", "PROTEIN", 156, 181], ["Int\u20106", "PROTEIN", 191, 196], ["human", "SPECIES", 34, 39], ["T\u2010cell leukaemia virus", "SPECIES", 40, 62], ["human T\u2010cell leukaemia virus type 1", "SPECIES", 34, 69], ["retroviruses human T\u2010cell leukaemia virus", "PROBLEM", 21, 62], ["PML NB", "OBSERVATION", 156, 162]]], ["Although PML NBs are thought to be implicated in retroviral pathogenesis, their role for retroviruses is still not fully understood.Other nuclear alterationsAbove, we discussed two subnuclear structures that are mostly by viruses.", [["PML NBs", "ANATOMY", 9, 16], ["nuclear", "ANATOMY", 138, 145], ["subnuclear structures", "ANATOMY", 181, 202], ["PML NBs", "GENE_OR_GENE_PRODUCT", 9, 16], ["retroviral", "ORGANISM", 49, 59], ["retroviruses", "ORGANISM", 89, 101], ["nuclear", "CELLULAR_COMPONENT", 138, 145], ["PML NBs", "PROBLEM", 9, 16], ["retroviral pathogenesis", "PROBLEM", 49, 72], ["retroviruses", "TREATMENT", 89, 101], ["Other nuclear alterations", "PROBLEM", 132, 157], ["PML NBs", "OBSERVATION", 9, 16], ["thought to be", "UNCERTAINTY", 21, 34], ["retroviral pathogenesis", "OBSERVATION", 49, 72], ["alterations", "OBSERVATION", 146, 157], ["subnuclear structures", "OBSERVATION", 181, 202], ["viruses", "OBSERVATION", 222, 229]]], ["However, during viral infections several other subnuclear structures, including the transport machinery (Fontoura et al., 2005), Cajal bodies (Kim et al., 2007), the nuclear lamina (Camozzi et al., 2008), as well as chromatin (You, 2010), are also targeted.", [["subnuclear structures", "ANATOMY", 47, 68], ["Cajal bodies", "ANATOMY", 129, 141], ["nuclear lamina", "ANATOMY", 166, 180], ["chromatin", "ANATOMY", 216, 225], ["viral infections", "DISEASE", 16, 32], ["nuclear lamina", "CELLULAR_COMPONENT", 166, 180], ["chromatin", "CELLULAR_COMPONENT", 216, 225], ["chromatin", "DNA", 216, 225], ["viral infections", "PROBLEM", 16, 32], ["viral", "OBSERVATION_MODIFIER", 16, 21], ["infections", "OBSERVATION", 22, 32], ["subnuclear structures", "OBSERVATION", 47, 68], ["Cajal bodies", "ANATOMY", 129, 141], ["nuclear lamina", "ANATOMY", 166, 180]]], ["Moreover, viruses can induce profound changes of the overall nuclear architecture.", [["nuclear", "ANATOMY", 61, 68], ["nuclear", "CELLULAR_COMPONENT", 61, 68], ["viruses", "PROBLEM", 10, 17], ["viruses", "OBSERVATION", 10, 17], ["profound", "OBSERVATION_MODIFIER", 29, 37], ["overall", "OBSERVATION_MODIFIER", 53, 60], ["nuclear architecture", "OBSERVATION", 61, 81]]], ["For example, African swine fever virus, a double\u2010stranded DNA virus that mainly replicates in the monocyte\u2010macrophage cell lineage and causes a lethal haemorraghic disease in domestic pigs, is prone to split the host cell nucleus.", [["monocyte\u2010macrophage cell lineage", "ANATOMY", 98, 130], ["cell nucleus", "ANATOMY", 217, 229], ["swine fever", "DISEASE", 21, 32], ["haemorraghic disease", "DISEASE", 151, 171], ["African swine fever virus", "ORGANISM", 13, 38], ["DNA", "CELLULAR_COMPONENT", 58, 61], ["monocyte\u2010macrophage cell lineage", "CELL", 98, 130], ["pigs", "ORGANISM", 184, 188], ["cell nucleus", "CELLULAR_COMPONENT", 217, 229], ["monocyte\u2010macrophage cell lineage", "CELL_TYPE", 98, 130], ["swine fever virus", "SPECIES", 21, 38], ["pigs", "SPECIES", 184, 188], ["African swine fever virus", "SPECIES", 13, 38], ["pigs", "SPECIES", 184, 188], ["African swine fever virus", "PROBLEM", 13, 38], ["a double\u2010stranded DNA virus", "PROBLEM", 40, 67], ["a lethal haemorraghic disease in domestic pigs", "PROBLEM", 142, 188], ["monocyte\u2010macrophage cell lineage", "OBSERVATION", 98, 130], ["lethal", "OBSERVATION_MODIFIER", 144, 150], ["haemorraghic", "OBSERVATION_MODIFIER", 151, 163], ["disease", "OBSERVATION", 164, 171], ["domestic pigs", "OBSERVATION", 175, 188], ["host cell nucleus", "OBSERVATION", 212, 229]]], ["Recently, we described the presence of an additional nucleus in cells that were infected with African swine fever virus.", [["nucleus", "ANATOMY", 53, 60], ["cells", "ANATOMY", 64, 69], ["swine fever", "DISEASE", 102, 113], ["nucleus", "CELLULAR_COMPONENT", 53, 60], ["cells", "CELL", 64, 69], ["African swine fever virus", "ORGANISM", 94, 119], ["swine fever virus", "SPECIES", 102, 119], ["African swine fever virus", "SPECIES", 94, 119], ["an additional nucleus in cells", "PROBLEM", 39, 69], ["African swine fever virus", "PROBLEM", 94, 119], ["nucleus in cells", "OBSERVATION", 53, 69], ["infected", "OBSERVATION_MODIFIER", 80, 88]]], ["The cytophotometry revealed that the DNA content in both nuclei did not exceed the diploid standard, which indicates that the additional nucleus was a consequence of fragmentation of cell nucleus (Karalova et al., 2011).", [["nuclei", "ANATOMY", 57, 63], ["nucleus", "ANATOMY", 137, 144], ["cell nucleus", "ANATOMY", 183, 195], ["DNA", "CELLULAR_COMPONENT", 37, 40], ["nuclei", "CELLULAR_COMPONENT", 57, 63], ["nucleus", "CELLULAR_COMPONENT", 137, 144], ["cell nucleus", "CELLULAR_COMPONENT", 183, 195], ["The cytophotometry", "TEST", 0, 18], ["the DNA content", "TEST", 33, 48], ["the additional nucleus", "PROBLEM", 122, 144], ["fragmentation of cell nucleus", "PROBLEM", 166, 195], ["DNA content", "OBSERVATION", 37, 48], ["diploid standard", "OBSERVATION", 83, 99], ["fragmentation", "OBSERVATION", 166, 179], ["cell nucleus", "OBSERVATION", 183, 195]]], ["However, the mechanism of fragmentation remains obscure and warrants further investigation.Concluding remarksUntil recently, with some exceptions, research into the interactions between viruses and the nucleus has been descriptive.", [["nucleus", "ANATOMY", 202, 209], ["nucleus", "CELLULAR_COMPONENT", 202, 209], ["fragmentation", "PROBLEM", 26, 39], ["further investigation", "TEST", 69, 90], ["fragmentation", "OBSERVATION", 26, 39], ["nucleus", "ANATOMY", 202, 209]]], ["The functional implications of these interactions are now being realized and progress is being made to clarify how and why viruses modify subnuclear structures.", [["subnuclear structures", "ANATOMY", 138, 159], ["subnuclear structures", "CELLULAR_COMPONENT", 138, 159]]], ["At the same time, many questions concerning virus\u2013nucleus interactions remain open.", [["virus\u2013nucleus", "ANATOMY", 44, 57], ["virus\u2013nucleus", "GENE_OR_GENE_PRODUCT", 44, 57], ["virus\u2013nucleus interactions", "PROBLEM", 44, 70]]], ["For example, it is still unclear why RNA virus proteins localize to the nucleolus or whether the PML NBs play a role for establishing herpesviral latency.", [["nucleolus", "ANATOMY", 72, 81], ["PML NBs", "ANATOMY", 97, 104], ["herpesviral", "ANATOMY", 134, 145], ["nucleolus", "CELLULAR_COMPONENT", 72, 81], ["PML NBs", "GENE_OR_GENE_PRODUCT", 97, 104], ["RNA virus proteins", "PROTEIN", 37, 55], ["RNA virus proteins", "PROBLEM", 37, 55], ["herpesviral latency", "PROBLEM", 134, 153], ["PML", "OBSERVATION", 97, 100]]], ["Thus, further studies are likely to provide new and exciting insights into viral and cellular biology as well as to uncover new avenues of therapeutic interests.", [["cellular", "ANATOMY", 85, 93], ["cellular", "CELL", 85, 93], ["further studies", "TEST", 6, 21]]]], "0d1875492a9f3620292a71fdc9d0060bb11b7d0c": [["IntroductionAll over the world, severe Acute Respiratory Syndrome tum and sore throat [ 6 , 7 ] .", [["Acute Respiratory Syndrome tum", "DISEASE", 39, 69], ["sore throat", "DISEASE", 74, 85], ["Acute Respiratory Syndrome tum", "SPECIES", 39, 69], ["severe Acute Respiratory Syndrome tum", "PROBLEM", 32, 69], ["sore throat", "PROBLEM", 74, 85], ["severe", "OBSERVATION_MODIFIER", 32, 38], ["Acute", "OBSERVATION_MODIFIER", 39, 44], ["Respiratory Syndrome", "OBSERVATION", 45, 65]]], ["In fact, however, many patients are 17 asymptomatic or have mild symptoms in early stages, and 18 so they do not realize being infected.", [["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["mild symptoms", "PROBLEM", 60, 73], ["infected", "PROBLEM", 127, 135], ["mild", "OBSERVATION_MODIFIER", 60, 64], ["symptoms", "OBSERVATION", 65, 73], ["infected", "OBSERVATION", 127, 135]]], ["Since COVID-19 is 19 highly contagious in early stages, such lack of recognition 20 can cause serious problems for the prevention of the spread 21 of COVID-19.", [["COVID-19", "DNA", 6, 14], ["COVID", "TEST", 6, 11], ["serious problems", "PROBLEM", 94, 110], ["COVID", "TEST", 150, 155], ["19 highly", "OBSERVATION_MODIFIER", 18, 27], ["contagious", "OBSERVATION_MODIFIER", 28, 38], ["early stages", "OBSERVATION_MODIFIER", 42, 54]]], ["Therefore, detection of COVID-19 in early, 22 even asymptomatic, stages will help us reduce transmission.", [["COVID-19", "DNA", 24, 32], ["COVID", "TEST", 24, 29]]], ["23 Recently, olfactory or gustatory dysfunction is often re- 24 ported as a symptom [ 8 , 9 ] .", [["olfactory", "ANATOMY", 13, 22], ["gustatory", "ANATOMY", 26, 35], ["gustatory dysfunction", "DISEASE", 26, 47], ["olfactory", "ORGAN", 13, 22], ["gustatory", "ORGAN", 26, 35], ["gustatory dysfunction", "PROBLEM", 26, 47]]], ["We need to pay more attention 25 because the symptom might be easily overlooked in clinical 26 field and so the diagnosis could be delayed.", [["the symptom", "PROBLEM", 41, 52]]], ["In this review, 27 we reviewed recent findings of the viral infection-related ol- 28 factory or gustatory dysfunctions to identify a correlation be- 29 tween the olfactory or gustatory symptoms and corona virus, 30 and the values of olfactory dysfunction as an early sign of 31 COVID-19, even in asymptomatic patients.", [["gustatory", "ANATOMY", 96, 105], ["olfactory", "ANATOMY", 162, 171], ["gustatory", "ANATOMY", 175, 184], ["olfactory", "ANATOMY", 233, 242], ["infection", "DISEASE", 60, 69], ["gustatory dysfunctions", "DISEASE", 96, 118], ["olfactory dysfunction", "DISEASE", 233, 254], ["gustatory", "ANATOMICAL_SYSTEM", 96, 105], ["olfactory", "ORGAN", 162, 171], ["gustatory", "ORGANISM_SUBDIVISION", 175, 184], ["corona virus", "ORGANISM", 198, 210], ["olfactory", "ORGAN", 233, 242], ["patients", "ORGANISM", 309, 317], ["patients", "SPECIES", 309, 317], ["the viral infection", "PROBLEM", 50, 69], ["gustatory dysfunctions", "PROBLEM", 96, 118], ["gustatory symptoms", "PROBLEM", 175, 193], ["corona virus", "PROBLEM", 198, 210], ["olfactory dysfunction", "PROBLEM", 233, 254], ["COVID", "TEST", 278, 283], ["viral", "OBSERVATION_MODIFIER", 54, 59], ["infection", "OBSERVATION", 60, 69]]], ["The 34 first keyword was viral infection, coronavirus, rhinovirus, in- 35 fluenza, COVID, SARS or MERS.", [["viral infection", "DISEASE", 25, 40], ["coronavirus", "DISEASE", 42, 53], ["rhinovirus", "DISEASE", 55, 65], ["SARS", "DISEASE", 90, 94], ["coronavirus", "ORGANISM", 42, 53], ["rhinovirus", "ORGANISM", 55, 65], ["coronavirus", "SPECIES", 42, 53], ["viral infection", "PROBLEM", 25, 40], ["coronavirus", "PROBLEM", 42, 53], ["rhinovirus", "PROBLEM", 55, 65], ["viral infection", "OBSERVATION", 25, 40]]], ["The second keyword was 36 anosmia, smell, or olfactory.", [["olfactory", "ANATOMY", 45, 54], ["anosmia", "DISEASE", 26, 33], ["olfactory", "ORGAN", 45, 54], ["anosmia", "PROBLEM", 26, 33]]], ["38 The articles that could not be obtained in the full text, Finally, we could find 21 papers that directly described 50 COVID-19 and olfactory symptoms; some of them also men-51 tioned gustatory dysfunction or ageusia.", [["olfactory", "ANATOMY", 134, 143], ["gustatory", "ANATOMY", 186, 195], ["gustatory dysfunction", "DISEASE", 186, 207], ["ageusia", "DISEASE", 211, 218], ["olfactory", "ORGAN", 134, 143], ["men", "ORGANISM", 172, 175], ["gustatory", "ORGANISM_SUBDIVISION", 186, 195], ["men", "SPECIES", 172, 175], ["COVID", "TEST", 121, 126], ["olfactory symptoms", "PROBLEM", 134, 152], ["gustatory dysfunction", "PROBLEM", 186, 207], ["ageusia", "PROBLEM", 211, 218]]], ["From these 21 pa-52 pers, 7 papers were clinical studies and others were com-53 mentary, letters, and editorial review ( Fig. 1 ) .", [["clinical studies", "TEST", 40, 56]]], ["A 55 study reported patients who initially complained of acute on-56 set anosmia (not COVID-19 infection) but finally diagnosed 57 with COVID-19 infection [10] .", [["anosmia", "DISEASE", 73, 80], ["infection", "DISEASE", 95, 104], ["COVID-19", "CHEMICAL", 136, 144], ["infection", "DISEASE", 145, 154], ["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["A 55 study", "TEST", 0, 10], ["acute on-56 set anosmia", "PROBLEM", 57, 80], ["COVID", "TEST", 86, 91], ["infection", "PROBLEM", 95, 104], ["COVID", "TEST", 136, 141], ["infection", "PROBLEM", 145, 154], ["acute", "OBSERVATION_MODIFIER", 57, 62], ["infection", "OBSERVATION", 145, 154]]], ["58 There were no restrictions for gender, age and national-59 ity.", [["no", "UNCERTAINTY", 14, 16]]], ["The studies with inclusion criteria were checked inde-60 pendently by 2 reviewers.", [["The studies", "TEST", 0, 11], ["inclusion criteria", "TEST", 17, 35]]], ["Clinical presentation 64 The common symptoms in COVID-19 patients were cough, 65 fever, myalgia, dyspnea, headache and loss of appetite.", [["COVID", "DISEASE", 48, 53], ["cough", "DISEASE", 71, 76], ["fever", "DISEASE", 81, 86], ["myalgia", "DISEASE", 88, 95], ["dyspnea", "DISEASE", 97, 104], ["headache", "DISEASE", 106, 114], ["loss of appetite", "DISEASE", 119, 135], ["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["The common symptoms", "PROBLEM", 25, 44], ["COVID", "TEST", 48, 53], ["cough", "PROBLEM", 71, 76], ["fever", "PROBLEM", 81, 86], ["myalgia", "PROBLEM", 88, 95], ["dyspnea", "PROBLEM", 97, 104], ["headache", "PROBLEM", 106, 114], ["loss of appetite", "PROBLEM", 119, 135], ["common", "OBSERVATION_MODIFIER", 29, 35], ["symptoms", "OBSERVATION", 36, 44], ["cough", "OBSERVATION", 71, 76], ["headache", "OBSERVATION", 106, 114]]], ["The 66 most common ENT symptoms were facial pain and nasal con-67 gestion [9] .", [["facial", "ANATOMY", 37, 43], ["facial pain", "DISEASE", 37, 48], ["common ENT symptoms", "PROBLEM", 12, 31], ["facial pain", "PROBLEM", 37, 48], ["facial", "ANATOMY", 37, 43], ["nasal", "ANATOMY", 53, 58]]], ["68 However, it has been recently reported that 33.9% of 59 69 COVID-19 patients in Italy complained of olfactory and/or 70 gustatory dysfunction and 11% complained of both dysfunc-71 tions [11] .", [["olfactory", "ANATOMY", 103, 112], ["gustatory", "ANATOMY", 123, 132], ["gustatory dysfunction", "DISEASE", 123, 144], ["patients", "ORGANISM", 71, 79], ["olfactory", "ORGAN", 103, 112], ["patients", "SPECIES", 71, 79], ["COVID", "TEST", 62, 67], ["olfactory and/or 70 gustatory dysfunction", "PROBLEM", 103, 144]]], ["47% of 114 COVID-19 patients in France com-72 plained anosmia [12] .", [["anosmia", "DISEASE", 54, 61], ["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["COVID", "TEST", 11, 16], ["anosmia", "PROBLEM", 54, 61]]], ["31.65% and 35.44% of 79 COVID-19 73 patients in Spain complained olfactory and gustatory dysfunc-74 tions.", [["olfactory", "ANATOMY", 65, 74], ["patients", "ORGANISM", 36, 44], ["olfactory", "ORGAN", 65, 74], ["patients", "SPECIES", 36, 44], ["COVID", "TEST", 24, 29], ["gustatory dysfunc", "TEST", 79, 96]]], ["These proportions were more prominent in COVID-19 75 patients than influenza patients [13] .", [["influenza", "DISEASE", 67, 76], ["patients", "ORGANISM", 53, 61], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 53, 61], ["patients", "SPECIES", 77, 85], ["COVID", "TEST", 41, 46], ["more prominent", "OBSERVATION_MODIFIER", 23, 37]]], ["According to the paper 76 from USA reported that 68% and 71% of 59 patients had ol-77 factory and gustatory dysfunction, respectively [14] .", [["gustatory dysfunction", "DISEASE", 98, 119], ["patients", "ORGANISM", 67, 75], ["gustatory", "ORGANISM_SUBDIVISION", 98, 107], ["patients", "SPECIES", 67, 75], ["gustatory dysfunction", "PROBLEM", 98, 119]]], ["98% of 78 60 patients from Iran were confirmed smell dysfunction by 79 University of Pennsylvania smell identification test (UPSIT) 80 [15] .", [["smell dysfunction", "DISEASE", 47, 64], ["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["smell dysfunction", "PROBLEM", 47, 64]]], ["And few articles said that COVID-19 patients without 81 severe symptoms complained these olfactory and/or gustatory 82 dysfunctions.", [["olfactory", "ANATOMY", 89, 98], ["patients", "ORGANISM", 36, 44], ["olfactory", "ORGAN", 89, 98], ["patients", "SPECIES", 36, 44], ["COVID", "TEST", 27, 32], ["81 severe symptoms", "PROBLEM", 53, 71], ["gustatory 82 dysfunctions", "PROBLEM", 106, 131]]], ["According to the larger-scale research from Eu-83 rope, 85.6% of the 417 mild-to-moderate COVID-19 patients 84 had olfactory dysfunctions and 88.8% gustatory dysfunctions.", [["olfactory", "ANATOMY", 115, 124], ["gustatory", "ANATOMY", 148, 157], ["COVID", "DISEASE", 90, 95], ["olfactory dysfunctions", "DISEASE", 115, 137], ["gustatory dysfunctions", "DISEASE", 148, 170], ["patients", "ORGANISM", 99, 107], ["olfactory", "ORGAN", 115, 124], ["patients", "SPECIES", 99, 107], ["Eu", "TEST", 44, 46], ["COVID", "TEST", 90, 95], ["olfactory dysfunctions", "PROBLEM", 115, 137], ["% gustatory dysfunctions", "PROBLEM", 146, 170]]], ["85 Phantosmia and parosmia were 12.6% and 32.4%, respec-86 tively.", [["parosmia", "DISEASE", 18, 26], ["Phantosmia", "TEST", 3, 13], ["parosmia", "TEST", 18, 26], ["respec", "TEST", 49, 55]]], ["Among the patients who did not complain of nasal 87 stuffiness and rhinorrhea, the rates of anosmia and hyposmia 88 were 66.2% and 13.5% [9] .", [["nasal 87 stuffiness", "DISEASE", 43, 62], ["rhinorrhea", "DISEASE", 67, 77], ["anosmia", "DISEASE", 92, 99], ["hyposmia", "DISEASE", 104, 112], ["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["nasal 87 stuffiness", "PROBLEM", 43, 62], ["rhinorrhea", "PROBLEM", 67, 77], ["anosmia", "PROBLEM", 92, 99], ["hyposmia", "TEST", 104, 112], ["nasal", "ANATOMY", 43, 48], ["stuffiness", "OBSERVATION", 52, 62], ["rhinorrhea", "OBSERVATION", 67, 77]]], ["From the other Italian article, 89 64.4% of 202 mild symptomatic COVID-19 patients were 90 reported alternations in smell or taste.", [["COVID", "DISEASE", 65, 70], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["mild symptomatic COVID", "TEST", 48, 70], ["alternations in smell or taste", "PROBLEM", 100, 130]]], ["About 37% of them 91 complained severe alternations.", [["severe alternations", "PROBLEM", 32, 51]]], ["68.3% of COVID-19 patients 92 with smell or taste alternations reported fatigue and 34.6% 93 reported nasal stuffiness [16] .", [["nasal", "ANATOMY", 102, 107], ["smell or taste alternations", "DISEASE", 35, 62], ["fatigue", "DISEASE", 72, 79], ["patients", "ORGANISM", 18, 26], ["nasal", "ORGANISM_SUBDIVISION", 102, 107], ["patients", "SPECIES", 18, 26], ["COVID", "TEST", 9, 14], ["taste alternations", "PROBLEM", 44, 62], ["fatigue", "PROBLEM", 72, 79], ["nasal stuffiness", "PROBLEM", 102, 118], ["nasal", "ANATOMY", 102, 107], ["stuffiness", "OBSERVATION", 108, 118]]], ["94 Contrary to the above papers, only 5.1% of 214 patients 95 complained of hyposmia and 5.6% hypogeusia in China [8] .", [["hyposmia", "DISEASE", 76, 84], ["hypogeusia", "DISEASE", 94, 104], ["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58], ["hyposmia", "PROBLEM", 76, 84], ["5.6% hypogeusia in China", "PROBLEM", 89, 113]]], ["96 Considering the papers, the rate of olfactory or gustatory dys-97 function is supposed to be different between Europe/USA and 98 China (or Asia).", [["olfactory", "ANATOMY", 39, 48], ["olfactory", "ORGAN", 39, 48], ["gustatory dys", "TEST", 52, 65]]], ["99 Another issue is the onset of olfactory dysfunction, which 100 varied among many papers.", [["olfactory", "ANATOMY", 33, 42], ["olfactory dysfunction", "DISEASE", 33, 54], ["olfactory", "ORGAN", 33, 42], ["olfactory dysfunction", "PROBLEM", 33, 54], ["dysfunction", "OBSERVATION", 43, 54]]], ["The onset of olfactory or gusta-101 tory dysfunction in the clinical course of COVID-19 might be 102 important.", [["olfactory", "ANATOMY", 13, 22], ["COVID-19", "CHEMICAL", 79, 87], ["olfactory", "ORGAN", 13, 22], ["olfactory or gusta-101 tory dysfunction", "PROBLEM", 13, 52], ["COVID", "TEST", 79, 84]]], ["A multicenter study in Europe showed that 85.6% 103 and 88% of total patients ( n = 417) reported olfactory and 104 gustatory dysfunctions, respectively, and 11.8% of COVID-105 19 patients with olfactory dysfunction appeared before other 106 general symptoms, 65.4% after the general symptoms, and 107 22.8% at the same time [9] .", [["olfactory", "ANATOMY", 98, 107], ["gustatory", "ANATOMY", 116, 125], ["olfactory", "ANATOMY", 194, 203], ["olfactory and 104 gustatory dysfunctions", "DISEASE", 98, 138], ["olfactory dysfunction", "DISEASE", 194, 215], ["patients", "ORGANISM", 69, 77], ["olfactory", "ORGAN", 98, 107], ["gustatory", "ORGAN", 116, 125], ["patients", "ORGANISM", 180, 188], ["olfactory", "ORGAN", 194, 203], ["patients", "SPECIES", 69, 77], ["patients", "SPECIES", 180, 188], ["A multicenter study", "TEST", 0, 19], ["olfactory and 104 gustatory dysfunctions", "PROBLEM", 98, 138], ["COVID", "TEST", 167, 172], ["olfactory dysfunction", "PROBLEM", 194, 215], ["general symptoms", "PROBLEM", 242, 258], ["the general symptoms", "PROBLEM", 272, 292]]], ["In Italy, 20.3% of COVID-19 108 patients reported olfactory dysfunction before other general 109 symptoms and 13.5% during hospitalization [11] .", [["olfactory", "ANATOMY", 50, 59], ["olfactory dysfunction", "DISEASE", 50, 71], ["patients", "ORGANISM", 32, 40], ["olfactory", "ORGAN", 50, 59], ["patients", "SPECIES", 32, 40], ["COVID", "TEST", 19, 24], ["olfactory dysfunction", "PROBLEM", 50, 71], ["other general 109 symptoms", "PROBLEM", 79, 105]]], ["From the 110 other study of Italy, 11.9% of COVID-19 patients ( n = 130) 111 complained of smell or taste alternations prior to other symp-112 for COVID-19 infection; only 74% of the tested patients were 133 positive and most of the responders were young [10] .", [["taste alternations", "DISEASE", 100, 118], ["infection", "DISEASE", 156, 165], ["patients", "ORGANISM", 53, 61], ["patients", "ORGANISM", 190, 198], ["patients", "SPECIES", 53, 61], ["patients", "SPECIES", 190, 198], ["COVID", "TEST", 44, 49], ["smell or taste alternations", "PROBLEM", 91, 118], ["other symp", "TEST", 128, 138], ["COVID-19 infection", "PROBLEM", 147, 165], ["infection", "OBSERVATION", 156, 165]]], ["134 From a case report, olfactory dysfunction was described as 135 'isolated sudden onset anosmia' because a patient with con-136 firmed COVID-19 complained of sudden onset anosmia with-137 out any other symptoms [21] .", [["olfactory", "ANATOMY", 24, 33], ["olfactory dysfunction", "DISEASE", 24, 45], ["anosmia", "DISEASE", 90, 97], ["anosmia", "DISEASE", 173, 180], ["olfactory", "ORGAN", 24, 33], ["patient", "ORGANISM", 109, 116], ["patient", "SPECIES", 109, 116], ["olfactory dysfunction", "PROBLEM", 24, 45], ["sudden onset anosmia'", "PROBLEM", 77, 98], ["sudden onset anosmia", "PROBLEM", 160, 180], ["any other symptoms", "PROBLEM", 194, 212]]], ["According to the other study 138 from Italy, 3% of COVID-19 patients ( n = 130) reported smell 139 or taste alternations as the sole symptom [16] .", [["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["the other study", "TEST", 13, 28], ["COVID", "TEST", 51, 56], ["smell", "TEST", 89, 94], ["the sole symptom", "PROBLEM", 124, 140]]], ["However, there 140 is also an article reporting that ENT symptoms can be accom-141 panied by anosmia [12] .", [["anosmia", "DISEASE", 93, 100], ["ENT symptoms", "PROBLEM", 53, 65], ["accom", "TEST", 73, 78], ["anosmia", "PROBLEM", 93, 100]]], ["142 In Korea, Korean center for disease control (KCDC) re-143 cently (on 6 April 2020) announced in a press release that 144 proportion of asymptomatic case was 33.3% based on the 145 presence or absence of symptoms at the time of confirmation 146 of COVID-19 (10,284 confirmed as positive among 466,804 147 tested, in republic of Korea until 6, April 2020) [22] .", [["disease control", "TREATMENT", 32, 47], ["symptoms", "PROBLEM", 207, 215], ["confirmation", "TEST", 231, 243], ["COVID", "TEST", 251, 256]]], ["148 There is a study showing that most of gustatory dysfunc-149 tion appeared as an early symptom before hospitalization [11] .", [["dysfunc-149 tion", "CHEMICAL", 52, 68], ["a study", "TEST", 13, 20], ["gustatory dysfunc", "TEST", 42, 59], ["an early symptom", "PROBLEM", 81, 97]]], ["150 Besides, there might be close correlation between olfactory 151 and gustatory dysfunction ( p < 0.001) [9] .", [["gustatory", "ANATOMY", 72, 81], ["gustatory dysfunction", "DISEASE", 72, 93], ["gustatory", "ORGAN", 72, 81], ["gustatory dysfunction", "PROBLEM", 72, 93]]], ["Considering above, 152 6 Y.J. Kang Barr viruses and some other coronavirus can be explained.", [["Kang Barr viruses", "ORGANISM", 30, 47], ["coronavirus", "ORGANISM", 63, 74], ["Kang Barr viruses", "SPECIES", 30, 47], ["Kang Barr viruses", "TREATMENT", 30, 47], ["some other coronavirus", "PROBLEM", 52, 74]]], ["180 However, in some cases, even if the acoustic rhinometry re-181 sult was normal, the olfactory function did not recover [28] .209The validated tests which could quickly and accurately 210 diagnose the olfactory dysfunction in the highly suspicious 211 COVID-19 patients are needed.", [["olfactory", "ANATOMY", 88, 97], ["olfactory", "ANATOMY", 204, 213], ["olfactory dysfunction", "DISEASE", 204, 225], ["olfactory", "ORGAN", 88, 97], ["olfactory", "ORGAN", 204, 213], ["patients", "ORGANISM", 264, 272], ["patients", "SPECIES", 264, 272], ["the acoustic rhinometry", "TEST", 36, 59], ["The validated tests", "TEST", 132, 151], ["the olfactory dysfunction", "PROBLEM", 200, 225], ["COVID", "TEST", 255, 260]]], ["The short version of the Ques-212 tionnaire of Olfactory Disorders Negative Statements (sQOD-213 NS) can be used to assess the quality of life of the COVID-19 214 patients with anosmia or hyposmia [9] .", [["anosmia", "DISEASE", 177, 184], ["hyposmia", "DISEASE", 188, 196], ["patients", "ORGANISM", 163, 171], ["patients", "SPECIES", 163, 171], ["Olfactory Disorders", "PROBLEM", 47, 66], ["NS", "TREATMENT", 97, 99], ["the COVID", "TEST", 146, 155], ["anosmia", "PROBLEM", 177, 184], ["hyposmia", "PROBLEM", 188, 196]]], ["The score was sig-215 nificantly lower in patients with anosmia than hyposmia or 216 normosmia.", [["anosmia", "DISEASE", 56, 63], ["hyposmia", "DISEASE", 69, 77], ["normosmia", "DISEASE", 85, 94], ["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["The score", "TEST", 0, 9], ["sig", "TEST", 14, 17], ["anosmia", "PROBLEM", 56, 63], ["hyposmia", "PROBLEM", 69, 77]]], ["217 Besides subjective questionnaires, commonly used olfac-218 tory tests are as follows: UPSIT, Cross-cultural Smell Identi-219 fication Test (CC-SIT; Sensonic, Inc, Haddon Heights, NJ), 220 T&T Olfactometry test (Daiichi Yakuhin Sangyo, Tokyo, 221 Japan), and other olfactory threshold tests [36] .", [["olfac", "TEST", 53, 58], ["Identi", "TEST", 118, 124], ["Test", "TEST", 138, 142], ["CC", "TEST", 144, 146], ["Sensonic", "TEST", 152, 160], ["other olfactory threshold tests", "TEST", 262, 293]]], ["Recently, few 222 cases of COVID-19 patients with olfactory dysfunction were 223 confirmed by UPSIT.", [["olfactory", "ANATOMY", 50, 59], ["COVID", "DISEASE", 27, 32], ["olfactory dysfunction", "DISEASE", 50, 71], ["patients", "ORGANISM", 36, 44], ["olfactory", "ORGAN", 50, 59], ["patients", "SPECIES", 36, 44], ["COVID", "TEST", 27, 32], ["olfactory dysfunction", "PROBLEM", 50, 71]]], ["There was no correlation between UP-224 SIT result and awareness of olfactory dysfunction in COVID-225 19 patients [15] .", [["olfactory", "ANATOMY", 68, 77], ["olfactory dysfunction", "DISEASE", 68, 89], ["olfactory", "ORGAN", 68, 77], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["olfactory dysfunction", "PROBLEM", 68, 89], ["COVID", "TEST", 93, 98]]], ["226 Also, acoustic rhinometry, rhinomanometry, CT, or MRI 227 could identify the mechanism of olfactory dysfunction mainly 228 due to conductive problems and identify other causes.", [["olfactory", "ANATOMY", 94, 103], ["olfactory dysfunction", "DISEASE", 94, 115], ["olfactory", "ORGAN", 94, 103], ["acoustic rhinometry", "TEST", 10, 29], ["rhinomanometry", "TEST", 31, 45], ["CT", "TEST", 47, 49], ["MRI", "TEST", 54, 57], ["olfactory dysfunction", "PROBLEM", 94, 115], ["conductive problems", "PROBLEM", 134, 153]]], ["How-229 ever, the usage of nasal endoscopy is not recommended in the 230 highly suspicious COVID-19 patients because it may provide 231 other people unnecessary virus exposure [37] .", [["nasal", "ANATOMY", 27, 32], ["nasal", "ORGAN", 27, 32], ["patients", "ORGANISM", 100, 108], ["people", "ORGANISM", 142, 148], ["patients", "SPECIES", 100, 108], ["people", "SPECIES", 142, 148], ["nasal endoscopy", "TEST", 27, 42]]], ["Treatments 233 In general, spontaneous recovery rates have been reported 234 higher in post-viral patients than post-traumatic patients, and 235 there are no definite treatment guidelines in the post-viral 236 patients presenting with olfactory or gustatory dysfunction, 237 including COVID-19.", [["olfactory", "ANATOMY", 235, 244], ["gustatory", "ANATOMY", 248, 257], ["olfactory or gustatory dysfunction", "DISEASE", 235, 269], ["patients", "ORGANISM", 98, 106], ["patients", "ORGANISM", 127, 135], ["patients", "ORGANISM", 210, 218], ["olfactory", "ORGAN", 235, 244], ["gustatory", "ORGANISM_SUBDIVISION", 248, 257], ["patients", "SPECIES", 98, 106], ["patients", "SPECIES", 127, 135], ["patients", "SPECIES", 210, 218], ["Treatments", "TREATMENT", 0, 10], ["olfactory or gustatory dysfunction", "PROBLEM", 235, 269], ["COVID", "TEST", 285, 290], ["no definite", "UNCERTAINTY", 155, 166]]], ["There are 2 issues on anosmia treatment 238 in COVID-19 patients.", [["anosmia", "DISEASE", 22, 29], ["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["anosmia treatment", "TREATMENT", 22, 39]]], ["239 The first issue is that early anomia treatment in COVID-19 240 patients can change clinical course of COVID-19.", [["anomia", "DISEASE", 34, 40], ["COVID-19", "CHEMICAL", 106, 114], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["early anomia treatment", "TREATMENT", 28, 50], ["COVID", "TEST", 106, 111], ["early", "OBSERVATION_MODIFIER", 28, 33], ["anomia", "OBSERVATION", 34, 40]]], ["But due to 241 lack of information, this issue is hard to be answered but early 242 detection appears more likely to be meaningful rather than 243 early treatment for COVID-19.", [["COVID", "TEST", 167, 172]]], ["The second one is whether 244 empirical oral steroid treatment for acute anosmia can do 245 harm to COVID-19 patients without any other symptom or 246 22.5% only gustatory dysfunction and 23.6% both remaining 320 olfactory and gustatory dysfunctions [9] .", [["oral", "ANATOMY", 40, 44], ["gustatory", "ANATOMY", 162, 171], ["olfactory", "ANATOMY", 213, 222], ["gustatory", "ANATOMY", 227, 236], ["steroid", "CHEMICAL", 45, 52], ["anosmia", "DISEASE", 73, 80], ["gustatory dysfunction", "DISEASE", 162, 183], ["gustatory dysfunctions", "DISEASE", 227, 249], ["steroid", "CHEMICAL", 45, 52], ["oral", "ORGANISM_SUBDIVISION", 40, 44], ["patients", "ORGANISM", 109, 117], ["olfactory", "ORGAN", 213, 222], ["patients", "SPECIES", 109, 117], ["empirical oral steroid treatment", "TREATMENT", 30, 62], ["acute anosmia", "PROBLEM", 67, 80], ["COVID", "TEST", 100, 105], ["any other symptom", "PROBLEM", 126, 143], ["gustatory dysfunction", "PROBLEM", 162, 183], ["gustatory dysfunctions", "PROBLEM", 227, 249]]], ["321 The time to decide the recovery of olfactory function was 322 suggested to be 2 weeks, because the viral loading signifi-323 cantly reduces in about 14 days [ 9 , 44 ] .", [["olfactory", "ANATOMY", 39, 48], ["signifi-323", "CHEMICAL", 117, 128], ["olfactory", "ORGAN", 39, 48], ["olfactory function", "TEST", 39, 57], ["the viral loading signifi", "TEST", 99, 124]]], ["But the further study 324 requires to decide the time to recovery and follow up long 325 term later.", [["the further study", "TEST", 4, 21]]], ["326 Considering from the other viral infections, the partial or 327 complete recovery of olfactory function could take several 328 months [45] .", [["olfactory", "ANATOMY", 89, 98], ["viral infections", "DISEASE", 31, 47], ["olfactory", "ORGAN", 89, 98], ["the other viral infections", "PROBLEM", 21, 47], ["viral", "OBSERVATION_MODIFIER", 31, 36], ["infections", "OBSERVATION", 37, 47]]], ["And in case of anosmia after SARS, the patient 329 was reported to suffer from anosmia continuously more than 330 2 years [18] .", [["anosmia", "DISEASE", 15, 22], ["SARS", "DISEASE", 29, 33], ["anosmia", "DISEASE", 79, 86], ["patient", "ORGANISM", 39, 46], ["patient", "SPECIES", 39, 46], ["anosmia", "PROBLEM", 15, 22], ["SARS", "PROBLEM", 29, 33], ["anosmia", "PROBLEM", 79, 86]]], ["331332The ongoing COVID-19 epidemic is still rapidly spreading 333 all over the world.", [["331332", "CHEMICAL", 0, 6], ["331332", "SPECIES", 0, 6], ["The ongoing COVID", "TEST", 6, 23], ["epidemic", "PROBLEM", 27, 35], ["rapidly", "OBSERVATION_MODIFIER", 45, 52], ["spreading", "OBSERVATION_MODIFIER", 53, 62]]], ["So it is very important to notice the early 334 sign of COVID-19 and get the information about progression 335 as soon as possible.", [["COVID", "TEST", 56, 61]]], ["Most of COVID-19 patients complain 336 of no symptoms or mild symptoms in early stages though 337 coughing, fever and difficulty breathing are main symptoms.", [["coughing", "DISEASE", 98, 106], ["fever", "DISEASE", 108, 113], ["difficulty breathing", "DISEASE", 118, 138], ["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["symptoms", "PROBLEM", 45, 53], ["mild symptoms", "PROBLEM", 57, 70], ["coughing", "PROBLEM", 98, 106], ["fever", "PROBLEM", 108, 113], ["difficulty breathing", "PROBLEM", 118, 138], ["main symptoms", "PROBLEM", 143, 156], ["mild", "OBSERVATION_MODIFIER", 57, 61]]], ["338 Up to date, the number of the COVID-19 patients with ol-339 factory and/or gustatory symptoms is rapidly increasing and, 340 though the onset of olfactory and/or gustatory symptoms in 341 the COVID-19 patients was reported varied, in general, most 342 of these 2 symptoms might precede or be accompanied by 343 other main mild general symptoms or no other symptoms 344 [16] .", [["olfactory", "ANATOMY", 149, 158], ["gustatory symptoms", "DISEASE", 79, 97], ["olfactory and/or gustatory symptoms", "DISEASE", 149, 184], ["patients", "ORGANISM", 43, 51], ["ol-339", "GENE_OR_GENE_PRODUCT", 57, 63], ["olfactory", "ORGAN", 149, 158], ["gustatory", "ANATOMICAL_SYSTEM", 166, 175], ["patients", "ORGANISM", 205, 213], ["patients", "SPECIES", 43, 51], ["patients", "SPECIES", 205, 213], ["the COVID", "TEST", 30, 39], ["gustatory symptoms", "PROBLEM", 79, 97], ["olfactory and/or gustatory symptoms", "PROBLEM", 149, 184], ["these 2 symptoms", "PROBLEM", 259, 275], ["mild general symptoms", "PROBLEM", 326, 347], ["other symptoms", "PROBLEM", 354, 368]]], ["Moreover, many cases (18.2%) have been reported for 345 the COVID-19 patients to complain of these 2 symptoms sud-346 denly without any other otolaryngologic symptoms, like rhi-347 norrhea or nasal obstructions [9] .", [["otolaryngologic", "ANATOMY", 142, 157], ["nasal", "ANATOMY", 192, 197], ["nasal obstructions", "DISEASE", 192, 210], ["patients", "ORGANISM", 69, 77], ["nasal obstructions", "PATHOLOGICAL_FORMATION", 192, 210], ["patients", "SPECIES", 69, 77], ["the COVID", "TEST", 56, 65], ["these 2 symptoms sud", "PROBLEM", 93, 113], ["any other otolaryngologic symptoms", "PROBLEM", 132, 166], ["rhi", "TEST", 173, 176], ["nasal obstructions", "PROBLEM", 192, 210], ["nasal", "ANATOMY", 192, 197], ["obstructions", "OBSERVATION", 198, 210]]], ["348 Based on the previous paper, the rates of asymptomatic 349 cases out of all SARS-CoV positive cases were reported 13% 350 among Singaporean health care workers [46] .", [["SARS", "DISEASE", 80, 84], ["SARS-CoV", "SPECIES", 80, 88], ["all SARS", "TEST", 76, 84]]], ["Furthermore, 351 according to WHO report for MERS-CoV, 21% of the 2228 352 cases from all over the world were reported to have no or 353 mild symptoms [47] .", [["MERS-CoV", "ORGANISM", 45, 53], ["MERS-CoV", "SPECIES", 45, 53], ["MERS", "TEST", 45, 49], ["CoV", "TEST", 50, 53], ["mild symptoms", "PROBLEM", 137, 150]]], ["354 Asymptomatic case proportion of COVID-19 was 33.3% 355 based on the presence or absence of symptoms at the time of 356 confirmation, which was higher than SARS-CoV and MERS-357 CoV, according to KCDC report (on 6 April 2020) [22] .", [["MERS-357 CoV", "ORGANISM", 172, 184], ["SARS-CoV", "SPECIES", 159, 167], ["MERS-357 CoV", "SPECIES", 172, 184], ["COVID", "TEST", 36, 41], ["symptoms", "PROBLEM", 95, 103]]], ["358 Therefore, we should pay more attention to olfactory 359 and/or gustatory symptoms in the suspicious COVID-19 pa-360 tients with or without the main COVID-19 symptoms because 361 asymptomatic COVID-19 infection (and/or transmission) is a 362 major public health issue at present.", [["olfactory 359", "ANATOMY", 47, 60], ["COVID-19", "CHEMICAL", 196, 204], ["infection", "DISEASE", 205, 214], ["olfactory 359", "MULTI-TISSUE_STRUCTURE", 47, 60], ["gustatory", "ORGANISM_SUBDIVISION", 68, 77], ["COVID-19", "SPECIES", 196, 204], ["gustatory symptoms", "PROBLEM", 68, 86], ["the suspicious COVID", "TEST", 90, 110], ["the main COVID", "TEST", 144, 158], ["symptoms", "PROBLEM", 162, 170], ["asymptomatic COVID", "PROBLEM", 183, 201], ["infection", "PROBLEM", 205, 214], ["infection", "OBSERVATION", 205, 214]]], ["However, the exact rate 363 of asymptomatic COVID-19 all over the world has not known 364 and further analysis should be done.", [["the exact rate", "TEST", 9, 23], ["asymptomatic COVID", "TEST", 31, 49], ["further analysis", "TEST", 94, 110]]], ["365 Even though the pathophysiologic mechanism of olfactory 366 or gustatory dysfunctions in COVID-19 patients has not been 367 clearly identified yet, it is also very interesting that the clini-368 cal manifestations of olfactory or gustatory dysfunctions were 369 different according to gender or races.", [["gustatory", "ANATOMY", 67, 76], ["olfactory", "ANATOMY", 221, 230], ["gustatory", "ANATOMY", 234, 243], ["gustatory dysfunctions", "DISEASE", 67, 89], ["olfactory or gustatory dysfunctions", "DISEASE", 221, 256], ["olfactory 366", "MULTI-TISSUE_STRUCTURE", 50, 63], ["gustatory", "ANATOMICAL_SYSTEM", 67, 76], ["patients", "ORGANISM", 102, 110], ["olfactory", "ORGAN", 221, 230], ["gustatory", "ORGAN", 234, 243], ["patients", "SPECIES", 102, 110], ["gustatory dysfunctions", "PROBLEM", 67, 89], ["COVID", "TEST", 93, 98], ["gustatory dysfunctions", "PROBLEM", 234, 256]]], ["370 Moreover, it is necessary to follow the clinical course and 371 the long-term results of olfactory and/or gustatory dysfunc-372 tions in the cured COVID-19 patients.", [["olfactory", "ANATOMY", 93, 102], ["olfactory", "ORGAN", 93, 102], ["patients", "ORGANISM", 160, 168], ["patients", "SPECIES", 160, 168], ["gustatory dysfunc", "TEST", 110, 127]]]], "0ca88a88c808dcbb12a6463af2a6c399df06864e": [["J o u r n a l P r e -p r o o fIntroductionOn December 31, 2019, the World Health Organization (WHO) learned of several cases of a respiratory illness clinically resembling viral pneumonia and manifesting as fever, cough, and shortness of breath.", [["respiratory", "ANATOMY", 130, 141], ["respiratory illness", "DISEASE", 130, 149], ["viral pneumonia", "DISEASE", 172, 187], ["fever", "DISEASE", 207, 212], ["cough", "DISEASE", 214, 219], ["shortness of breath", "DISEASE", 225, 244], ["a respiratory illness", "PROBLEM", 128, 149], ["viral pneumonia", "PROBLEM", 172, 187], ["fever", "PROBLEM", 207, 212], ["cough", "PROBLEM", 214, 219], ["shortness of breath", "PROBLEM", 225, 244], ["respiratory", "ANATOMY", 130, 141], ["viral", "OBSERVATION_MODIFIER", 172, 177], ["pneumonia", "OBSERVATION", 178, 187]]], ["The newly discovered virus emerging from Wuhan City, Hubei Province of China, has been temporarily named \"novel coronavirus\" (2019-nCoV) [1] .", [["coronavirus", "ORGANISM", 112, 123], ["virus", "OBSERVATION", 21, 26]]], ["This new coronavirus belongs to the seventh member of the family of coronaviruses that infect humans being different from severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) [2, 3] .", [["Acute Respiratory Syndrome", "DISEASE", 129, 155], ["SARS", "DISEASE", 157, 161], ["Middle East Respiratory Syndrome", "DISEASE", 167, 199], ["MERS", "DISEASE", 201, 205], ["coronavirus", "ORGANISM", 9, 20], ["coronaviruses", "ORGANISM", 68, 81], ["humans", "ORGANISM", 94, 100], ["humans", "SPECIES", 94, 100], ["humans", "SPECIES", 94, 100], ["Middle East Respiratory Syndrome (MERS)", "SPECIES", 167, 206], ["severe Acute Respiratory Syndrome", "PROBLEM", 122, 155], ["SARS)", "PROBLEM", 157, 162], ["Middle East Respiratory Syndrome", "PROBLEM", 167, 199], ["coronavirus", "OBSERVATION", 9, 20], ["severe", "OBSERVATION_MODIFIER", 122, 128], ["Acute", "OBSERVATION_MODIFIER", 129, 134], ["Respiratory Syndrome", "OBSERVATION", 135, 155], ["Middle", "ANATOMY_MODIFIER", 167, 173], ["Respiratory Syndrome", "OBSERVATION", 179, 199]]], ["Coronavirus disease 2019 (COVID-19) is defined as illness caused by a novel coronavirus now called severe acute respiratory syndrome coronavirus 2 [4] .IntroductionThe outbreak is escalating quickly, with thousands of confirmed COVID-19 cases reported globally.", [["Coronavirus disease", "DISEASE", 0, 19], ["COVID-19", "CHEMICAL", 26, 34], ["illness", "DISEASE", 50, 57], ["coronavirus", "DISEASE", 76, 87], ["acute respiratory syndrome coronavirus", "DISEASE", 106, 144], ["coronavirus", "SPECIES", 76, 87], ["Coronavirus disease 2019 (COVID-19", "SPECIES", 0, 34], ["severe acute respiratory syndrome coronavirus", "SPECIES", 99, 144], ["Coronavirus disease", "PROBLEM", 0, 19], ["COVID", "TEST", 26, 31], ["a novel coronavirus", "PROBLEM", 68, 87], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 99, 144], ["COVID", "TEST", 228, 233], ["severe", "OBSERVATION_MODIFIER", 99, 105], ["acute", "OBSERVATION_MODIFIER", 106, 111], ["respiratory syndrome", "OBSERVATION", 112, 132]]], ["On January 30, the China reported the first confirmed instance of person-to-person spread of the virus [5] .", [["person", "SPECIES", 66, 72], ["person", "SPECIES", 76, 82], ["the virus", "PROBLEM", 93, 102]]], ["And then, infections have been identified in other Chinese cities., besides, several exported cases have been confirmed in other countries in Thailand, Japan, South Korea, and the USA [6] .", [["infections", "DISEASE", 10, 20], ["infections", "PROBLEM", 10, 20], ["infections", "OBSERVATION", 10, 20]]], ["Now, the COVID-19 has led to a world-wide pandemia, which has affected also Europe, Australia, New Zealand, Africa etc [7] .IntroductionProven cases of COVID-19 have been acquired both in the community and hospital setting.", [["COVID-19", "CHEMICAL", 9, 17], ["pandemia", "DISEASE", 42, 50], ["COVID-19", "DNA", 9, 17], ["wide pandemia", "PROBLEM", 37, 50], ["wide", "OBSERVATION_MODIFIER", 37, 41], ["pandemia", "OBSERVATION", 42, 50], ["New", "OBSERVATION_MODIFIER", 95, 98], ["Zealand", "OBSERVATION_MODIFIER", 99, 106]]], ["The source of COVID-19 is not yet clear, but the origin of the infection has been associated with bat [8].", [["infection", "DISEASE", 63, 72], ["COVID-19", "CHEMICAL", 14, 22], ["COVID-19", "GENE_OR_GENE_PRODUCT", 14, 22], ["COVID-19", "DNA", 14, 22], ["COVID", "TEST", 14, 19], ["the infection", "PROBLEM", 59, 72], ["clear", "OBSERVATION", 34, 39], ["infection", "OBSERVATION", 63, 72]]], ["COVID-19 has been detected in healthy patients with or without known comorbidities before, with a larger proportion of reported cases in this group.", [["COVID-19", "CHEMICAL", 0, 8], ["COVID-19", "GENE_OR_GENE_PRODUCT", 0, 8], ["patients", "ORGANISM", 38, 46], ["COVID-19", "DNA", 0, 8], ["patients", "SPECIES", 38, 46], ["known comorbidities", "PROBLEM", 63, 82]]], ["Patients with diabetes, hypertension, chronic renal failure, cardiomyopathy, decreased immunity and malignancy seem to be at a higher risk for developing severe disease [6] .", [["renal", "ANATOMY", 46, 51], ["diabetes", "DISEASE", 14, 22], ["hypertension", "DISEASE", 24, 36], ["chronic renal failure", "DISEASE", 38, 59], ["cardiomyopathy", "DISEASE", 61, 75], ["decreased immunity", "DISEASE", 77, 95], ["malignancy", "DISEASE", 100, 110], ["Patients", "ORGANISM", 0, 8], ["renal", "ORGAN", 46, 51], ["Patients", "SPECIES", 0, 8], ["diabetes", "PROBLEM", 14, 22], ["hypertension", "PROBLEM", 24, 36], ["chronic renal failure", "PROBLEM", 38, 59], ["cardiomyopathy", "PROBLEM", 61, 75], ["decreased immunity", "PROBLEM", 77, 95], ["malignancy", "PROBLEM", 100, 110], ["developing severe disease", "PROBLEM", 143, 168], ["diabetes", "OBSERVATION", 14, 22], ["hypertension", "OBSERVATION", 24, 36], ["chronic", "OBSERVATION_MODIFIER", 38, 45], ["renal", "ANATOMY", 46, 51], ["failure", "OBSERVATION", 52, 59], ["cardiomyopathy", "OBSERVATION", 61, 75], ["decreased", "OBSERVATION_MODIFIER", 77, 86], ["severe", "OBSERVATION_MODIFIER", 154, 160], ["disease", "OBSERVATION", 161, 168]]], ["The current symptoms J o u r n a l P r e -p r o o f 5 patients with confirmed COVID-19 infection included limited analysis of chest radiographs [6] .", [["chest", "ANATOMY", 126, 131], ["infection", "DISEASE", 87, 96], ["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["The current symptoms", "PROBLEM", 0, 20], ["a l P r e -p r o o f 5 patients", "TEST", 31, 62], ["COVID", "TEST", 78, 83], ["infection", "PROBLEM", 87, 96], ["chest radiographs", "TEST", 126, 143], ["infection", "OBSERVATION", 87, 96], ["chest", "ANATOMY", 126, 131]]], ["The aim of this study was to review and better describe the chest CT findings in patients with COVID-19.Patient populationFrom Jan 24, 2020 to Mar 5, 2020, we reviewed a case series of chest CT scan from 34 patients infected with COVID-19 to identify and characterize the most common findings.", [["chest", "ANATOMY", 60, 65], ["patients", "ORGANISM", 81, 89], ["patients", "ORGANISM", 207, 215], ["patients", "SPECIES", 81, 89], ["Patient", "SPECIES", 104, 111], ["patients", "SPECIES", 207, 215], ["this study", "TEST", 11, 21], ["the chest CT findings", "TEST", 56, 77], ["COVID", "TEST", 95, 100], ["chest CT scan", "TEST", 185, 198], ["COVID", "TEST", 230, 235], ["chest", "ANATOMY", 60, 65], ["chest", "ANATOMY", 185, 190]]], ["11 patients (32.35%) had an exposure to individuals from Wuhan, China, the remaining patients had an history of contact with the person who had been exposed to individuals from Wuhan proven COVID-19.", [["patients", "ORGANISM", 3, 11], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 3, 11], ["patients", "SPECIES", 85, 93], ["person", "SPECIES", 129, 135]]], ["The patients were admitted to five hospitals in four Cities of Shandong province.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]], ["All were positive for COVID-19 via laboratory testing of respiratory secretions.Patient populationNineteen patients underwent a second CT examination within 3 to 5 days as their symptoms worsened.Patient populationThe median age of 19 patients was 50.00 years (interquartile range [IQR] = 41-59 years).Patient populationWritten informed consent was waived by our institutional review board for these retrospective cases.Patient populationApproval for this study was obtained from the local ethics committees of five hospitals.", [["respiratory secretions", "ANATOMY", 57, 79], ["patients", "ORGANISM", 107, 115], ["patients", "ORGANISM", 235, 243], ["Patient", "SPECIES", 80, 87], ["patients", "SPECIES", 107, 115], ["Patient", "SPECIES", 196, 203], ["patients", "SPECIES", 235, 243], ["Patient", "SPECIES", 302, 309], ["Patient", "SPECIES", 420, 427], ["COVID", "TEST", 22, 27], ["laboratory testing", "TEST", 35, 53], ["respiratory secretions", "PROBLEM", 57, 79], ["a second CT examination", "TEST", 126, 149], ["their symptoms", "PROBLEM", 172, 186], ["this study", "TEST", 451, 461], ["positive", "OBSERVATION", 9, 17], ["respiratory", "ANATOMY", 57, 68], ["secretions", "OBSERVATION", 69, 79], ["worsened", "OBSERVATION_MODIFIER", 187, 195]]], ["No link between the researchers and the patients was available [3] .CT TechniquesAll scans were performed in supine position during end-inspiration without intravenous contrast.", [["intravenous", "ANATOMY", 156, 167], ["patients", "ORGANISM", 40, 48], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 156, 167], ["patients", "SPECIES", 40, 48], ["All scans", "TEST", 81, 90]]], ["At the time of entry into the study, each patient fulfilled the diagnostic criteria for COVID-19 used in each unit by respiratory samples tested by real-time reverse-transcriptase-polymerase chain reaction (rRT-PCR).", [["respiratory samples", "ANATOMY", 118, 137], ["COVID-19", "CHEMICAL", 88, 96], ["patient", "ORGANISM", 42, 49], ["COVID-19", "DNA", 88, 96], ["reverse-transcriptase", "PROTEIN", 158, 179], ["patient", "SPECIES", 42, 49], ["the study", "TEST", 26, 35], ["COVID", "TEST", 88, 93], ["respiratory samples", "TEST", 118, 137], ["polymerase chain reaction", "PROBLEM", 180, 205]]], ["The clinical, laboratory and CT imaging were available to evaluate in all patients.", [["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["CT imaging", "TEST", 29, 39]]], ["Thin-section CT was performed from the J o u r n a l P r e -p r o o f 6 section thickness and 5-mm gap.", [["Thin-section CT", "TEST", 0, 15], ["a l P r e -p r o o f 6 section thickness", "TEST", 49, 89]]], ["The images were photographed at conventional lung window settings (window level, -600 Hu; window width, 1,000-1,500 Hu).Analysis of CT imagesTwo fellowship-trained radiologists independently and blindly reviewed all CT images with approximately over 4 years of experience each in thoracic CT.", [["lung", "ANATOMY", 45, 49], ["thoracic", "ANATOMY", 280, 288], ["lung", "ORGAN", 45, 49], ["The images", "TEST", 0, 10], ["CT images", "TEST", 132, 141], ["all CT images", "TEST", 212, 225], ["thoracic CT", "TEST", 280, 291], ["lung", "ANATOMY", 45, 49], ["600 Hu", "OBSERVATION_MODIFIER", 82, 88], ["Hu", "OBSERVATION_MODIFIER", 116, 118], ["thoracic", "ANATOMY", 280, 288]]], ["Images were reviewed retrospectively and final decisions were reached by consensus.", [["Images", "TEST", 0, 6]]], ["Cases of disagreement about CT findings between initial radiologist interpretations were reviewed by a third thoracic radiologist with 10 years of experience.", [["CT findings", "TEST", 28, 39], ["thoracic", "ANATOMY", 109, 117]]], ["The decision radiologist determined a final decision for the patients by discussing and reviewing cases in the relevant literatures.", [["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69]]], ["No negative control cases were set.Analysis of CT imagesCT images were evaluated for the presence and distribution of parenchymal abnormalities, including (1) pure ground-glass opacity (GGO), which was defined as increased lung density with no obscuration of the underlying lung marks; (2) fine reticular pattern, which meant GGO with reticulation or intralobular networks which was regular, more uniform than crazy-paving pattern, and of the same size; (3) GGO with consolidation, which was defined as increased lung density with obscuration of the underlying lung marks; (4) consolidation;Analysis of CT images(5) air bronchogram(s); (6) crazy-paving pattern, which consisted of scattered or diffuse ground-glass attenuation with superimposed interlobular septal thickening and intralobular lines, irregular and higher density than fine reticular pattern; (7) intralesional vacuole sign, it was defined as lower-density shadow or air J o u r n a l P r e -p r o o f Interestingly, not all patients showed any of these CT findings in their initial stages and these radiological findings might be absent.", [["parenchymal", "ANATOMY", 118, 129], ["lung", "ANATOMY", 223, 227], ["lung", "ANATOMY", 274, 278], ["reticular", "ANATOMY", 295, 304], ["intralobular networks", "ANATOMY", 351, 372], ["lung", "ANATOMY", 513, 517], ["lung", "ANATOMY", 561, 565], ["interlobular septal", "ANATOMY", 745, 764], ["intralobular lines", "ANATOMY", 780, 798], ["vacuole", "ANATOMY", 876, 883], ["parenchymal abnormalities", "DISEASE", 118, 143], ["GGO", "DISEASE", 326, 329], ["parenchymal", "TISSUE", 118, 129], ["lung", "ORGAN", 223, 227], ["lung", "ORGAN", 274, 278], ["intralobular networks", "MULTI-TISSUE_STRUCTURE", 351, 372], ["lung", "ORGAN", 513, 517], ["lung", "ORGAN", 561, 565], ["interlobular septal", "PATHOLOGICAL_FORMATION", 745, 764], ["intralobular lines", "CELL", 780, 798], ["vacuole", "CELLULAR_COMPONENT", 876, 883], ["patients", "ORGANISM", 990, 998], ["patients", "SPECIES", 990, 998], ["Analysis of CT imagesCT images", "TEST", 35, 65], ["parenchymal abnormalities", "PROBLEM", 118, 143], ["pure ground-glass opacity", "PROBLEM", 159, 184], ["increased lung density", "PROBLEM", 213, 235], ["obscuration of the underlying lung marks", "PROBLEM", 244, 284], ["fine reticular pattern", "PROBLEM", 290, 312], ["reticulation", "PROBLEM", 335, 347], ["intralobular networks", "PROBLEM", 351, 372], ["GGO", "PROBLEM", 458, 461], ["consolidation", "PROBLEM", 467, 480], ["increased lung density", "PROBLEM", 503, 525], ["obscuration of the underlying lung marks", "PROBLEM", 531, 571], ["consolidation", "PROBLEM", 577, 590], ["CT images", "TEST", 603, 612], ["air bronchogram(s); (6) crazy-paving pattern", "PROBLEM", 616, 660], ["scattered or diffuse ground-glass attenuation", "PROBLEM", 681, 726], ["superimposed interlobular septal thickening", "PROBLEM", 732, 775], ["intralobular lines", "PROBLEM", 780, 798], ["irregular and higher density than fine reticular pattern", "PROBLEM", 800, 856], ["intralesional vacuole sign", "PROBLEM", 862, 888], ["lower-density shadow", "PROBLEM", 908, 928], ["these CT findings", "TEST", 1013, 1030], ["these radiological findings", "TEST", 1059, 1086], ["negative", "OBSERVATION", 3, 11], ["parenchymal", "ANATOMY_MODIFIER", 118, 129], ["abnormalities", "OBSERVATION", 130, 143], ["glass opacity", "OBSERVATION", 171, 184], ["GGO", "OBSERVATION_MODIFIER", 186, 189], ["increased", "OBSERVATION_MODIFIER", 213, 222], ["lung", "ANATOMY", 223, 227], ["density", "OBSERVATION", 228, 235], ["no", "UNCERTAINTY", 241, 243], ["obscuration", "OBSERVATION_MODIFIER", 244, 255], ["lung", "ANATOMY", 274, 278], ["fine", "OBSERVATION_MODIFIER", 290, 294], ["reticular pattern", "OBSERVATION", 295, 312], ["GGO", "OBSERVATION_MODIFIER", 326, 329], ["reticulation", "OBSERVATION_MODIFIER", 335, 347], ["intralobular", "ANATOMY_MODIFIER", 351, 363], ["more uniform", "OBSERVATION_MODIFIER", 392, 404], ["paving pattern", "OBSERVATION_MODIFIER", 416, 430], ["size", "OBSERVATION_MODIFIER", 448, 452], ["GGO", "OBSERVATION", 458, 461], ["consolidation", "OBSERVATION", 467, 480], ["increased", "OBSERVATION_MODIFIER", 503, 512], ["lung", "ANATOMY", 513, 517], ["density", "OBSERVATION", 518, 525], ["obscuration", "OBSERVATION_MODIFIER", 531, 542], ["lung", "ANATOMY", 561, 565], ["consolidation", "OBSERVATION", 577, 590], ["air bronchogram", "OBSERVATION", 616, 631], ["scattered", "OBSERVATION_MODIFIER", 681, 690], ["diffuse", "OBSERVATION_MODIFIER", 694, 701], ["ground-glass attenuation", "OBSERVATION", 702, 726], ["superimposed", "OBSERVATION_MODIFIER", 732, 744], ["interlobular", "ANATOMY_MODIFIER", 745, 757], ["septal", "ANATOMY_MODIFIER", 758, 764], ["thickening", "OBSERVATION", 765, 775], ["intralobular lines", "OBSERVATION", 780, 798], ["irregular", "OBSERVATION_MODIFIER", 800, 809], ["higher density", "OBSERVATION_MODIFIER", 814, 828], ["reticular pattern", "OBSERVATION", 839, 856], ["vacuole sign", "OBSERVATION", 876, 888], ["density shadow", "OBSERVATION", 914, 928], ["air J", "OBSERVATION", 932, 937]]], ["We found that 1 of 34 patients had normal initial chest CT.", [["chest", "ANATOMY", 50, 55], ["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["initial chest CT", "TEST", 42, 58], ["chest", "ANATOMY", 50, 55]]], ["This shows that CT imaging may lack whole sensitivity and does not show a negative predictive value.", [["CT imaging", "TEST", 16, 26], ["whole sensitivity", "TEST", 36, 53]]], ["Therefore, we can't solely depend on CT to completely exclude presence of COVID-19.", [["COVID-19", "CHEMICAL", 74, 82], ["CT", "TEST", 37, 39], ["COVID", "TEST", 74, 79]]], ["The main reason is that COVID-19 infection may take time to demonstrate as a disease prior to visible abnormalities on CT.", [["infection", "DISEASE", 33, 42], ["COVID-19", "ORGANISM", 24, 32], ["COVID-19 infection", "PROBLEM", 24, 42], ["a disease", "PROBLEM", 75, 84], ["visible abnormalities", "PROBLEM", 94, 115], ["CT", "TEST", 119, 121], ["main", "OBSERVATION_MODIFIER", 4, 8], ["infection", "OBSERVATION", 33, 42]]], ["Lung cavitation, discrete pulmonary nodules, and lymphadenopathy were not observed.", [["Lung", "ANATOMY", 0, 4], ["pulmonary nodules", "ANATOMY", 26, 43], ["lymphadenopathy", "DISEASE", 49, 64], ["Lung", "ORGAN", 0, 4], ["pulmonary nodules", "PATHOLOGICAL_FORMATION", 26, 43], ["Lung cavitation", "PROBLEM", 0, 15], ["discrete pulmonary nodules", "PROBLEM", 17, 43], ["lymphadenopathy", "PROBLEM", 49, 64], ["cavitation", "OBSERVATION", 5, 15], ["discrete", "OBSERVATION_MODIFIER", 17, 25], ["pulmonary", "ANATOMY", 26, 35], ["nodules", "OBSERVATION", 36, 43], ["lymphadenopathy", "OBSERVATION", 49, 64]]], ["Some of the patients also had underlying lung diseases such as fibrosis and emphysema.", [["lung", "ANATOMY", 41, 45], ["lung diseases", "DISEASE", 41, 54], ["fibrosis", "DISEASE", 63, 71], ["emphysema", "DISEASE", 76, 85], ["patients", "ORGANISM", 12, 20], ["lung", "ORGAN", 41, 45], ["patients", "SPECIES", 12, 20], ["underlying lung diseases", "PROBLEM", 30, 54], ["fibrosis", "PROBLEM", 63, 71], ["emphysema", "PROBLEM", 76, 85], ["lung", "ANATOMY", 41, 45], ["diseases", "OBSERVATION", 46, 54], ["fibrosis", "OBSERVATION", 63, 71], ["emphysema", "OBSERVATION", 76, 85]]], ["These features were all recorded for the patients with the coronavirus infections.Analysis of CT imagesThe 4 patients with no symptoms had typical CT findings of COVID-19 in our study.", [["coronavirus infections", "DISEASE", 59, 81], ["patients", "ORGANISM", 41, 49], ["coronavirus", "ORGANISM", 59, 70], ["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 41, 49], ["patients", "SPECIES", 109, 117], ["the coronavirus infections", "PROBLEM", 55, 81], ["CT images", "TEST", 94, 103], ["symptoms", "PROBLEM", 126, 134], ["COVID", "TEST", 162, 167], ["our study", "TEST", 174, 183], ["coronavirus infections", "OBSERVATION", 59, 81]]], ["This suggests that CT examination is also important for those with an epidemiological history, although there are no clinical symptoms.", [["CT examination", "TEST", 19, 33], ["clinical symptoms", "PROBLEM", 117, 134], ["no", "UNCERTAINTY", 114, 116]]], ["The WHO suggested contact precautions when resolving suspected cases being infected with COVID-19 [17] .", [["COVID-19", "CHEMICAL", 89, 97], ["contact precautions", "TREATMENT", 18, 37], ["COVID", "TEST", 89, 94]]], ["Timely identification of patients is needed for those patients who may present with unusual or mild symptoms, or carry COVID-19 not being recognized, rRT-PCR testing yielding false-negative results [19] .Analysis of CT imagesThus, patients who were exposure or travel to areas of COVID-19 outbreak and were with suggestive imaging findings may aid in early isolation.", [["patients", "ORGANISM", 25, 33], ["patients", "ORGANISM", 54, 62], ["patients", "ORGANISM", 231, 239], ["patients", "SPECIES", 25, 33], ["patients", "SPECIES", 54, 62], ["patients", "SPECIES", 231, 239], ["unusual or mild symptoms", "PROBLEM", 84, 108], ["COVID", "TEST", 119, 124], ["rRT", "TEST", 150, 153], ["PCR testing", "TEST", 154, 165], ["Analysis of CT images", "TEST", 204, 225], ["COVID", "TEST", 280, 285], ["imaging findings", "TEST", 323, 339]]], ["Generally, the CT outcomes reported for COVID-19 are resembling to those reported with MERS-CoV [20, 21] and SARS-CoV [22, 23] , not surprised because the responsible virus is also coronavirus.", [["coronavirus", "DISEASE", 181, 192], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 87, 95], ["SARS-CoV", "ORGANISM", 109, 117], ["MERS-CoV", "SPECIES", 87, 95], ["SARS-CoV", "SPECIES", 109, 117], ["the CT outcomes", "TEST", 11, 26], ["COVID", "TEST", 40, 45], ["MERS", "TEST", 87, 91], ["CoV", "TEST", 92, 95], ["SARS-CoV", "TEST", 109, 117], ["the responsible virus", "PROBLEM", 151, 172], ["coronavirus", "PROBLEM", 181, 192], ["virus", "OBSERVATION", 167, 172], ["coronavirus", "OBSERVATION", 181, 192]]], ["Although we managed to radiologically observe the COVID-19 infected individuals, there are still many questions to be answered and further study is required to understand how patients fare after treatment.", [["patients", "ORGANISM", 175, 183], ["patients", "SPECIES", 175, 183], ["further study", "TEST", 131, 144], ["treatment", "TREATMENT", 195, 204]]]], "31b43767440cb19003d22bd82c936624b2cdcf75": [["IntroductionInhalational injury involves damage to the respiratory tract and lungs by heat, smoke and toxic inhalants [1] with incidence increasing with the size of the burn injury as well as the age of the patient [2, 3] .", [["respiratory tract", "ANATOMY", 55, 72], ["lungs", "ANATOMY", 77, 82], ["Inhalational injury", "DISEASE", 12, 31], ["damage to the respiratory tract", "DISEASE", 41, 72], ["burn", "DISEASE", 169, 173], ["respiratory tract", "ORGANISM_SUBDIVISION", 55, 72], ["lungs", "ORGAN", 77, 82], ["patient", "ORGANISM", 207, 214], ["patient", "SPECIES", 207, 214], ["IntroductionInhalational injury", "PROBLEM", 0, 31], ["damage to the respiratory tract", "PROBLEM", 41, 72], ["the burn injury", "PROBLEM", 165, 180], ["respiratory tract", "ANATOMY", 55, 72], ["lungs", "ANATOMY", 77, 82], ["burn", "OBSERVATION", 169, 173]]], ["Along with pulmonary complications, inhalation injury is responsible for up to 77% of all deaths following burn injury and is most often a consequence of carbon monoxide poisoning [4, 5] .", [["pulmonary", "ANATOMY", 11, 20], ["pulmonary complications", "DISEASE", 11, 34], ["inhalation injury", "DISEASE", 36, 53], ["deaths", "DISEASE", 90, 96], ["burn injury", "DISEASE", 107, 118], ["carbon monoxide", "CHEMICAL", 154, 169], ["poisoning", "DISEASE", 170, 179], ["carbon monoxide", "CHEMICAL", 154, 169], ["pulmonary", "ORGAN", 11, 20], ["carbon monoxide", "SIMPLE_CHEMICAL", 154, 169], ["pulmonary complications", "PROBLEM", 11, 34], ["inhalation injury", "PROBLEM", 36, 53], ["burn injury", "PROBLEM", 107, 118], ["carbon monoxide poisoning", "PROBLEM", 154, 179], ["pulmonary", "ANATOMY", 11, 20], ["complications", "OBSERVATION", 21, 34], ["inhalation injury", "OBSERVATION", 36, 53]]], ["Smoke inhalation is present in 2-30% of all flame burn injuries; however, mucosal injury at the level of the vocal folds as a result of inhaled heat is rare [6] .IntroductionThe management of the burn patient with concomitant inhalation injury is widely accepted to be complex.", [["mucosal", "ANATOMY", 74, 81], ["vocal folds", "ANATOMY", 109, 120], ["burn injuries", "DISEASE", 50, 63], ["burn", "DISEASE", 196, 200], ["inhalation injury", "DISEASE", 226, 243], ["mucosal", "MULTI-TISSUE_STRUCTURE", 74, 81], ["vocal", "ORGAN", 109, 114], ["patient", "ORGANISM", 201, 208], ["patient", "SPECIES", 201, 208], ["all flame burn injuries", "PROBLEM", 40, 63], ["mucosal injury", "PROBLEM", 74, 88], ["the burn", "PROBLEM", 192, 200], ["concomitant inhalation injury", "PROBLEM", 214, 243], ["injuries", "OBSERVATION", 55, 63], ["mucosal", "ANATOMY", 74, 81], ["injury", "OBSERVATION", 82, 88], ["vocal folds", "ANATOMY", 109, 120], ["burn", "OBSERVATION", 196, 200], ["inhalation injury", "OBSERVATION", 226, 243]]], ["Inhalation injury is well known to be an independent risk factor for mortality and is also associated with significant morbidity, which may be observed as early or late sequelae [7, 8] .", [["Inhalation injury", "DISEASE", 0, 17], ["Inhalation injury", "PROBLEM", 0, 17], ["significant morbidity", "PROBLEM", 107, 128], ["morbidity", "OBSERVATION", 119, 128]]], ["Immediately following inhalation injury, risk of respiratory distress and airway compromise frequently necessitate the need for intubation and mechanical ventilation.", [["respiratory", "ANATOMY", 49, 60], ["airway", "ANATOMY", 74, 80], ["inhalation injury", "DISEASE", 22, 39], ["respiratory distress", "DISEASE", 49, 69], ["airway", "MULTI-TISSUE_STRUCTURE", 74, 80], ["inhalation injury", "PROBLEM", 22, 39], ["respiratory distress", "PROBLEM", 49, 69], ["airway compromise", "PROBLEM", 74, 91], ["intubation", "TREATMENT", 128, 138], ["mechanical ventilation", "TREATMENT", 143, 165], ["respiratory distress", "OBSERVATION", 49, 69], ["airway", "ANATOMY", 74, 80], ["compromise", "OBSERVATION", 81, 91]]], ["Patients with significant airway involvement of their burn often develop direct mucosal injury to the respiratory tract, mucosal sloughing, and inflammation ( Fig. 1) , potentially leading to airway obstruction and impaired gas exchange.", [["airway", "ANATOMY", 26, 32], ["mucosal", "ANATOMY", 80, 87], ["respiratory tract", "ANATOMY", 102, 119], ["mucosal", "ANATOMY", 121, 128], ["airway", "ANATOMY", 192, 198], ["burn", "DISEASE", 54, 58], ["injury to the respiratory tract", "DISEASE", 88, 119], ["inflammation", "DISEASE", 144, 156], ["airway obstruction", "DISEASE", 192, 210], ["Patients", "ORGANISM", 0, 8], ["airway", "MULTI-TISSUE_STRUCTURE", 26, 32], ["mucosal", "MULTI-TISSUE_STRUCTURE", 80, 87], ["respiratory tract", "ORGANISM_SUBDIVISION", 102, 119], ["mucosal", "PATHOLOGICAL_FORMATION", 121, 128], ["airway", "MULTI-TISSUE_STRUCTURE", 192, 198], ["Patients", "SPECIES", 0, 8], ["significant airway involvement", "PROBLEM", 14, 44], ["their burn", "PROBLEM", 48, 58], ["direct mucosal injury to the respiratory tract", "PROBLEM", 73, 119], ["mucosal sloughing", "PROBLEM", 121, 138], ["inflammation", "PROBLEM", 144, 156], ["airway obstruction", "PROBLEM", 192, 210], ["impaired gas exchange", "PROBLEM", 215, 236], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["airway", "ANATOMY", 26, 32], ["involvement", "OBSERVATION", 33, 44], ["mucosal", "ANATOMY", 80, 87], ["injury", "OBSERVATION", 88, 94], ["respiratory tract", "ANATOMY", 102, 119], ["mucosal", "ANATOMY", 121, 128], ["sloughing", "OBSERVATION", 129, 138], ["inflammation", "OBSERVATION", 144, 156], ["potentially leading to", "UNCERTAINTY", 169, 191], ["airway", "ANATOMY", 192, 198], ["obstruction", "OBSERVATION", 199, 210], ["impaired", "OBSERVATION_MODIFIER", 215, 223], ["gas exchange", "OBSERVATION", 224, 236]]], ["These physiological changes in addition to higher fluid resuscitation requirements lead to an increased risk for pulmonary and airway oedema, acute respiratory distress syndrome (ARDS), ventilator associated pneumonia (VAP), multiple organ dysfunction syndrome (MODS) and therefore longer duration of mechanical ventilation and length of stay in the Intensive Care Unit (ICU) [9] .", [["fluid", "ANATOMY", 50, 55], ["pulmonary", "ANATOMY", 113, 122], ["airway", "ANATOMY", 127, 133], ["respiratory", "ANATOMY", 148, 159], ["organ", "ANATOMY", 234, 239], ["pulmonary and airway oedema", "DISEASE", 113, 140], ["acute respiratory distress syndrome", "DISEASE", 142, 177], ["ARDS", "DISEASE", 179, 183], ["ventilator associated pneumonia", "DISEASE", 186, 217], ["VAP", "DISEASE", 219, 222], ["multiple organ dysfunction syndrome", "DISEASE", 225, 260], ["MODS", "DISEASE", 262, 266], ["pulmonary", "ORGAN", 113, 122], ["airway", "MULTI-TISSUE_STRUCTURE", 127, 133], ["organ", "ORGAN", 234, 239], ["These physiological changes", "PROBLEM", 0, 27], ["higher fluid resuscitation requirements", "TREATMENT", 43, 82], ["an increased risk", "PROBLEM", 91, 108], ["pulmonary and airway oedema", "PROBLEM", 113, 140], ["acute respiratory distress syndrome", "PROBLEM", 142, 177], ["ARDS)", "PROBLEM", 179, 184], ["ventilator associated pneumonia", "PROBLEM", 186, 217], ["VAP", "PROBLEM", 219, 222], ["multiple organ dysfunction syndrome", "PROBLEM", 225, 260], ["MODS", "PROBLEM", 262, 266], ["mechanical ventilation", "TREATMENT", 301, 323], ["higher", "OBSERVATION_MODIFIER", 43, 49], ["fluid resuscitation", "OBSERVATION", 50, 69], ["increased", "OBSERVATION_MODIFIER", 94, 103], ["pulmonary", "ANATOMY", 113, 122], ["airway", "ANATOMY", 127, 133], ["oedema", "OBSERVATION", 134, 140], ["acute", "OBSERVATION_MODIFIER", 142, 147], ["respiratory distress syndrome", "OBSERVATION", 148, 177], ["pneumonia", "OBSERVATION", 208, 217], ["multiple", "OBSERVATION_MODIFIER", 225, 233], ["organ", "ANATOMY", 234, 239], ["dysfunction", "OBSERVATION", 240, 251], ["mechanical ventilation", "OBSERVATION", 301, 323]]], ["Potential late consequences of inhalation injury may also occur.", [["inhalation injury", "DISEASE", 31, 48], ["inhalation injury", "PROBLEM", 31, 48], ["inhalation injury", "OBSERVATION", 31, 48]]], ["These may evidence as scarring, contracture and stenosis or stricture of the mucosal tissue, with subsequent impacts on physiological function of those structures affected [10] .IntroductionDue to the early and potentially long-term damage to the laryngeal and pharyngeal structures, dysphagia and dysphonia are not uncommon in this population.", [["mucosal tissue", "ANATOMY", 77, 91], ["laryngeal", "ANATOMY", 247, 256], ["pharyngeal structures", "ANATOMY", 261, 282], ["contracture", "DISEASE", 32, 43], ["stenosis", "DISEASE", 48, 56], ["stricture", "DISEASE", 60, 69], ["dysphagia", "DISEASE", 284, 293], ["dysphonia", "DISEASE", 298, 307], ["stricture", "PATHOLOGICAL_FORMATION", 60, 69], ["mucosal tissue", "TISSUE", 77, 91], ["laryngeal", "ORGAN", 247, 256], ["pharyngeal structures", "MULTI-TISSUE_STRUCTURE", 261, 282], ["scarring", "PROBLEM", 22, 30], ["contracture", "PROBLEM", 32, 43], ["stenosis", "PROBLEM", 48, 56], ["stricture of the mucosal tissue", "PROBLEM", 60, 91], ["IntroductionDue", "TREATMENT", 178, 193], ["long-term damage to the laryngeal and pharyngeal structures", "PROBLEM", 223, 282], ["dysphagia", "PROBLEM", 284, 293], ["dysphonia", "PROBLEM", 298, 307], ["may evidence as", "UNCERTAINTY", 6, 21], ["scarring", "OBSERVATION", 22, 30], ["contracture", "OBSERVATION", 32, 43], ["stenosis", "OBSERVATION", 48, 56], ["stricture", "OBSERVATION", 60, 69], ["mucosal tissue", "ANATOMY", 77, 91], ["impacts", "OBSERVATION_MODIFIER", 109, 116], ["long-term", "OBSERVATION_MODIFIER", 223, 232], ["damage", "OBSERVATION", 233, 239], ["laryngeal", "ANATOMY", 247, 256], ["pharyngeal structures", "ANATOMY", 261, 282], ["dysphagia", "OBSERVATION", 284, 293], ["dysphonia", "OBSERVATION", 298, 307]]], ["It is already known that dysphagia is a common consequence of burn injury (\u00b1 inhalation injury), with the prevalence rate of dysphagia following thermal burn injury in the adult population documented to be 11.18% in the general adult population [11] and up to 46.97% in the aged (\u2265 75 years) burn population [12] .", [["dysphagia", "DISEASE", 25, 34], ["burn injury", "DISEASE", 62, 73], ["inhalation injury", "DISEASE", 77, 94], ["dysphagia", "DISEASE", 125, 134], ["burn injury", "DISEASE", 153, 164], ["burn", "DISEASE", 292, 296], ["dysphagia", "PROBLEM", 25, 34], ["burn injury", "PROBLEM", 62, 73], ["inhalation injury", "PROBLEM", 77, 94], ["dysphagia", "PROBLEM", 125, 134], ["thermal burn injury", "PROBLEM", 145, 164], ["dysphagia", "OBSERVATION", 25, 34]]], ["A number of predictive factors for dysphagia development post burns have also been identified [11] and subsequently validated [13] .", [["dysphagia", "DISEASE", 35, 44], ["burns", "DISEASE", 62, 67], ["predictive factors", "PROBLEM", 12, 30], ["dysphagia development post burns", "PROBLEM", 35, 67]]], ["These factors, with consideration to advancing age, include the presence of head and neck burns, total burn surface area (TBSA) \u2265 18%, need for ICU admission and mechanical ventilation, and presence of tracheostomyand inhalation injury.", [["head", "ANATOMY", 76, 80], ["neck", "ANATOMY", 85, 89], ["burn surface area", "ANATOMY", 103, 120], ["head and neck burns", "DISEASE", 76, 95], ["burn", "DISEASE", 103, 107], ["inhalation injury", "DISEASE", 218, 235], ["head", "ORGANISM_SUBDIVISION", 76, 80], ["neck", "ORGANISM_SUBDIVISION", 85, 89], ["head and neck burns", "PROBLEM", 76, 95], ["total burn surface area", "TREATMENT", 97, 120], ["mechanical ventilation", "TREATMENT", 162, 184], ["tracheostomyand inhalation injury", "PROBLEM", 202, 235], ["head", "ANATOMY", 76, 80], ["neck", "ANATOMY", 85, 89], ["burns", "OBSERVATION", 90, 95], ["total", "OBSERVATION_MODIFIER", 97, 102], ["burn", "OBSERVATION_MODIFIER", 103, 107], ["surface", "OBSERVATION_MODIFIER", 108, 115], ["mechanical ventilation", "OBSERVATION", 162, 184], ["inhalation injury", "OBSERVATION", 218, 235]]], ["However, whilst inhalation injury has been identified as a predictor for dysphagia and its complications, the incidence and severity of dysphagia, and the pattern of recovery specifically in the subset of patients with burn injury and associated inhalation injury are not well understood.IntroductionDysphagia following burn injury, not specifically with an inhalation component, has been characterised as presenting with deficits in both the motor as well as sensory aspects of swallowing function with onset evident early in the acute admission.", [["inhalation injury", "DISEASE", 16, 33], ["dysphagia", "DISEASE", 73, 82], ["dysphagia", "DISEASE", 136, 145], ["burn injury", "DISEASE", 219, 230], ["inhalation injury", "DISEASE", 246, 263], ["IntroductionDysphagia", "DISEASE", 288, 309], ["burn injury", "DISEASE", 320, 331], ["patients", "ORGANISM", 205, 213], ["patients", "SPECIES", 205, 213], ["whilst inhalation injury", "PROBLEM", 9, 33], ["dysphagia", "PROBLEM", 73, 82], ["its complications", "PROBLEM", 87, 104], ["dysphagia", "PROBLEM", 136, 145], ["burn injury", "PROBLEM", 219, 230], ["associated inhalation injury", "PROBLEM", 235, 263], ["IntroductionDysphagia", "PROBLEM", 288, 309], ["burn injury", "PROBLEM", 320, 331], ["an inhalation component", "PROBLEM", 355, 378], ["deficits", "PROBLEM", 422, 430], ["dysphagia", "OBSERVATION", 136, 145], ["inhalation injury", "OBSERVATION", 246, 263], ["burn injury", "OBSERVATION", 320, 331]]], ["In many cases, complete recovery can be achieved prior to hospital discharge [14, 15] , although a small proportion of patients will experience more severe swallowing impairment with a lengthy and at times incomplete recovery [14, 16] .", [["swallowing impairment", "DISEASE", 156, 177], ["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 119, 127], ["more severe swallowing impairment", "PROBLEM", 144, 177], ["small", "OBSERVATION_MODIFIER", 99, 104], ["severe", "OBSERVATION_MODIFIER", 149, 155], ["swallowing", "OBSERVATION", 156, 166]]], ["Initiation of oral intake following burn injury has been documented to take longer in patients identified with dysphagia than in those without [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] with lengthy periods of enteral nutrition often necessary.", [["oral", "ANATOMY", 14, 18], ["burn injury", "DISEASE", 36, 47], ["dysphagia", "DISEASE", 111, 120], ["[14] [15] [16] [17] [18] [19] [20] [21] [22]", "CHEMICAL", 143, 187], ["[14] [15] [16] [17] [18] [19] [20] [21] [22]", "CHEMICAL", 143, 187], ["oral", "ORGANISM_SUBDIVISION", 14, 18], ["patients", "ORGANISM", 86, 94], ["[14] [15] [16] [17] [18] [19] [20] [21] [22] [23]", "SIMPLE_CHEMICAL", 143, 192], ["patients", "SPECIES", 86, 94], ["burn injury", "PROBLEM", 36, 47], ["dysphagia", "PROBLEM", 111, 120], ["enteral nutrition", "TREATMENT", 217, 234]]], ["Resolution of dysphagia after burn injury also follows a variable, and sometimes protracted period of recovery.", [["dysphagia", "DISEASE", 14, 23], ["burn injury", "DISEASE", 30, 41], ["dysphagia", "PROBLEM", 14, 23], ["burn injury", "PROBLEM", 30, 41], ["dysphagia", "OBSERVATION", 14, 23], ["burn", "OBSERVATION_MODIFIER", 30, 34], ["injury", "OBSERVATION", 35, 41], ["protracted", "OBSERVATION_MODIFIER", 81, 91]]], ["Burn patients, identified with dysphagia, have been reported to take between 1 and 222 days to achieve their premorbid swallowing function as defined by reaching premorbid oral diet and fluids and no longer requiring the aid of supplementary nutrition, therapeutic or compensatory manoeuvres [14-16, 18, 20] .IntroductionExamination of dysphagia severity in a large cohort (n = 438) of patients following thermal burn injury, of which 6.85% were identified as having concomitant inhalation injury, has revealed that 41% presented with severe dysphagia at the point of initial swallowing assessment [14] .", [["oral", "ANATOMY", 172, 176], ["dysphagia", "DISEASE", 31, 40], ["dysphagia", "DISEASE", 336, 345], ["burn injury", "DISEASE", 413, 424], ["inhalation injury", "DISEASE", 479, 496], ["dysphagia", "DISEASE", 542, 551], ["patients", "ORGANISM", 5, 13], ["oral", "ORGANISM_SUBDIVISION", 172, 176], ["patients", "ORGANISM", 386, 394], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 386, 394], ["dysphagia", "PROBLEM", 31, 40], ["fluids", "TREATMENT", 186, 192], ["supplementary nutrition", "TREATMENT", 228, 251], ["compensatory manoeuvres", "TREATMENT", 268, 291], ["IntroductionExamination", "TEST", 309, 332], ["dysphagia severity", "PROBLEM", 336, 354], ["thermal burn injury", "PROBLEM", 405, 424], ["concomitant inhalation injury", "PROBLEM", 467, 496], ["severe dysphagia", "PROBLEM", 535, 551], ["initial swallowing assessment", "TEST", 568, 597], ["inhalation injury", "OBSERVATION", 479, 496], ["severe", "OBSERVATION_MODIFIER", 535, 541], ["dysphagia", "OBSERVATION", 542, 551]]], ["However, no specific sub-analysis of those patients with or without inhalation injury was conducted to determine any differential patterns of dysphagia severity.", [["inhalation injury", "DISEASE", 68, 85], ["dysphagia", "DISEASE", 142, 151], ["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["inhalation injury", "PROBLEM", 68, 85], ["dysphagia severity", "PROBLEM", 142, 160], ["no", "UNCERTAINTY", 9, 11], ["dysphagia", "OBSERVATION", 142, 151]]], ["Considering that increased dysphagia severity and duration to recovery has also been connected to other factors necessary to managing inhalation injury, including endotracheal tube size and duration of intubation and tracheostomy [11, 13, [24] [25] [26] [27] , it is possible that dysphagia severity in this cohort will be even higher than in the head and neck burn population.", [["endotracheal tube", "ANATOMY", 163, 180], ["head", "ANATOMY", 347, 351], ["neck", "ANATOMY", 356, 360], ["dysphagia", "DISEASE", 27, 36], ["inhalation injury", "DISEASE", 134, 151], ["dysphagia", "DISEASE", 281, 290], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 163, 180], ["head", "ORGANISM_SUBDIVISION", 347, 351], ["and neck", "CANCER", 352, 360], ["increased dysphagia severity", "PROBLEM", 17, 45], ["managing inhalation injury", "PROBLEM", 125, 151], ["endotracheal tube size", "TREATMENT", 163, 185], ["intubation", "TREATMENT", 202, 212], ["tracheostomy", "TREATMENT", 217, 229], ["dysphagia severity", "PROBLEM", 281, 299], ["neck burn population", "PROBLEM", 356, 376], ["increased", "OBSERVATION_MODIFIER", 17, 26], ["dysphagia", "OBSERVATION", 27, 36], ["endotracheal tube", "OBSERVATION", 163, 180], ["size", "OBSERVATION_MODIFIER", 181, 185], ["head", "ANATOMY", 347, 351], ["neck", "ANATOMY", 356, 360], ["burn", "OBSERVATION", 361, 365]]], ["The application of enteral feeding following burn injury is also necessary, not only as an adjunct to managing nutritional sequelae associated with dysphagia alone but also to ensure adequate nourishment to facilitate wound healing, physical and psychological rehabilitation [28] .", [["wound", "ANATOMY", 218, 223], ["burn injury", "DISEASE", 45, 56], ["dysphagia", "DISEASE", 148, 157], ["wound", "PATHOLOGICAL_FORMATION", 218, 223], ["enteral feeding", "TREATMENT", 19, 34], ["burn injury", "PROBLEM", 45, 56], ["nutritional sequelae", "PROBLEM", 111, 131], ["dysphagia", "PROBLEM", 148, 157], ["wound healing", "PROBLEM", 218, 231]]], ["Duration of enteral feeding in the general thermal burns population has been shown to be lengthy and often extends beyond the time that dysphagia has resolved [14] [15] [16] 23] .", [["burns", "DISEASE", 51, 56], ["dysphagia", "DISEASE", 136, 145], ["[14] [15] [16] 23", "CHEMICAL", 159, 176], ["enteral feeding", "TREATMENT", 12, 27], ["dysphagia", "PROBLEM", 136, 145]]], ["Again, there is high probability this also will be protracted in those with concomitant inhalation injury.IntroductionThe presence of dysphagia post thermal burn injury has been reported to be connected with increased hospital length of stay, morbidity and mortality as well as requiring increased periods of Speech-Language Pathology (SLP) intervention [12, 14] .", [["inhalation injury", "DISEASE", 88, 105], ["dysphagia", "DISEASE", 134, 143], ["burn injury", "DISEASE", 157, 168], ["high probability", "PROBLEM", 16, 32], ["concomitant inhalation injury", "PROBLEM", 76, 105], ["dysphagia", "PROBLEM", 134, 143], ["thermal burn injury", "PROBLEM", 149, 168], ["morbidity", "PROBLEM", 243, 252], ["high probability", "OBSERVATION", 16, 32], ["inhalation injury", "OBSERVATION", 88, 105], ["dysphagia", "OBSERVATION", 134, 143], ["burn injury", "OBSERVATION", 157, 168]]], ["Consequently, the literature to date clearly describes that dysphagia is a considerable issue with substantial contribution to the burden of treatment for a patient with thermal burn injury.", [["dysphagia", "DISEASE", 60, 69], ["burn injury", "DISEASE", 178, 189], ["patient", "ORGANISM", 157, 164], ["patient", "SPECIES", 157, 164], ["dysphagia", "PROBLEM", 60, 69], ["treatment", "TREATMENT", 141, 150], ["thermal burn injury", "PROBLEM", 170, 189], ["dysphagia", "OBSERVATION", 60, 69], ["injury", "OBSERVATION", 183, 189]]], ["Although data detailing the presentation and clinical progression of dysphagia for the general burn population are developing, and predictive factors including inhalation injury have been identified, clinical details regarding the incidence and clinical progression in the subset of patients who also present with inhalation injury are lacking.", [["dysphagia", "DISEASE", 69, 78], ["burn", "DISEASE", 95, 99], ["inhalation injury", "DISEASE", 160, 177], ["inhalation injury", "DISEASE", 314, 331], ["patients", "ORGANISM", 283, 291], ["patients", "SPECIES", 283, 291], ["dysphagia", "PROBLEM", 69, 78], ["the general burn population", "PROBLEM", 83, 110], ["inhalation injury", "PROBLEM", 160, 177], ["inhalation injury", "PROBLEM", 314, 331], ["injury", "OBSERVATION", 325, 331]]], ["The aim of this study was therefore, to determine the incidence of dysphagia and describe the clinical profile of swallowing function for those admitted with inhalation burn injury, and contrast this with known patterns of recovery for those without inhalation injury post burn.ParticipantsThe model of care for severe burn injury is centralised to key specialist services within each state/territory in Australia.", [["dysphagia", "DISEASE", 67, 76], ["burn injury", "DISEASE", 169, 180], ["inhalation injury", "DISEASE", 250, 267], ["burn", "DISEASE", 273, 277], ["burn injury", "DISEASE", 319, 330], ["Participants", "SPECIES", 278, 290], ["this study", "TEST", 11, 21], ["dysphagia", "PROBLEM", 67, 76], ["inhalation burn injury", "PROBLEM", 158, 180], ["inhalation injury", "PROBLEM", 250, 267], ["burn", "PROBLEM", 273, 277], ["severe burn injury", "PROBLEM", 312, 330], ["dysphagia", "OBSERVATION", 67, 76]]], ["The NSW Statewide Burn Injury Service (SBIS) at Concord Repatriation General Hospital (CRGH) campus receives all patients in accordance with the Australian and New Zealand Burns Association (ANZBA) transfer guidelines, which includes those patients with cutaneous burn injury and concomitant inhalation burn injury.", [["cutaneous", "ANATOMY", 254, 263], ["Injury", "DISEASE", 23, 29], ["burn injury", "DISEASE", 264, 275], ["burn injury", "DISEASE", 303, 314], ["patients", "ORGANISM", 113, 121], ["patients", "ORGANISM", 240, 248], ["patients", "SPECIES", 113, 121], ["patients", "SPECIES", 240, 248], ["cutaneous burn injury", "PROBLEM", 254, 275], ["concomitant inhalation burn injury", "PROBLEM", 280, 314], ["Burn", "OBSERVATION_MODIFIER", 18, 22], ["Injury", "OBSERVATION", 23, 29], ["cutaneous", "ANATOMY", 254, 263], ["concomitant", "OBSERVATION_MODIFIER", 280, 291], ["inhalation burn", "OBSERVATION", 292, 307]]], ["Within the SBIS at CRGH, SLP services are an integrated part of the multidisciplinary care team and a blanket referral system is in place to see all patients fulfilling a set of criteria inclusive of head and neck burns, suspected inhalation injury, ICU admission, mechanical ventilation, tracheostomy, concomitant neurological injury and age greater than 75 years.", [["head", "ANATOMY", 200, 204], ["neck", "ANATOMY", 209, 213], ["neurological", "ANATOMY", 315, 327], ["head and neck burns", "DISEASE", 200, 219], ["inhalation injury", "DISEASE", 231, 248], ["neurological injury", "DISEASE", 315, 334], ["patients", "ORGANISM", 149, 157], ["head", "ORGANISM_SUBDIVISION", 200, 204], ["neck", "ORGANISM_SUBDIVISION", 209, 213], ["patients", "SPECIES", 149, 157], ["a blanket referral system", "TREATMENT", 100, 125], ["head and neck burns", "PROBLEM", 200, 219], ["inhalation injury", "PROBLEM", 231, 248], ["mechanical ventilation", "TREATMENT", 265, 287], ["tracheostomy", "TREATMENT", 289, 301], ["concomitant neurological injury", "PROBLEM", 303, 334], ["head", "ANATOMY", 200, 204], ["neck", "ANATOMY", 209, 213], ["burns", "OBSERVATION", 214, 219], ["inhalation injury", "OBSERVATION", 231, 248], ["mechanical ventilation", "OBSERVATION", 265, 287], ["tracheostomy", "OBSERVATION", 289, 301]]], ["For the current study, all patients admitted to the SBIS at CRGH campus over a ten-year period (January 2008 to December 2017) for treatment of an acute thermal burn injury with the intention to treat being survival were identified through the SBIS database, then cross referenced with CRGH medical and SLP records.", [["SBIS", "DISEASE", 52, 56], ["burn injury", "DISEASE", 161, 172], ["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["the current study", "TEST", 4, 21], ["treatment", "TREATMENT", 131, 140], ["an acute thermal burn injury", "PROBLEM", 144, 172], ["the SBIS database", "TEST", 240, 257], ["acute", "OBSERVATION_MODIFIER", 147, 152], ["thermal", "OBSERVATION_MODIFIER", 153, 160], ["burn", "OBSERVATION", 161, 165]]], ["For inclusion in the study, patients must have had confirmed inhalation injury on laryngoscopy, had been assessed by the SLP service in accordance with the pre-existing blanket referral system, and have no prior medical record history of pre-existing burn injury, dysphagia, dysphonia, neurological or head and neck pathology.", [["neurological", "ANATOMY", 286, 298], ["head", "ANATOMY", 302, 306], ["neck", "ANATOMY", 311, 315], ["inhalation injury", "DISEASE", 61, 78], ["burn injury", "DISEASE", 251, 262], ["dysphagia", "DISEASE", 264, 273], ["dysphonia", "DISEASE", 275, 284], ["neurological or head and neck pathology", "DISEASE", 286, 325], ["patients", "ORGANISM", 28, 36], ["head", "ORGANISM_SUBDIVISION", 302, 306], ["neck", "ORGANISM_SUBDIVISION", 311, 315], ["patients", "SPECIES", 28, 36], ["the study", "TEST", 17, 26], ["inhalation injury", "PROBLEM", 61, 78], ["laryngoscopy", "TEST", 82, 94], ["pre-existing burn injury", "PROBLEM", 238, 262], ["dysphagia", "PROBLEM", 264, 273], ["dysphonia", "PROBLEM", 275, 284], ["neurological or head and neck pathology", "PROBLEM", 286, 325], ["dysphagia", "OBSERVATION", 264, 273], ["dysphonia", "OBSERVATION", 275, 284], ["head", "ANATOMY", 302, 306], ["neck", "ANATOMY", 311, 315], ["pathology", "OBSERVATION", 316, 325]]], ["The study was conducted with full ethical clearance (CRGH Human Research and Ethics Committee: AU/1/7A68315).ProcedureInformation was obtained through a retrospective medical and SLP record review.", [["Human", "ORGANISM", 58, 63], ["Human", "SPECIES", 58, 63], ["The study", "TEST", 0, 9]]], ["For all eligible participants, information was collected from the time of initial injury and throughout the complete duration of inpatient treatment as well as outpatient care, until the time of dysphagia and dysphonia resolution or until swallowing and voice functioning had plateaued such that no further gains from treatment were anticipated.", [["dysphagia", "DISEASE", 195, 204], ["dysphonia", "DISEASE", 209, 218], ["participants", "SPECIES", 17, 29], ["initial injury", "PROBLEM", 74, 88], ["inpatient treatment", "TREATMENT", 129, 148], ["dysphagia", "PROBLEM", 195, 204], ["dysphonia resolution", "PROBLEM", 209, 229], ["treatment", "TREATMENT", 318, 327], ["injury", "OBSERVATION", 82, 88]]], ["From the medical charts, key demographic and medical information was collected for all cases including age, gender, %TBSA burn, mechanism of burn, anatomical location of burn, hospital length of stay (LOS), ICU LOS, days of mechanical ventilation and presence of tracheostomy.ProcedureSpecific information pertaining to dysphagia, dysphonia and its recovery were then compiled from medical and SLP records.", [["burn", "DISEASE", 122, 126], ["burn", "DISEASE", 141, 145], ["burn", "DISEASE", 170, 174], ["dysphagia", "DISEASE", 320, 329], ["dysphonia", "DISEASE", 331, 340], ["burn", "PROBLEM", 141, 145], ["mechanical ventilation", "TREATMENT", 224, 246], ["tracheostomy", "TREATMENT", 263, 275], ["dysphagia", "PROBLEM", 320, 329], ["dysphonia", "PROBLEM", 331, 340], ["burn", "OBSERVATION", 170, 174], ["mechanical ventilation", "OBSERVATION", 224, 246], ["tracheostomy", "OBSERVATION", 263, 275], ["dysphonia", "OBSERVATION", 331, 340]]], ["As the SLP service is an integrated part of the SBIS at CRGH in both the inpatient and outpatient setting, patients are reviewed on a daily basis initially and subsequently as clinically indicated until premorbid level of swallow and voice functioning is achieved or plateaued such that further gains are not anticipated.Assessment of Swallow FunctionAs per the routine clinical procedures followed within this service swallowing function was assessed by a Clinical Swallowing Examination (CSE) within 24 h of admission for non-intubated patients or within 24 h post extubation if the patient were mechanically ventilated at the point of hospital admission.", [["patients", "ORGANISM", 107, 115], ["patients", "ORGANISM", 538, 546], ["patient", "ORGANISM", 585, 592], ["patients", "SPECIES", 107, 115], ["patients", "SPECIES", 538, 546], ["patient", "SPECIES", 585, 592], ["a Clinical Swallowing Examination", "TEST", 455, 488], ["extubation", "TREATMENT", 567, 577], ["mechanically ventilated", "PROBLEM", 598, 621]]], ["Following this initial CSE, regular reassessment occurred during the course of management until the patient was determined to have regained premorbid swallowing function.", [["patient", "ORGANISM", 100, 107], ["patient", "SPECIES", 100, 107], ["management", "TREATMENT", 79, 89]]], ["When required, patients within this burns service will be referred for a FEES assessment.", [["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["a FEES assessment", "TEST", 71, 88]]], ["FEES is conducted in preference to a videofluoroscopic assessment to minimise the need for transporting the patient to the VFSS suite and risk of infection.", [["infection", "DISEASE", 146, 155], ["patient", "ORGANISM", 108, 115], ["patient", "SPECIES", 108, 115], ["a videofluoroscopic assessment", "TEST", 35, 65], ["infection", "PROBLEM", 146, 155], ["infection", "OBSERVATION", 146, 155]]], ["Factors currently limiting routine use of FEES assessment for patients within the burns unit are operational, created by staffing and equipment resource limitations.Assessment of Swallow FunctionThe CSE assessments were conducted by one of two SLPs working in the services with 19 and 8 years of experience in burn injury management, respectively.", [["burns", "DISEASE", 82, 87], ["burn injury", "DISEASE", 310, 321], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["FEES assessment", "TEST", 42, 57], ["The CSE assessments", "TEST", 195, 214], ["burn injury management", "TREATMENT", 310, 332]]], ["The CSE procedure involved review of medical status, visual inspection of the oro-musculature and assessment of cranial nerves, then trials of selected fluid and food textures as clinically appropriate.", [["cranial nerves", "ANATOMY", 112, 126], ["fluid", "ANATOMY", 152, 157], ["cranial nerves", "MULTI-TISSUE_STRUCTURE", 112, 126], ["The CSE procedure", "TREATMENT", 0, 17], ["visual inspection", "TEST", 53, 70], ["the oro-musculature", "TEST", 74, 93], ["assessment", "TEST", 98, 108], ["selected fluid and food textures", "TREATMENT", 143, 175], ["cranial nerves", "ANATOMY", 112, 126]]], ["The hyolaryngeal complex was palpated during each swallow and where feasible (considering skin integrity, etc.) and concurrent cervical auscultation was used as supplemental information to help inform the final clinical decision regarding swallow integrity.", [["skin", "ANATOMY", 90, 94], ["cervical", "ANATOMY", 127, 135], ["skin", "ORGAN", 90, 94], ["cervical", "ORGAN", 127, 135], ["hyolaryngeal complex", "PROTEIN", 4, 24], ["The hyolaryngeal complex", "PROBLEM", 0, 24], ["concurrent cervical auscultation", "TEST", 116, 148], ["skin", "ANATOMY", 90, 94], ["cervical", "ANATOMY", 127, 135]]], ["Appropriate diet and fluid consistencies along with other compensatory and therapeutic manoeuvres were recommended with the aim to rehabilitate swallowing function, minimise aspiration risk as well as maximise nutritional input.", [["fluid", "ANATOMY", 21, 26], ["fluid consistencies", "TREATMENT", 21, 40], ["therapeutic manoeuvres", "TREATMENT", 75, 97], ["aspiration risk", "PROBLEM", 174, 189]]], ["Clinical outcomes of the assessment were reported using the Functional Oral Intake Scale (FOIS).", [["Oral", "ANATOMY", 71, 75], ["the assessment", "TEST", 21, 35]]], ["The FOIS [29] is a 7-point scale used to define dysphagia presence and severity, based on the degree of food and fluid modification as well as the need for enteral nutrition (1 = nothing by mouth; 3 = tube dependent with consistent intake of food and fluid; 7 = total oral diet with no restriction).Assessment of Swallow FunctionThroughout the admission, ongoing SLP swallowing management was delivered in accordance with individual patient needs and consistent with the clinical guidelines of Speech Pathology Australia [30] .", [["mouth", "ANATOMY", 190, 195], ["oral", "ANATOMY", 268, 272], ["dysphagia", "DISEASE", 48, 57], ["mouth", "ORGANISM_SUBDIVISION", 190, 195], ["tube", "TISSUE", 201, 205], ["oral", "ORGANISM_SUBDIVISION", 268, 272], ["patient", "ORGANISM", 433, 440], ["patient", "SPECIES", 433, 440], ["dysphagia presence and severity", "PROBLEM", 48, 79], ["fluid modification", "TREATMENT", 113, 131], ["enteral nutrition", "TREATMENT", 156, 173], ["ongoing SLP swallowing management", "TREATMENT", 355, 388], ["dysphagia", "OBSERVATION", 48, 57], ["fluid", "OBSERVATION", 113, 118]]], ["Clinical practice remained standard and did not alter for the duration of this study.", [["this study", "TEST", 74, 84]]], ["Conclusion of dysphagia treatment was deemed final once the SLP determined the patient's swallowing function had either reached premorbid status, or had plateaued (i.e. minimal changes noted and further advancement unlikely).Assessment of Swallow FunctionSeveral endpoints were computed to examine the recovery of swallowing function consistent with prior studies [14-18, 22, 23] .", [["dysphagia", "DISEASE", 14, 23], ["patient", "ORGANISM", 79, 86], ["patient", "SPECIES", 79, 86], ["dysphagia treatment", "TREATMENT", 14, 33], ["the patient's swallowing function", "TEST", 75, 108], ["swallowing function", "TEST", 314, 333], ["prior studies", "TEST", 350, 363], ["dysphagia", "OBSERVATION", 14, 23]]], ["Days to initiate oral feeding (DIOF) was defined as the number of days between the time of hospital admission and commencing first oral intake.", [["oral", "ANATOMY", 17, 21], ["oral", "ANATOMY", 131, 135], ["oral", "ORGANISM_SUBDIVISION", 17, 21], ["oral", "ORGANISM_SUBDIVISION", 131, 135], ["oral feeding (DIOF)", "TREATMENT", 17, 36]]], ["Days to resolution of dysphagia (DROD) was calculated as the number of days between hospital admission, resolution of premorbid swallowing function and resumption of premorbid oral diet and fluids without the aid of compensatory and/or therapeutic manoeuvres.", [["oral", "ANATOMY", 176, 180], ["dysphagia", "DISEASE", 22, 31], ["oral", "ORGANISM_SUBDIVISION", 176, 180], ["dysphagia", "PROBLEM", 22, 31], ["premorbid swallowing function", "PROBLEM", 118, 147], ["premorbid oral diet", "TREATMENT", 166, 185], ["fluids", "TREATMENT", 190, 196], ["compensatory and/or therapeutic manoeuvres", "TREATMENT", 216, 258], ["dysphagia", "OBSERVATION", 22, 31]]], ["Enteral feeding is a necessity in most patients with large burn injury due to the extremely high metabolic demands that ensue to combat catabolism and facilitate wound healing, hence it is not a surrogate marker of dysphagia in this clinical population.", [["Enteral", "ANATOMY", 0, 7], ["wound", "ANATOMY", 162, 167], ["burn injury", "DISEASE", 59, 70], ["dysphagia", "DISEASE", 215, 224], ["patients", "ORGANISM", 39, 47], ["wound", "PATHOLOGICAL_FORMATION", 162, 167], ["patients", "SPECIES", 39, 47], ["Enteral feeding", "TREATMENT", 0, 15], ["large burn injury", "PROBLEM", 53, 70], ["the extremely high metabolic demands", "PROBLEM", 78, 114], ["combat catabolism", "PROBLEM", 129, 146], ["wound healing", "PROBLEM", 162, 175], ["dysphagia", "PROBLEM", 215, 224], ["large", "OBSERVATION_MODIFIER", 53, 58], ["burn", "OBSERVATION", 59, 63], ["wound", "OBSERVATION_MODIFIER", 162, 167], ["healing", "OBSERVATION", 168, 175], ["dysphagia", "OBSERVATION", 215, 224]]], ["Days of enteral feeding (DOEF) was expressed as the number of days that enteral feeding was in place regardless of swallowing diagnosis or management.Assessment of Swallow FunctionClinical outcomes data from the initial and discharge CSE were used to create a severity rating for dysphagia as per Rumbach et al. [14] where Mild Dysphagia was defined as requiring one level of restriction in either the food or fluid category (e.g. thin fluids and a soft dental diet) with the patient able to safely consume the majority of the modified meal; Moderate Dysphagia was defined as requiring one or more levels of restriction to both food and fluid consistencies to minimise aspiration risk (e.g. Mildly thick fluids and pureed solids) and the patient able to safely consume at least half of modified texture meal and Severe Dysphagia was defined as a high aspiration risk for all food and fluid consistencies with the patient being placed Nil By Mouth, with or without small trials of modified food or fluids only.Assessment of Laryngeal Pathology and Vocal FunctionLaryngeal/pharyngeal injury was documented using laryngoscopy, conducted routinely at clinically appropriate time points as determined by the managing SLP and/or ENT Surgeon until at least 6 months post injury, unless resolution of laryngeal pathology occurred earlier.", [["enteral", "ANATOMY", 8, 15], ["Laryngeal", "ANATOMY", 1023, 1032], ["pharyngeal", "ANATOMY", 1071, 1081], ["laryngeal", "ANATOMY", 1293, 1302], ["dysphagia", "DISEASE", 280, 289], ["Dysphagia", "DISEASE", 328, 337], ["Dysphagia", "DISEASE", 551, 560], ["Dysphagia", "DISEASE", 819, 828], ["pharyngeal injury", "DISEASE", 1071, 1088], ["patient", "ORGANISM", 476, 483], ["patient", "ORGANISM", 738, 745], ["patient", "ORGANISM", 913, 920], ["Laryngeal", "ORGAN", 1023, 1032], ["pharyngeal", "ORGAN", 1071, 1081], ["laryngeal", "ORGAN", 1293, 1302], ["patient", "SPECIES", 476, 483], ["patient", "SPECIES", 738, 745], ["patient", "SPECIES", 913, 920], ["enteral feeding", "TREATMENT", 8, 23], ["enteral feeding", "TREATMENT", 72, 87], ["management", "TREATMENT", 139, 149], ["dysphagia", "PROBLEM", 280, 289], ["Mild Dysphagia", "PROBLEM", 323, 337], ["fluid category (e.g. thin fluids", "TREATMENT", 410, 442], ["a soft dental diet", "TREATMENT", 447, 465], ["the modified meal", "TREATMENT", 523, 540], ["Moderate Dysphagia", "PROBLEM", 542, 560], ["fluid consistencies", "TREATMENT", 637, 656], ["aspiration risk", "PROBLEM", 669, 684], ["Mildly thick fluids and pureed solids", "TREATMENT", 691, 728], ["modified texture meal", "TREATMENT", 786, 807], ["Severe Dysphagia", "PROBLEM", 812, 828], ["a high aspiration risk", "PROBLEM", 844, 866], ["fluid consistencies", "TREATMENT", 884, 903], ["Assessment", "TEST", 1009, 1019], ["Laryngeal Pathology", "TEST", 1023, 1042], ["Vocal FunctionLaryngeal/pharyngeal injury", "PROBLEM", 1047, 1088], ["laryngoscopy", "TEST", 1110, 1122], ["injury", "PROBLEM", 1264, 1270], ["laryngeal pathology", "PROBLEM", 1293, 1312], ["Mild", "OBSERVATION_MODIFIER", 323, 327], ["Dysphagia", "OBSERVATION", 328, 337], ["Moderate", "OBSERVATION_MODIFIER", 542, 550], ["Dysphagia", "OBSERVATION", 551, 560], ["Severe", "OBSERVATION_MODIFIER", 812, 818], ["Dysphagia", "OBSERVATION", 819, 828], ["Laryngeal", "ANATOMY", 1023, 1032], ["Pathology", "OBSERVATION", 1033, 1042], ["Vocal", "ANATOMY", 1047, 1052], ["pharyngeal", "ANATOMY", 1071, 1081], ["injury", "OBSERVATION", 1082, 1088], ["laryngeal", "ANATOMY", 1293, 1302], ["pathology", "OBSERVATION", 1303, 1312]]], ["Reports from each laryngoscopy were reviewed for salient features with presence of anatomical and physiological pathology noted.", [["each laryngoscopy", "TEST", 13, 30], ["anatomical and physiological pathology", "PROBLEM", 83, 121], ["pathology", "OBSERVATION", 112, 121]]], ["From the regular SLP assessments, the presence of dysphonia was routinely examined using perceptual assessment by the managing SLP and reported as a dichotomous rating (present/absent) throughout the complete duration of inpatient admission as well as outpatient treatment until at least 6 months post injury.", [["dysphonia", "DISEASE", 50, 59], ["the regular SLP assessments", "TEST", 5, 32], ["dysphonia", "PROBLEM", 50, 59], ["perceptual assessment", "TEST", 89, 110], ["a dichotomous rating", "PROBLEM", 147, 167], ["outpatient treatment", "TREATMENT", 252, 272], ["injury", "PROBLEM", 302, 308], ["dysphonia", "OBSERVATION", 50, 59]]], ["Flexible Endoscopic Evaluation of Swallowing (FEES) was not routinely implemented at the time of laryngoscopy.", [["Flexible Endoscopic Evaluation", "TEST", 0, 30], ["laryngoscopy", "TEST", 97, 109]]], ["This was due to either the acuity of the patient condition at the time of the procedure (e.g. laryngoscopy conducted in the emergency department for the primary reason of assessing airway patency and indication for intubation) or timing of procedure not permitting presence of a SLP to conduct FEES.Statistical AnalysesAll data were entered into an Excel database, then descriptive and inferential statistics were conducted using the Statistical Package for the Social Sciences (SPSS) Version 24.0.", [["airway", "ANATOMY", 181, 187], ["patient", "ORGANISM", 41, 48], ["airway", "MULTI-TISSUE_STRUCTURE", 181, 187], ["patient", "SPECIES", 41, 48], ["the procedure", "TREATMENT", 74, 87], ["laryngoscopy", "TEST", 94, 106], ["airway patency", "TREATMENT", 181, 195], ["intubation", "TREATMENT", 215, 225], ["procedure", "TREATMENT", 240, 249], ["Statistical Analyses", "TEST", 299, 319]]], ["Data analysis took part in two stages.", [["Data analysis", "TEST", 0, 13]]], ["Initial analysis involved descriptive analysis of the present study's inhalation cohort (Inhal_1, n = 38).", [["Initial analysis", "TEST", 0, 16], ["descriptive analysis", "TEST", 26, 46], ["the present study", "TEST", 50, 67]]], ["Then any differences in the data between those patients with and without dysphagia within the inhalation injury cohort were examined.Statistical AnalysesIn the second stage analysis, data from the current study's cohort were directly compared to previously published outcomes data from Rumbach et al. [14] .", [["dysphagia", "DISEASE", 73, 82], ["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55], ["dysphagia", "PROBLEM", 73, 82], ["the inhalation injury", "PROBLEM", 90, 111], ["Statistical Analyses", "TEST", 133, 153], ["the second stage analysis", "TEST", 156, 181], ["the current study", "TEST", 193, 210]]], ["Access to the original data set for their 438 participants was provided with institutional ethical approval and consent by the study authors.", [["participants", "SPECIES", 46, 58]]], ["The original data set was subdivided into two population subgroups for the current research: (a) those with inhalation injury (Inhal_2, n = 30) and (b) a non-inhalation injury subset (Non-Inhal, n = 408).", [["inhalation injury", "DISEASE", 108, 125], ["inhalation injury", "PROBLEM", 108, 125], ["a non-inhalation injury subset", "PROBLEM", 152, 182]]], ["Comparisons (Chi-square and t tests) were conducted between the current and published inhalation cohorts, and between the current inhalation cohort and the published cohort with no inhalation injury.", [["inhalation injury", "DISEASE", 181, 198], ["Chi-square and t tests", "TEST", 13, 35], ["the current inhalation cohort", "TREATMENT", 118, 147], ["inhalation injury", "PROBLEM", 181, 198], ["no", "UNCERTAINTY", 178, 180], ["inhalation injury", "OBSERVATION", 181, 198]]], ["Significance was set at p < 0.05.Inhalation CohortOver the study period, 144 patients were admitted post thermal burn injury with suspected inhalation component, to the New South Wales SBIS CRGH Campus.", [["burn injury", "DISEASE", 113, 124], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["thermal burn injury", "PROBLEM", 105, 124], ["suspected inhalation component", "PROBLEM", 130, 160], ["burn injury", "OBSERVATION", 113, 124], ["inhalation component", "OBSERVATION", 140, 160]]], ["Inhalation injury was confirmed on laryngoscopy in 38 participants (26 male; 12 female; mean age 40.82 years, range 17-71, SD 14.30) who formed the study cohort.", [["Inhalation injury", "DISEASE", 0, 17], ["participants", "SPECIES", 54, 66], ["Inhalation injury", "PROBLEM", 0, 17], ["laryngoscopy", "TEST", 35, 47]]], ["The percent total body surface area (TBSA) ranged from 1-90% (mean 35.28, SD 23.55) with 100% exhibiting head and neck burns.", [["body surface area", "ANATOMY", 18, 35], ["head", "ANATOMY", 105, 109], ["neck", "ANATOMY", 114, 118], ["head and neck burns", "DISEASE", 105, 124], ["body", "ORGANISM_SUBDIVISION", 18, 22], ["head", "ORGANISM_SUBDIVISION", 105, 109], ["neck", "ORGANISM_SUBDIVISION", 114, 118], ["The percent total body surface area", "TREATMENT", 0, 35], ["TBSA", "TEST", 37, 41], ["SD", "TEST", 74, 76], ["head and neck burns", "PROBLEM", 105, 124], ["percent", "OBSERVATION_MODIFIER", 4, 11], ["total", "OBSERVATION_MODIFIER", 12, 17], ["body", "OBSERVATION_MODIFIER", 18, 22], ["surface", "OBSERVATION_MODIFIER", 23, 30], ["head", "ANATOMY", 105, 109], ["neck", "ANATOMY", 114, 118], ["burns", "OBSERVATION", 119, 124]]], ["Mechanical ventilation was required in 97% with a mean duration of 9.62 days ventilation (range 0-24 days, SD 6.36) and 18% required a tracheostomy.", [["Mechanical ventilation", "TREATMENT", 0, 22], ["a tracheostomy", "TREATMENT", 133, 147], ["ventilation", "OBSERVATION", 11, 22], ["tracheostomy", "OBSERVATION", 135, 147]]], ["Hospital LOS ranged considerably from two and up to 213 days, with a mean of 60.2 days.", [["Hospital LOS", "TEST", 0, 12]]], ["On initial laryngoscopy (within 24 h of hospital admission), all participants exhibited evidence thermal injury to the pharyngeal and/or laryngeal mucosa.", [["pharyngeal", "ANATOMY", 119, 129], ["laryngeal mucosa", "ANATOMY", 137, 153], ["pharyngeal", "ORGAN", 119, 129], ["laryngeal mucosa", "MULTI-TISSUE_STRUCTURE", 137, 153], ["participants", "SPECIES", 65, 77], ["initial laryngoscopy", "TEST", 3, 23], ["thermal injury to the pharyngeal and/or laryngeal mucosa", "PROBLEM", 97, 153], ["thermal", "OBSERVATION_MODIFIER", 97, 104], ["injury", "OBSERVATION", 105, 111], ["pharyngeal", "ANATOMY", 119, 129], ["laryngeal mucosa", "ANATOMY", 137, 153]]], ["Laryngoscopy within one week of extubation or insertion of tracheostomy revealed persistent sloughy mucosal tissue in 8%, significant oedema and erythema in 37%, granulation or ulceration in 45% and restricted laryngeal movement in 45%.", [["sloughy mucosal tissue", "ANATOMY", 92, 114], ["granulation", "ANATOMY", 162, 173], ["laryngeal", "ANATOMY", 210, 219], ["oedema", "DISEASE", 134, 140], ["erythema", "DISEASE", 145, 153], ["granulation", "DISEASE", 162, 173], ["ulceration", "DISEASE", 177, 187], ["mucosal tissue", "TISSUE", 100, 114], ["laryngeal", "ORGAN", 210, 219], ["Laryngoscopy", "TEST", 0, 12], ["extubation", "TREATMENT", 32, 42], ["insertion of tracheostomy", "TREATMENT", 46, 71], ["persistent sloughy mucosal tissue", "PROBLEM", 81, 114], ["significant oedema", "PROBLEM", 122, 140], ["erythema", "PROBLEM", 145, 153], ["granulation", "PROBLEM", 162, 173], ["ulceration", "PROBLEM", 177, 187], ["tracheostomy", "OBSERVATION", 59, 71], ["persistent", "OBSERVATION_MODIFIER", 81, 91], ["sloughy", "OBSERVATION_MODIFIER", 92, 99], ["mucosal tissue", "ANATOMY", 100, 114], ["significant", "OBSERVATION_MODIFIER", 122, 133], ["oedema", "OBSERVATION", 134, 140], ["erythema", "OBSERVATION", 145, 153], ["37%", "OBSERVATION_MODIFIER", 157, 160], ["granulation", "OBSERVATION_MODIFIER", 162, 173], ["ulceration", "OBSERVATION", 177, 187], ["45%", "OBSERVATION_MODIFIER", 191, 194], ["laryngeal", "ANATOMY", 210, 219], ["movement", "OBSERVATION", 220, 228]]], ["Six months post injury, persistent laryngeal pathology was apparent on laryngoscopy in 47.37% of participants.", [["laryngeal", "ANATOMY", 35, 44], ["laryngeal", "ORGAN", 35, 44], ["participants", "SPECIES", 97, 109], ["injury", "PROBLEM", 16, 22], ["persistent laryngeal pathology", "PROBLEM", 24, 54], ["laryngoscopy", "TEST", 71, 83], ["injury", "OBSERVATION", 16, 22], ["persistent", "OBSERVATION_MODIFIER", 24, 34], ["laryngeal", "ANATOMY", 35, 44], ["pathology", "OBSERVATION", 45, 54]]], ["This pathology specifically involved the presence of scar tissue with resultant contracture in varying degrees at the level of the true vocal cords, false vocal cords, aryepiglottic folds, and anterior and posterior glottis which restricted laryngeal function.", [["scar tissue", "ANATOMY", 53, 64], ["vocal cords", "ANATOMY", 136, 147], ["vocal cords", "ANATOMY", 155, 166], ["aryepiglottic folds", "ANATOMY", 168, 187], ["anterior", "ANATOMY", 193, 201], ["posterior glottis", "ANATOMY", 206, 223], ["laryngeal", "ANATOMY", 241, 250], ["scar", "DISEASE", 53, 57], ["contracture", "DISEASE", 80, 91], ["scar tissue", "TISSUE", 53, 64], ["vocal cords", "MULTI-TISSUE_STRUCTURE", 136, 147], ["vocal cords", "MULTI-TISSUE_STRUCTURE", 155, 166], ["aryepiglottic folds", "TISSUE", 168, 187], ["anterior", "ORGAN", 193, 201], ["posterior glottis", "MULTI-TISSUE_STRUCTURE", 206, 223], ["laryngeal", "ORGAN", 241, 250], ["This pathology", "TEST", 0, 14], ["scar tissue", "PROBLEM", 53, 64], ["resultant contracture in varying degrees", "PROBLEM", 70, 110], ["aryepiglottic folds, and anterior and posterior glottis", "PROBLEM", 168, 223], ["scar tissue", "OBSERVATION", 53, 64], ["resultant", "OBSERVATION_MODIFIER", 70, 79], ["contracture", "OBSERVATION", 80, 91], ["varying degrees", "OBSERVATION_MODIFIER", 95, 110], ["true", "ANATOMY_MODIFIER", 131, 135], ["vocal cords", "ANATOMY", 136, 147], ["false", "OBSERVATION", 149, 154], ["vocal cords", "ANATOMY", 155, 166], ["aryepiglottic folds", "ANATOMY", 168, 187], ["anterior", "ANATOMY_MODIFIER", 193, 201], ["posterior", "ANATOMY_MODIFIER", 206, 215], ["glottis", "ANATOMY", 216, 223], ["laryngeal function", "OBSERVATION", 241, 259]]], ["In two cases, airway patency was also compromised to the degree that tracheostomy and laser cordotomy were necessary.", [["airway", "ANATOMY", 14, 20], ["airway", "MULTI-TISSUE_STRUCTURE", 14, 20], ["airway patency", "TREATMENT", 14, 28], ["tracheostomy", "TREATMENT", 69, 81], ["laser cordotomy", "TREATMENT", 86, 101], ["airway", "ANATOMY", 14, 20], ["patency", "OBSERVATION", 21, 28], ["tracheostomy", "OBSERVATION", 69, 81], ["laser cordotomy", "OBSERVATION", 86, 101]]], ["All participants (100%) exhibited dysphonia on clinical examination ( Table 1) .Inhalation CohortIncidence of dysphagia was 89.47% in the cohort with inhalation injury.", [["dysphonia", "DISEASE", 34, 43], ["dysphagia", "DISEASE", 110, 119], ["inhalation injury", "DISEASE", 150, 167], ["participants", "SPECIES", 4, 16], ["dysphonia", "PROBLEM", 34, 43], ["clinical examination", "TEST", 47, 67], ["dysphagia", "PROBLEM", 110, 119], ["inhalation injury", "PROBLEM", 150, 167], ["dysphonia", "OBSERVATION", 34, 43], ["dysphagia", "OBSERVATION", 110, 119], ["injury", "OBSERVATION", 161, 167]]], ["Mean DIOF was 24.69 days (range 1-200 days, SD 42.87).", [["Mean DIOF", "TEST", 0, 9]]], ["Dysphagia severity at the point of initial swallow assessment was severe in 78.9% of participants, moderate in 7.9%, and mild in 2.6% with 10.5% exhibiting no clinical dysphagia at all.", [["Dysphagia", "DISEASE", 0, 9], ["dysphagia", "DISEASE", 168, 177], ["participants", "SPECIES", 85, 97], ["Dysphagia severity", "PROBLEM", 0, 18], ["initial swallow assessment", "TEST", 35, 61], ["clinical dysphagia", "PROBLEM", 159, 177], ["moderate", "OBSERVATION_MODIFIER", 99, 107], ["mild", "OBSERVATION_MODIFIER", 121, 125], ["dysphagia", "OBSERVATION", 168, 177]]], ["At the point of discharge from the acute care facility, 97.4% had completely recovered their swallow function to premorbid ability, whilst 2.6% continued to exhibit severe dysphagia with complete dependence on enteral nutrition.", [["dysphagia", "DISEASE", 172, 181], ["severe dysphagia", "PROBLEM", 165, 181], ["enteral nutrition", "TREATMENT", 210, 227], ["severe", "OBSERVATION_MODIFIER", 165, 171], ["dysphagia", "OBSERVATION", 172, 181]]], ["Analysis of all cases included in this study revealed a low incidence of instrumental assessments being conducted, with only 7 (18.4%) participants undergoing a FEES procedure at some point during their admission.", [["participants", "ORGANISM", 135, 147], ["participants", "SPECIES", 135, 147], ["all cases", "TEST", 12, 21], ["this study", "TEST", 34, 44], ["instrumental assessments", "TEST", 73, 97], ["a FEES procedure", "TREATMENT", 159, 175], ["low incidence", "OBSERVATION_MODIFIER", 56, 69]]], ["However, unfortunately as the timing of when this assessment occurred for each patient, and due to the low numbers of studies conducted, these data were not analysed or included in the current paper as it was deemed insufficient to make any conclusions or patterns regarding dysphagia presentation or recovery.Inhalation CohortComparison of participants in the inhalation cohort who were identified either with (n = 34) and without (n = 4) dysphagia is also reported in Table 1 .", [["dysphagia", "DISEASE", 275, 284], ["dysphagia", "DISEASE", 440, 449], ["patient", "ORGANISM", 79, 86], ["patient", "SPECIES", 79, 86], ["participants", "SPECIES", 341, 353], ["this assessment", "TEST", 45, 60], ["the low numbers of studies", "PROBLEM", 99, 125], ["dysphagia presentation", "PROBLEM", 275, 297], ["dysphagia", "PROBLEM", 440, 449]]], ["Due to small and uneven group numbers, statistical comparisons were not conducted.", [["small and uneven group numbers", "PROBLEM", 7, 37], ["small", "OBSERVATION_MODIFIER", 7, 12]]], ["However, patterns reveal those with dysphagia took longer to commence oral intake (mean 27.0 vs 6.5 days), longer to achieve premorbid swallowing function (mean 47.2 vs 10.3 days) and had a greater duration of enteral feeding (mean 49.6 vs 10 days), compared to their non-dysphagic counterparts.", [["oral", "ANATOMY", 70, 74], ["dysphagia", "DISEASE", 36, 45], ["oral", "ORGANISM_SUBDIVISION", 70, 74], ["dysphagia", "PROBLEM", 36, 45], ["mean", "TEST", 156, 160], ["enteral feeding", "TREATMENT", 210, 225], ["dysphagia", "OBSERVATION", 36, 45]]], ["Further to this, patients with dysphagia had Table 1 Description of the total inhalation cohort, including sub-analysis of those with/ without dysphagia TBSA total body surface area, DIOF days to initiate oral feeding, DOEF days of enteral feeding, DROD days to resolution of dysphagia, ETT endotracheal tube, ICU intensive care unit, LOS length of stay compared to those without dysphagia.", [["body surface area", "ANATOMY", 164, 181], ["oral", "ANATOMY", 205, 209], ["dysphagia", "DISEASE", 31, 40], ["dysphagia", "DISEASE", 143, 152], ["dysphagia", "DISEASE", 276, 285], ["dysphagia", "DISEASE", 380, 389], ["patients", "ORGANISM", 17, 25], ["oral", "ORGANISM_SUBDIVISION", 205, 209], ["patients", "SPECIES", 17, 25], ["dysphagia", "PROBLEM", 31, 40], ["the total inhalation cohort", "TREATMENT", 68, 95], ["dysphagia", "PROBLEM", 143, 152], ["oral feeding", "TREATMENT", 205, 217], ["enteral feeding", "TREATMENT", 232, 247], ["dysphagia", "PROBLEM", 276, 285], ["ETT endotracheal tube", "TREATMENT", 287, 308], ["dysphagia", "PROBLEM", 380, 389], ["dysphagia", "OBSERVATION", 276, 285], ["endotracheal tube", "OBSERVATION", 291, 308]]], ["Whilst it is well documented that intubation duration is associated with presence and severity of dysphagia, the results above suggest that there are additional factors beyond intubation duration that are associated with risk for dysphagia in the inhalation burn population.", [["dysphagia", "DISEASE", 98, 107], ["dysphagia", "DISEASE", 230, 239], ["dysphagia", "PROBLEM", 98, 107], ["dysphagia", "PROBLEM", 230, 239], ["the inhalation burn population", "TREATMENT", 243, 273], ["dysphagia", "OBSERVATION", 98, 107]]], ["This will be further explored within the discussion section of the manuscript below.Comparison to Published Inhalation Cohort DataComparing the current study's inhalation cohort (Inhal_1; n = 38) to the 2012 published inhalation cohort (Inhal_2; n = 30) of Rumbach and colleagues [14] , all participants presented with burn injury to the head and neck region, with both cohorts comparable for age (p = 0.917) and size of burn injury (p = 0.394).", [["head", "ANATOMY", 338, 342], ["neck", "ANATOMY", 347, 351], ["burn injury", "DISEASE", 319, 330], ["burn injury", "DISEASE", 421, 432], ["participants", "ORGANISM", 291, 303], ["head", "ORGANISM_SUBDIVISION", 338, 342], ["neck", "ORGAN", 347, 351], ["participants", "SPECIES", 291, 303], ["'s inhalation cohort (Inhal_1; n", "TREATMENT", 157, 189], ["burn injury to the head and neck region", "PROBLEM", 319, 358], ["burn injury", "PROBLEM", 421, 432], ["injury", "OBSERVATION", 324, 330], ["head", "ANATOMY", 338, 342], ["neck", "ANATOMY", 347, 351], ["region", "ANATOMY_MODIFIER", 352, 358], ["size", "OBSERVATION_MODIFIER", 413, 417], ["burn", "OBSERVATION_MODIFIER", 421, 425], ["injury", "OBSERVATION", 426, 432]]], ["Similarly, a high proportion of patients received mechanical ventilation (97.8% vs 90%) with a comparable duration of intubation (p = 0.743).", [["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["mechanical ventilation", "TREATMENT", 50, 72], ["intubation", "TREATMENT", 118, 128], ["high", "OBSERVATION_MODIFIER", 13, 17]]], ["Further to this, the rate of tracheostomy insertion lacked significant variability at 18.4% and 20%, respectively (p = 0.8686).", [["tracheostomy insertion", "TREATMENT", 29, 51], ["significant variability", "PROBLEM", 59, 82], ["tracheostomy", "OBSERVATION", 29, 41], ["significant", "OBSERVATION_MODIFIER", 59, 70], ["variability", "OBSERVATION_MODIFIER", 71, 82]]], ["Both hospital LOS as well as ICU LOS were again similar (p = 0.62; p = 0.872) across the two groups.", [["ICU LOS", "TEST", 29, 36], ["p", "TEST", 67, 68]]], ["Importantly, the incidence of dysphagia in the current study (Inhal_1; 89.5% dysphagic) was comparable (p = 0.7267) to the rate described by Rumbach et al. [14] (Inhal_2; 86.7% dysphagic).", [["dysphagia", "DISEASE", 30, 39], ["dysphagia", "PROBLEM", 30, 39], ["the current study", "TEST", 43, 60], ["Inhal_1", "TEST", 62, 69], ["the rate", "TEST", 119, 127], ["Inhal_2", "TEST", 162, 169], ["dysphagia", "OBSERVATION", 30, 39]]], ["There was, however, a significant difference (p = 0.007) in DOEF between the two inhalation groups, with participants in the current study requiring a greater period of enteral feeding by approximately 13 days.", [["participants", "SPECIES", 105, 117], ["a significant difference", "PROBLEM", 20, 44], ["the current study", "TEST", 121, 138], ["enteral feeding", "TREATMENT", 169, 184], ["significant", "OBSERVATION_MODIFIER", 22, 33], ["difference", "OBSERVATION_MODIFIER", 34, 44]]], ["These data are summarised in Table 2 .Comparison to Published Inhalation Cohort DataInterestingly, dysphagia severity was significantly higher in the Inhal_1 cohort (78.9% severe dysphagia) compared to the Inhal_2 cohort (43.3% severe dysphagia) at the point of initial assessment (p = 0.0027); however, resolution wasComparison to Published Non-inhalation Cohort DataComparisons between the inhalation cohort (Inhal_1; n = 38) and the published non-inhalation cohort (Non-Inhal; n = 408) of Rumbach et al. [14] , revealed that age was comparable across the two groups.", [["dysphagia", "DISEASE", 99, 108], ["dysphagia", "DISEASE", 179, 188], ["dysphagia", "DISEASE", 235, 244], ["dysphagia severity", "PROBLEM", 99, 117], ["severe dysphagia", "PROBLEM", 172, 188], ["severe dysphagia", "PROBLEM", 228, 244], ["initial assessment", "TEST", 262, 280], ["the inhalation cohort", "TREATMENT", 388, 409]]], ["However, the proportion of head and neck burns (100% Inhal_1 vs 26.2% Non-Inhal; p < 0.0001) and rate of tracheostomy insertion (18.42% Inhal_1 vs 0.49%; Non-Inhal; p < 0.0001) were both significantly greater for those with inhalation injury.", [["head", "ANATOMY", 27, 31], ["neck", "ANATOMY", 36, 40], ["head and neck burns", "DISEASE", 27, 46], ["inhalation injury", "DISEASE", 224, 241], ["head", "ORGANISM_SUBDIVISION", 27, 31], ["neck", "ORGAN", 36, 40], ["head and neck burns", "PROBLEM", 27, 46], ["Inhal_1", "TEST", 53, 60], ["tracheostomy insertion", "TREATMENT", 105, 127], ["Inhal_1", "TEST", 136, 143], ["Non-Inhal", "TEST", 154, 163], ["inhalation injury", "PROBLEM", 224, 241], ["head", "ANATOMY", 27, 31], ["neck", "ANATOMY", 36, 40], ["burns", "OBSERVATION", 41, 46], ["tracheostomy", "OBSERVATION", 105, 117], ["injury", "OBSERVATION", 235, 241]]], ["Furthermore, the inhalation cohort had a higher percentage TBSA burn (p = 0.000), longer duration of endotracheal intubation (p = 0.000), as well as greater hospital (p = 0.000) and ICU LOS (p = 0.000) than their non-inhalation injury counterparts.Comparison to Published Non-inhalation Cohort DataIncidence of dysphagia was significantly greater (p < 0.0001) in participants with inhalation injury (Inhal_1; 89.47% dysphagic) compared to those without (Non-Inhal; 5.6% dysphagic).", [["endotracheal", "ANATOMY", 101, 113], ["burn", "DISEASE", 64, 68], ["dysphagia", "DISEASE", 311, 320], ["inhalation injury", "DISEASE", 381, 398], ["participants", "SPECIES", 363, 375], ["endotracheal intubation", "TREATMENT", 101, 124], ["their non-inhalation injury counterparts", "PROBLEM", 207, 247], ["dysphagia", "PROBLEM", 311, 320], ["inhalation injury", "PROBLEM", 381, 398], ["Inhal_1", "TEST", 400, 407], ["Inhal", "TEST", 458, 463], ["dysphagia", "OBSERVATION", 311, 320]]], ["In addition, DIOF was significantly greater (p < 0.0001) in the current inhalation cohort (Inhal_1; mean DIOF = 24.69 days) compared to those without inhalation injury (Non-Inhal; mean DIOF = 0.089 days).", [["inhalation injury", "DISEASE", 150, 167], ["DIOF", "SIMPLE_CHEMICAL", 13, 17], ["mean DIOF", "TEST", 100, 109], ["inhalation injury", "PROBLEM", 150, 167], ["significantly", "OBSERVATION_MODIFIER", 22, 35], ["greater", "OBSERVATION_MODIFIER", 36, 43]]], ["Similarly, DROD was significantly elevated (p < 0.0001) in those with inhalation injury (Inhal_1; mean DROD = 29.79 days) compared to those without (Non-Inhal; mean DROD = 1.67 days).", [["inhalation injury", "DISEASE", 70, 87], ["DROD", "TEST", 11, 15], ["significantly elevated", "PROBLEM", 20, 42], ["inhalation injury", "PROBLEM", 70, 87], ["mean DROD", "TEST", 98, 107], ["significantly", "OBSERVATION_MODIFIER", 20, 33], ["elevated", "OBSERVATION_MODIFIER", 34, 42]]], ["Lastly, DOEF was also significantly longer (p < 0.0001) in those with inhalation injury (Inhal_1; mean DOEF = 45.03 days) versus those without inhalation injury (Non-Inhal; mean DOEF = 1.96 days).Comparison to Published Non-inhalation Cohort DataDysphagia severity was predictably greater (p < 0.0001) at initial assessment for the inhalation injury cohort in the present study (Inhal_1; 78.9% severe dysphagia) compared to those without inhalation injury (Non-Inhal; 1.7% severe dysphagia) (Fig. 2) ; however, by the time of hospital discharge, the proportion of those with functional swallowing were analogous (p = 0.226) (Fig. 3 ).DiscussionThis study demonstrates that within our cohort of 38 participants, the presence of dysphagia is 16 times higher in patients with burn injury and a concomitant inhalation injury than those with no inhalation injury in the study of Rumbach et al. [14] .", [["inhalation injury", "DISEASE", 70, 87], ["inhalation injury", "DISEASE", 143, 160], ["inhalation injury", "DISEASE", 332, 349], ["dysphagia", "DISEASE", 401, 410], ["inhalation injury", "DISEASE", 438, 455], ["dysphagia", "DISEASE", 480, 489], ["dysphagia", "DISEASE", 727, 736], ["burn injury", "DISEASE", 773, 784], ["inhalation injury", "DISEASE", 803, 820], ["inhalation injury", "DISEASE", 840, 857], ["DOEF", "SIMPLE_CHEMICAL", 8, 12], ["participants", "ORGANISM", 697, 709], ["patients", "ORGANISM", 759, 767], ["participants", "SPECIES", 697, 709], ["patients", "SPECIES", 759, 767], ["inhalation injury", "PROBLEM", 70, 87], ["mean DOEF", "TEST", 98, 107], ["inhalation injury", "PROBLEM", 143, 160], ["Published Non-inhalation Cohort DataDysphagia severity", "TEST", 210, 264], ["initial assessment", "TEST", 305, 323], ["the inhalation injury", "PROBLEM", 328, 349], ["the present study", "TEST", 360, 377], ["Inhal_1", "TEST", 379, 386], ["% severe dysphagia", "PROBLEM", 392, 410], ["inhalation injury", "PROBLEM", 438, 455], ["Inhal", "TEST", 461, 466], ["1.7% severe dysphagia", "PROBLEM", 468, 489], ["This study", "TEST", 644, 654], ["dysphagia", "PROBLEM", 727, 736], ["burn injury", "PROBLEM", 773, 784], ["a concomitant inhalation injury", "PROBLEM", 789, 820], ["inhalation injury", "PROBLEM", 840, 857], ["the study", "TEST", 861, 870], ["dysphagia", "OBSERVATION", 727, 736], ["16 times higher", "OBSERVATION_MODIFIER", 740, 755], ["concomitant", "OBSERVATION_MODIFIER", 791, 802], ["inhalation injury", "OBSERVATION", 803, 820]]], ["Further to this, laryngeal pathology due to inhalation injury is associated with an increase in dysphagia severity, with dysphagia recovery considerably protracted compared to their non-inhalation injury counterparts.", [["laryngeal", "ANATOMY", 17, 26], ["inhalation injury", "DISEASE", 44, 61], ["dysphagia", "DISEASE", 96, 105], ["dysphagia", "DISEASE", 121, 130], ["laryngeal", "ORGAN", 17, 26], ["laryngeal pathology", "PROBLEM", 17, 36], ["inhalation injury", "PROBLEM", 44, 61], ["an increase in dysphagia severity", "PROBLEM", 81, 114], ["dysphagia recovery", "PROBLEM", 121, 139], ["their non-inhalation injury counterparts", "PROBLEM", 176, 216], ["laryngeal", "ANATOMY", 17, 26], ["pathology", "OBSERVATION", 27, 36], ["increase", "OBSERVATION_MODIFIER", 84, 92], ["dysphagia", "OBSERVATION", 96, 105]]], ["The present data highlight that the SLP services need to be actively involved in the early and ongoing management of patients with inhalation injury in order to proactively support dysphagia risk and enhance swallow safety and recovery.DiscussionThere are a number of potential precipitating factors behind the mechanism of dysphagia in this population.", [["inhalation injury", "DISEASE", 131, 148], ["dysphagia", "DISEASE", 181, 190], ["dysphagia", "DISEASE", 324, 333], ["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125], ["inhalation injury", "PROBLEM", 131, 148], ["dysphagia risk", "PROBLEM", 181, 195], ["dysphagia", "PROBLEM", 324, 333], ["dysphagia", "OBSERVATION", 324, 333]]], ["Firstly, a majority of patients (97.37%) in the current study received intubation and mechanical ventilation with mean duration of 9.37 days, as part of their treatment.", [["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["the current study", "TEST", 44, 61], ["intubation", "TREATMENT", 71, 81], ["mechanical ventilation", "TREATMENT", 86, 108], ["their treatment", "TREATMENT", 153, 168], ["mechanical ventilation", "OBSERVATION", 86, 108]]], ["Rumbach and colleagues [13] have previously identified that the presence of ICU admission and mechanical ventilation hold positive predictive value at 56.82% and 59.92%, respectively, for the development of dysphagia.", [["dysphagia", "DISEASE", 207, 216], ["mechanical ventilation", "TREATMENT", 94, 116], ["dysphagia", "PROBLEM", 207, 216], ["dysphagia", "OBSERVATION", 207, 216]]], ["Further to this, endotracheal intubation and mechanical ventilation is well recognised in the literature to be associated with dysphagia [31] with current incidence rates of dysphagia post extubation documented up to 62% [32] .", [["endotracheal", "ANATOMY", 17, 29], ["dysphagia", "DISEASE", 127, 136], ["dysphagia", "DISEASE", 174, 183], ["endotracheal intubation", "TREATMENT", 17, 40], ["mechanical ventilation", "TREATMENT", 45, 67], ["dysphagia", "PROBLEM", 127, 136], ["dysphagia", "PROBLEM", 174, 183], ["extubation", "TREATMENT", 189, 199], ["mechanical ventilation", "OBSERVATION", 45, 67]]], ["Mechanisms for dysphagia in the intubated population have been proposed to be related to both the underlying medical diagnosis as well as the period of oropharyngeal muscle disuse and associated atrophy [33, 34] .", [["oropharyngeal muscle", "ANATOMY", 152, 172], ["dysphagia", "DISEASE", 15, 24], ["oropharyngeal muscle disuse", "DISEASE", 152, 179], ["atrophy", "DISEASE", 195, 202], ["oropharyngeal", "ORGANISM_SUBDIVISION", 152, 165], ["muscle", "ORGAN", 166, 172], ["dysphagia", "PROBLEM", 15, 24], ["oropharyngeal muscle disuse", "PROBLEM", 152, 179], ["associated atrophy", "PROBLEM", 184, 202], ["dysphagia", "OBSERVATION", 15, 24], ["oropharyngeal muscle", "ANATOMY", 152, 172], ["disuse", "OBSERVATION", 173, 179], ["atrophy", "OBSERVATION", 195, 202]]], ["Furthermore, the potential physiological and anatomical damage as a result of the endotracheal tube itself cannot be dismissed.", [["endotracheal tube", "ANATOMY", 82, 99], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 82, 99], ["the potential physiological and anatomical damage", "PROBLEM", 13, 62], ["the endotracheal tube", "TREATMENT", 78, 99], ["anatomical damage", "OBSERVATION", 45, 62], ["endotracheal tube", "OBSERVATION", 82, 99]]], ["The presence of muscle atrophy and localised endotracheal tube trauma is acknowledged to be probable in the present study population.", [["muscle", "ANATOMY", 16, 22], ["endotracheal tube", "ANATOMY", 45, 62], ["muscle atrophy", "DISEASE", 16, 30], ["endotracheal tube trauma", "DISEASE", 45, 69], ["muscle", "ORGAN", 16, 22], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 45, 62], ["muscle atrophy", "PROBLEM", 16, 30], ["localised endotracheal tube trauma", "PROBLEM", 35, 69], ["muscle", "ANATOMY", 16, 22], ["atrophy", "OBSERVATION", 23, 30], ["localised", "OBSERVATION_MODIFIER", 35, 44], ["endotracheal tube", "OBSERVATION", 45, 62], ["trauma", "OBSERVATION", 63, 69], ["acknowledged to be probable", "UNCERTAINTY", 73, 100]]], ["However, given the rate of dysphagia following inhalation injury exceeds documented rates of dysphagia following endotracheal intubation, this suggests that there are additional processes that are impacting swallow integrity in this cohort.DiscussionA second causative factor for dysphagia in those patients with inhalation injury is the effect of the burn injury itself on oral, pharyngeal and laryngeal mucosa sensory and motor function.", [["endotracheal", "ANATOMY", 113, 125], ["oral", "ANATOMY", 374, 378], ["pharyngeal", "ANATOMY", 380, 390], ["laryngeal mucosa", "ANATOMY", 395, 411], ["dysphagia", "DISEASE", 27, 36], ["inhalation injury", "DISEASE", 47, 64], ["dysphagia", "DISEASE", 93, 102], ["dysphagia", "DISEASE", 280, 289], ["inhalation injury", "DISEASE", 313, 330], ["burn", "DISEASE", 352, 356], ["patients", "ORGANISM", 299, 307], ["oral", "ORGANISM_SUBDIVISION", 374, 378], ["pharyngeal", "ORGANISM_SUBDIVISION", 380, 390], ["laryngeal mucosa", "MULTI-TISSUE_STRUCTURE", 395, 411], ["patients", "SPECIES", 299, 307], ["dysphagia", "PROBLEM", 27, 36], ["inhalation injury", "PROBLEM", 47, 64], ["dysphagia", "PROBLEM", 93, 102], ["endotracheal intubation", "TREATMENT", 113, 136], ["additional processes", "PROBLEM", 167, 187], ["dysphagia", "PROBLEM", 280, 289], ["inhalation injury", "PROBLEM", 313, 330], ["the burn injury", "PROBLEM", 348, 363], ["oral, pharyngeal and laryngeal mucosa sensory", "TEST", 374, 419], ["endotracheal intubation", "OBSERVATION", 113, 136], ["injury", "OBSERVATION", 357, 363], ["pharyngeal", "ANATOMY", 380, 390], ["laryngeal mucosa", "ANATOMY", 395, 411], ["motor function", "OBSERVATION", 424, 438]]], ["Histologically, whilst mucosa of the tongue blade, hard and soft palate appear to be resistant to the development of scar tissue and contractures following thermal inhalation or ingestion burn injury, the floor of mouth, pharyngeal and especially laryngeal mucosa are not [35] .", [["mucosa", "ANATOMY", 23, 29], ["tongue blade", "ANATOMY", 37, 49], ["soft palate", "ANATOMY", 60, 71], ["scar tissue", "ANATOMY", 117, 128], ["mouth", "ANATOMY", 214, 219], ["pharyngeal", "ANATOMY", 221, 231], ["laryngeal mucosa", "ANATOMY", 247, 263], ["scar", "DISEASE", 117, 121], ["contractures", "DISEASE", 133, 145], ["burn injury", "DISEASE", 188, 199], ["mucosa", "MULTI-TISSUE_STRUCTURE", 23, 29], ["tongue blade", "MULTI-TISSUE_STRUCTURE", 37, 49], ["palate", "ORGAN", 65, 71], ["scar tissue", "TISSUE", 117, 128], ["mouth", "ORGANISM_SUBDIVISION", 214, 219], ["pharyngeal", "ORGAN", 221, 231], ["laryngeal mucosa", "MULTI-TISSUE_STRUCTURE", 247, 263], ["hard and soft palate", "PROBLEM", 51, 71], ["scar tissue", "PROBLEM", 117, 128], ["contractures", "PROBLEM", 133, 145], ["thermal inhalation", "TREATMENT", 156, 174], ["ingestion burn injury", "PROBLEM", 178, 199], ["pharyngeal and especially laryngeal mucosa", "PROBLEM", 221, 263], ["mucosa", "ANATOMY", 23, 29], ["tongue", "ANATOMY", 37, 43], ["blade", "ANATOMY_MODIFIER", 44, 49], ["soft palate", "ANATOMY", 60, 71], ["resistant", "OBSERVATION", 85, 94], ["scar tissue", "OBSERVATION", 117, 128], ["contractures", "OBSERVATION", 133, 145], ["mouth", "ANATOMY", 214, 219], ["pharyngeal", "ANATOMY", 221, 231], ["laryngeal mucosa", "ANATOMY", 247, 263]]], ["As such, injury to these anatomical sites are associated with elevated risk for the development of scar tissue and contractures with subsequent impact upon motor and sensory function [36] .", [["scar tissue", "ANATOMY", 99, 110], ["scar", "DISEASE", 99, 103], ["contractures", "DISEASE", 115, 127], ["scar tissue", "TISSUE", 99, 110], ["injury to these anatomical sites", "PROBLEM", 9, 41], ["elevated risk", "PROBLEM", 62, 75], ["scar tissue", "PROBLEM", 99, 110], ["contractures", "PROBLEM", 115, 127], ["injury", "OBSERVATION", 9, 15], ["scar", "OBSERVATION", 99, 103], ["contractures", "OBSERVATION", 115, 127]]], ["This may be postulated to represent as a reduction of airway protection during swallowing in addition to a reduction in airway responsiveness should an aspiration event occur.", [["airway", "ANATOMY", 54, 60], ["airway", "ANATOMY", 120, 126], ["airway", "MULTI-TISSUE_STRUCTURE", 54, 60], ["airway", "MULTI-TISSUE_STRUCTURE", 120, 126], ["airway protection", "TREATMENT", 54, 71], ["a reduction in airway responsiveness", "PROBLEM", 105, 141], ["an aspiration event", "PROBLEM", 149, 168], ["reduction", "OBSERVATION_MODIFIER", 41, 50], ["airway protection", "OBSERVATION", 54, 71], ["reduction", "OBSERVATION_MODIFIER", 107, 116], ["airway", "ANATOMY", 120, 126], ["aspiration", "OBSERVATION", 152, 162]]], ["This is supported by the work of Clayton et al. [16, 24, 37] and Rumbach et al. [14, [18] [19] [20] 27] who have previously highlighted that oral, pharyngeal and laryngeal sensory deficits are common features of the burn injured patient with dysphagia.DiscussionThirdly, the presence of acute deconditioning beyond the degree that is caused by presence of the endotracheal tube and associated oropharyngeal muscle disuse should not be underappreciated.", [["oral", "ANATOMY", 141, 145], ["pharyngeal", "ANATOMY", 147, 157], ["laryngeal", "ANATOMY", 162, 171], ["endotracheal tube", "ANATOMY", 360, 377], ["oropharyngeal muscle", "ANATOMY", 393, 413], ["laryngeal sensory deficits", "DISEASE", 162, 188], ["burn", "DISEASE", 216, 220], ["dysphagia", "DISEASE", 242, 251], ["muscle disuse", "DISEASE", 407, 420], ["oral", "ORGANISM_SUBDIVISION", 141, 145], ["pharyngeal", "ORGAN", 147, 157], ["laryngeal", "ORGAN", 162, 171], ["patient", "ORGANISM", 229, 236], ["endotracheal tube", "TISSUE", 360, 377], ["oropharyngeal muscle", "ORGAN", 393, 413], ["patient", "SPECIES", 229, 236], ["Rumbach et al.", "TEST", 65, 79], ["oral, pharyngeal and laryngeal sensory deficits", "PROBLEM", 141, 188], ["dysphagia", "PROBLEM", 242, 251], ["acute deconditioning", "PROBLEM", 287, 307], ["the endotracheal tube", "TREATMENT", 356, 377], ["associated oropharyngeal muscle disuse", "PROBLEM", 382, 420], ["pharyngeal", "ANATOMY", 147, 157], ["laryngeal", "ANATOMY", 162, 171], ["sensory deficits", "OBSERVATION", 172, 188], ["dysphagia", "OBSERVATION", 242, 251], ["acute", "OBSERVATION_MODIFIER", 287, 292], ["deconditioning", "OBSERVATION", 293, 307], ["endotracheal tube", "OBSERVATION", 360, 377], ["oropharyngeal muscle", "ANATOMY", 393, 413], ["disuse", "OBSERVATION", 414, 420], ["should not be", "UNCERTAINTY", 421, 434]]], ["Severe burn injury frequently induces a hypermetabolic state in burn sizes above 20 percent of the total body surface area, which can subsequently result in loss of muscle mass [28] .", [["body surface area", "ANATOMY", 105, 122], ["muscle", "ANATOMY", 165, 171], ["burn injury", "DISEASE", 7, 18], ["burn", "DISEASE", 64, 68], ["loss of muscle mass", "DISEASE", 157, 176], ["body", "ORGANISM_SUBDIVISION", 105, 109], ["muscle", "ORGAN", 165, 171], ["Severe burn injury", "PROBLEM", 0, 18], ["a hypermetabolic state in burn sizes", "PROBLEM", 38, 74], ["loss of muscle mass", "PROBLEM", 157, 176], ["burn", "OBSERVATION_MODIFIER", 7, 11], ["injury", "OBSERVATION", 12, 18], ["hypermetabolic state", "OBSERVATION", 40, 60], ["burn", "OBSERVATION_MODIFIER", 64, 68], ["sizes", "OBSERVATION_MODIFIER", 69, 74], ["20 percent", "OBSERVATION_MODIFIER", 81, 91], ["total body", "ANATOMY_MODIFIER", 99, 109], ["surface", "ANATOMY_MODIFIER", 110, 117], ["loss", "OBSERVATION_MODIFIER", 157, 161], ["muscle", "ANATOMY", 165, 171], ["mass", "OBSERVATION", 172, 176]]], ["In the current study, the mean burn size of participants was 35.28%, thus indicating that a substantial portion of participants in this cohort had a burn size that would result in catabolism, strongly inferring that they may be at risk for acute deconditioning including oropharyngeal muscle atrophy with its resultant effects on swallow physiology.", [["oropharyngeal muscle", "ANATOMY", 271, 291], ["burn", "DISEASE", 31, 35], ["burn", "DISEASE", 149, 153], ["muscle atrophy", "DISEASE", 285, 299], ["participants", "ORGANISM", 44, 56], ["oropharyngeal", "ORGANISM_SUBDIVISION", 271, 284], ["muscle", "ORGAN", 285, 291], ["participants", "SPECIES", 44, 56], ["participants", "SPECIES", 115, 127], ["the current study", "TEST", 3, 20], ["the mean burn size", "TEST", 22, 40], ["a burn size", "PROBLEM", 147, 158], ["acute deconditioning", "PROBLEM", 240, 260], ["oropharyngeal muscle atrophy", "PROBLEM", 271, 299], ["swallow physiology", "PROBLEM", 330, 348], ["size", "OBSERVATION_MODIFIER", 36, 40], ["substantial", "OBSERVATION_MODIFIER", 92, 103], ["portion", "OBSERVATION_MODIFIER", 104, 111], ["size", "OBSERVATION_MODIFIER", 154, 158], ["acute", "OBSERVATION_MODIFIER", 240, 245], ["deconditioning", "OBSERVATION", 246, 260], ["oropharyngeal muscle", "ANATOMY", 271, 291], ["atrophy", "OBSERVATION", 292, 299]]], ["This is also supported by previous work examining the profile of dysphagia following severe burn injury [14, [16] [17] [18] [19] [20] 27] , which documents that the primary characteristics of dysphagia following thermal burn injury include oral and pharyngeal phase deficits with the presence of reduced base of tongue retraction as well as impaired pharyngeal constriction that manifests as pharyngeal retention and elevated aspiration risk.DiscussionThe extraordinarily high rate as well as greater severity of dysphagia in the present study highlights that early and rigorous dysphagia rehabilitation is paramount.", [["oral", "ANATOMY", 240, 244], ["pharyngeal", "ANATOMY", 249, 259], ["tongue", "ANATOMY", 312, 318], ["pharyngeal", "ANATOMY", 350, 360], ["pharyngeal", "ANATOMY", 392, 402], ["dysphagia", "DISEASE", 65, 74], ["burn injury", "DISEASE", 92, 103], ["dysphagia", "DISEASE", 192, 201], ["burn injury", "DISEASE", 220, 231], ["oral and pharyngeal phase deficits", "DISEASE", 240, 274], ["impaired pharyngeal constriction", "DISEASE", 341, 373], ["pharyngeal retention", "DISEASE", 392, 412], ["dysphagia", "DISEASE", 513, 522], ["dysphagia", "DISEASE", 579, 588], ["[16] [17] [18] [19] [20] 27", "SIMPLE_CHEMICAL", 109, 136], ["oral", "ORGANISM_SUBDIVISION", 240, 244], ["tongue", "ORGAN", 312, 318], ["pharyngeal", "ORGAN", 350, 360], ["pharyngeal", "ORGANISM_SUBDIVISION", 392, 402], ["dysphagia", "PROBLEM", 65, 74], ["severe burn injury", "PROBLEM", 85, 103], ["dysphagia", "PROBLEM", 192, 201], ["thermal burn injury", "PROBLEM", 212, 231], ["oral and pharyngeal phase deficits", "PROBLEM", 240, 274], ["reduced base of tongue retraction", "PROBLEM", 296, 329], ["impaired pharyngeal constriction", "PROBLEM", 341, 373], ["pharyngeal retention", "PROBLEM", 392, 412], ["elevated aspiration risk", "PROBLEM", 417, 441], ["dysphagia", "PROBLEM", 513, 522], ["the present study", "TEST", 526, 543], ["rigorous dysphagia rehabilitation", "TREATMENT", 570, 603], ["dysphagia", "OBSERVATION", 192, 201], ["pharyngeal", "ANATOMY", 249, 259], ["reduced", "OBSERVATION_MODIFIER", 296, 303], ["base", "OBSERVATION_MODIFIER", 304, 308], ["tongue retraction", "OBSERVATION", 312, 329], ["pharyngeal constriction", "ANATOMY", 350, 373], ["pharyngeal", "ANATOMY", 392, 402], ["retention", "OBSERVATION", 403, 412], ["elevated", "OBSERVATION_MODIFIER", 417, 425], ["aspiration", "OBSERVATION", 426, 436], ["dysphagia", "OBSERVATION", 513, 522], ["dysphagia", "OBSERVATION", 579, 588]]], ["Prevention and minimisation of the effects of deconditioning as well as contractures on swallow function is necessary to optimise functional swallowing outcomes.", [["contractures", "DISEASE", 72, 84], ["deconditioning", "PROBLEM", 46, 60], ["contractures on swallow function", "PROBLEM", 72, 104]]], ["Evidence is emerging within the literature support this concept [16, [18] [19] [20] ; however, further work is required to more clearly define optimal treatment methods to expedite safe transition to oral intake in this challenging population.DiscussionIt is also important to consider that laryngeal pathology as a result of inhalation injury may not only adversely affect swallow function in the short term during the patient's immediate treatment post burn injury, but it may also compromise patient function later in life as a causative factor for the reduction of physiological reserve.", [["oral", "ANATOMY", 200, 204], ["laryngeal", "ANATOMY", 291, 300], ["inhalation injury", "DISEASE", 326, 343], ["oral", "ORGANISM_SUBDIVISION", 200, 204], ["laryngeal", "ORGAN", 291, 300], ["patient", "ORGANISM", 420, 427], ["patient", "ORGANISM", 495, 502], ["patient", "SPECIES", 420, 427], ["patient", "SPECIES", 495, 502], ["laryngeal pathology", "PROBLEM", 291, 310], ["inhalation injury", "PROBLEM", 326, 343], ["burn injury", "PROBLEM", 455, 466], ["laryngeal", "ANATOMY", 291, 300], ["pathology", "OBSERVATION", 301, 310], ["short term", "OBSERVATION_MODIFIER", 398, 408], ["physiological reserve", "OBSERVATION", 569, 590]]], ["Whilst the majority of patients who are cognitively and neurologically intact will learn to adapt to changes in laryngeal anatomy and physiology as it relates to swallowing, should an event occur to compromise that cognitive and neurological level of function, it is plausible to hypothesise that their ability to continue to adapt and compensate following an insult may be compromised.DiscussionOne aspect that was not comparable between the two inhalation cohorts was the duration of enteral feeding.", [["laryngeal", "ANATOMY", 112, 121], ["neurological", "ANATOMY", 229, 241], ["patients", "ORGANISM", 23, 31], ["laryngeal", "ORGAN", 112, 121], ["patients", "SPECIES", 23, 31], ["changes in laryngeal anatomy", "PROBLEM", 101, 129], ["an insult", "PROBLEM", 357, 366], ["enteral feeding", "TREATMENT", 486, 501], ["laryngeal", "ANATOMY", 112, 121]]], ["There are two possible explanations for this.", [["possible explanations for", "UNCERTAINTY", 14, 39]]], ["Firstly, it is plausible that one cohort may have had issues with wound healing or increased nutritional needs for any one of a number of facets of burn rehabilitation, necessitating increased duration of supplementary nutrition.", [["wound", "ANATOMY", 66, 71], ["burn", "DISEASE", 148, 152], ["wound", "PATHOLOGICAL_FORMATION", 66, 71], ["wound healing", "PROBLEM", 66, 79], ["increased nutritional needs", "PROBLEM", 83, 110], ["burn rehabilitation", "TREATMENT", 148, 167], ["supplementary nutrition", "TREATMENT", 205, 228]]], ["Secondly, given that these two cohorts were from two independent burn units, it is equally possible that habitual practices of each respective burn unit dietitian may vary slightly.", [["burn", "DISEASE", 65, 69], ["two independent burn units", "TREATMENT", 49, 75], ["equally possible", "UNCERTAINTY", 83, 99]]], ["As no specific nutritional parameters were recorded as a primary endpoint in this study, this aspect cannot be controlled for.", [["this study", "TEST", 77, 87]]], ["The severity of dysphagia at the initial assessment of the 2 inhalation cohorts was also found to differ.", [["dysphagia", "DISEASE", 16, 25], ["dysphagia", "PROBLEM", 16, 25], ["the initial assessment", "TEST", 29, 51], ["severity", "OBSERVATION_MODIFIER", 4, 12], ["dysphagia", "OBSERVATION", 16, 25]]], ["As there was no significant difference in severity or injury presentation between the two cohorts, the reasons for this difference cannot be explained by the current data available.LimitationsThe current study is limited by the retrospective nature of the data collection, and as such, it is acknowledged that the data available was limited to those assessments conducted as part of routine clinical care.", [["injury presentation", "PROBLEM", 54, 73], ["The current study", "TEST", 192, 209], ["the data collection", "TEST", 252, 271], ["the data", "TEST", 310, 318], ["those assessments", "TEST", 344, 361], ["routine clinical care", "TREATMENT", 383, 404], ["no", "UNCERTAINTY", 13, 15], ["significant", "OBSERVATION_MODIFIER", 16, 27], ["difference", "OBSERVATION_MODIFIER", 28, 38], ["severity", "OBSERVATION_MODIFIER", 42, 50], ["injury", "OBSERVATION", 54, 60]]], ["A prospective study of burn patients that includes set time points at which patients could complete a full battery of outcome measures pertaining to swallowing would be beneficial to fully appreciate the specifics regarding patterns of dysphagia recovery and presence of long-term laryngotracheal dysfunction.", [["laryngotracheal", "ANATOMY", 281, 296], ["burn", "DISEASE", 23, 27], ["dysphagia", "DISEASE", 236, 245], ["laryngotracheal dysfunction", "DISEASE", 281, 308], ["patients", "ORGANISM", 28, 36], ["patients", "ORGANISM", 76, 84], ["laryngotracheal", "ORGAN", 281, 296], ["patients", "SPECIES", 28, 36], ["patients", "SPECIES", 76, 84], ["A prospective study", "TEST", 0, 19], ["outcome measures", "TREATMENT", 118, 134], ["swallowing", "TREATMENT", 149, 159], ["dysphagia recovery", "PROBLEM", 236, 254], ["long-term laryngotracheal dysfunction", "PROBLEM", 271, 308], ["long-term", "OBSERVATION_MODIFIER", 271, 280], ["laryngotracheal dysfunction", "OBSERVATION", 281, 308]]], ["The small sample size is also a potential issue due to the known high level of heterogeneity in the clinical burn population.", [["burn", "DISEASE", 109, 113], ["The small sample size", "PROBLEM", 0, 21], ["the clinical burn population", "PROBLEM", 96, 124], ["small", "OBSERVATION_MODIFIER", 4, 9], ["sample", "OBSERVATION_MODIFIER", 10, 16], ["size", "OBSERVATION_MODIFIER", 17, 21], ["high", "OBSERVATION_MODIFIER", 65, 69], ["heterogeneity", "OBSERVATION", 79, 92]]], ["However, given that characteristics of the current inhalation cohort did not differ significantly on most parameters from those with inhalation injury reported by Rumbach et al. [14] , which was set in a separate Statewide service within the same country, the authors believe that patterns reported here are potentially true indications of the nature of recovery post inhalation burn injury.LimitationsThere are also known issues with diagnosing patients with inhalation injury.", [["inhalation injury", "DISEASE", 133, 150], ["burn injury", "DISEASE", 379, 390], ["inhalation injury", "DISEASE", 460, 477], ["patients", "ORGANISM", 446, 454], ["patients", "SPECIES", 446, 454], ["inhalation injury", "PROBLEM", 133, 150], ["inhalation burn injury", "PROBLEM", 368, 390], ["inhalation injury", "PROBLEM", 460, 477], ["inhalation burn", "OBSERVATION", 368, 383]]], ["The diagnosis itself of inhalational injury is often based on history and clinical suspicion [38] .", [["inhalational injury", "DISEASE", 24, 43], ["inhalational injury", "PROBLEM", 24, 43], ["clinical suspicion", "TEST", 74, 92]]], ["In this study, however, a minimum of visual inspection via laryngoscopy was required to determine presence of inhalation injury.", [["inhalation injury", "DISEASE", 110, 127], ["this study", "TEST", 3, 13], ["visual inspection", "TEST", 37, 54], ["laryngoscopy", "TEST", 59, 71], ["inhalation injury", "PROBLEM", 110, 127], ["inhalation injury", "OBSERVATION", 110, 127]]], ["Various other modalities are also available to confirm the diagnosis, such as bronchoscopy, however, there are currently no agreed standard criteria for establishing the severity of this diagnosis.LimitationsFinally, there are multiple issues acknowledged regarding basing the diagnosis of dysphagia on a CSE alone.", [["dysphagia", "DISEASE", 290, 299], ["CSE", "CHEMICAL", 305, 308], ["bronchoscopy", "TEST", 78, 90], ["dysphagia", "PROBLEM", 290, 299], ["multiple", "OBSERVATION_MODIFIER", 227, 235], ["dysphagia", "OBSERVATION", 290, 299]]], ["The authors fully acknowledge that a CSE does not provide the diagnostic information as available from instrumental assessments such as FEES or videofluoroscopy.", [["instrumental assessments", "TEST", 103, 127], ["videofluoroscopy", "TEST", 144, 160]]], ["Recognising the issues associated with a CSE, it is accepted that sub-clinical symptoms of dysphagia may have been missed, or severity of dysphagia not fully appreciated.", [["dysphagia", "DISEASE", 91, 100], ["dysphagia", "DISEASE", 138, 147], ["clinical symptoms", "PROBLEM", 70, 87], ["dysphagia", "PROBLEM", 91, 100], ["dysphagia", "PROBLEM", 138, 147], ["dysphagia", "OBSERVATION", 138, 147]]], ["As such the data presented within this study may be in fact an under-representation of the true incidence and severity of dysphagia.", [["dysphagia", "DISEASE", 122, 131], ["this study", "TEST", 34, 44], ["dysphagia", "PROBLEM", 122, 131], ["dysphagia", "OBSERVATION", 122, 131]]], ["Future prospective studies incorporating regular instrumental assessment are needed to fully understand the influence of damage to the pharyngeal and laryngeal structures on swallow function.", [["pharyngeal", "ANATOMY", 135, 145], ["laryngeal structures", "ANATOMY", 150, 170], ["pharyngeal", "ORGAN", 135, 145], ["laryngeal structures", "MULTI-TISSUE_STRUCTURE", 150, 170], ["Future prospective studies", "TEST", 0, 26], ["regular instrumental assessment", "TEST", 41, 72], ["damage to the pharyngeal and laryngeal structures", "PROBLEM", 121, 170], ["pharyngeal", "ANATOMY", 135, 145], ["laryngeal", "ANATOMY", 150, 159]]], ["The authors also accept that there is debate regarding the added benefit of including cervical auscultation in the CSE and its value in informing on swallow integrity [39] .", [["cervical", "ANATOMY", 86, 94], ["cervical", "ORGAN", 86, 94], ["cervical auscultation", "TEST", 86, 107], ["cervical", "ANATOMY", 86, 94]]], ["Auscultation was simply used in this study as an adjunct measure to add to the clinical information being collected on each patient and its limitations are acknowledged.", [["patient", "ORGANISM", 124, 131], ["patient", "SPECIES", 124, 131], ["Auscultation", "TEST", 0, 12], ["this study", "TEST", 32, 42]]], ["The FOIS scale also has known limitations when applied in this population due to the long-term dependence of many patients on non-oral feeding for reasons other than dysphagia.", [["dysphagia", "DISEASE", 166, 175], ["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122], ["non-oral feeding", "TREATMENT", 126, 142], ["dysphagia", "PROBLEM", 166, 175], ["long-term dependence", "OBSERVATION_MODIFIER", 85, 105]]], ["However, the absence of population specific/sensitive tools limits choice of outcome measures at present.ConclusionThe incidence of dysphagia in patients with inhalation injury is extremely high: 16 times greater than in those with burn injury but without an inhalation component in the present study.", [["dysphagia", "DISEASE", 132, 141], ["inhalation injury", "DISEASE", 159, 176], ["burn injury", "DISEASE", 232, 243], ["patients", "ORGANISM", 145, 153], ["patients", "SPECIES", 145, 153], ["outcome measures", "TREATMENT", 77, 93], ["dysphagia", "PROBLEM", 132, 141], ["inhalation injury", "PROBLEM", 159, 176], ["burn injury", "PROBLEM", 232, 243], ["an inhalation component", "PROBLEM", 256, 279], ["the present study", "TEST", 283, 300], ["dysphagia", "OBSERVATION", 132, 141], ["high", "OBSERVATION_MODIFIER", 190, 194], ["16 times greater", "OBSERVATION_MODIFIER", 196, 212], ["injury", "OBSERVATION", 237, 243], ["without", "UNCERTAINTY", 248, 255], ["inhalation", "OBSERVATION", 259, 269]]], ["Laryngeal pathology due to inhalation injury increases not only dysphagia severity but also the duration to dysphagia recovery.", [["Laryngeal", "ANATOMY", 0, 9], ["inhalation injury", "DISEASE", 27, 44], ["dysphagia", "DISEASE", 64, 73], ["dysphagia", "DISEASE", 108, 117], ["Laryngeal", "ORGAN", 0, 9], ["Laryngeal pathology", "PROBLEM", 0, 19], ["inhalation injury", "PROBLEM", 27, 44], ["dysphagia severity", "PROBLEM", 64, 82], ["dysphagia recovery", "PROBLEM", 108, 126]]]], "PMC7181916": [["The zoonotic introductions and ongoing outbreaks of Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) pose a global threat (1,2) necessitating continuous serosurveillance to monitor virus spread alongside the development of vaccine and antibodies as countermeasures.", [["Middle East respiratory syndrome (MERS) coronavirus", "DISEASE", 52, 103], ["Middle East respiratory", "ORGANISM", 52, 75], ["MERS) coronavirus", "ORGANISM", 86, 103], ["MERS-CoV", "ORGANISM", 105, 113], ["Middle East respiratory syndrome (MERS) coronavirus", "SPECIES", 52, 103], ["MERS-CoV", "SPECIES", 105, 113], ["The zoonotic introductions", "TREATMENT", 0, 26], ["Middle East respiratory syndrome", "PROBLEM", 52, 84], ["coronavirus", "PROBLEM", 92, 103], ["a global threat", "PROBLEM", 120, 135], ["continuous serosurveillance", "TREATMENT", 156, 183], ["virus spread", "PROBLEM", 195, 207], ["vaccine", "TREATMENT", 237, 244], ["antibodies", "TREATMENT", 249, 259], ["zoonotic", "OBSERVATION_MODIFIER", 4, 12], ["Middle", "ANATOMY_MODIFIER", 52, 58], ["respiratory syndrome", "OBSERVATION", 64, 84]]], ["Both approaches require validated assays to evaluate specific antibody responses.", [["validated assays", "TEST", 24, 40], ["specific antibody responses", "TEST", 53, 80]]], ["Although MERS-CoV serologic assays have been developed (2\u20136), those detecting functional antibodies cannot be applied in all laboratories and can require Biosafety Level 3 (BSL-3) containment.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 9, 17], ["functional antibodies", "PROTEIN", 78, 99], ["MERS-CoV", "SPECIES", 9, 17], ["CoV serologic assays", "TEST", 14, 34], ["functional antibodies", "PROBLEM", 78, 99], ["Biosafety Level", "TEST", 154, 169], ["BSL", "TEST", 173, 176]]], ["Recombinant protein-based immunoassays are easier to operate and standardize and do not require BSL-3 containment.", [["BSL-3", "GENE_OR_GENE_PRODUCT", 96, 101], ["Recombinant protein", "TEST", 0, 19]]], ["However, MERS-CoV protein-based assays developed thus far can only detect antibody binding and give no information on antibody functionality.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 9, 17], ["MERS-CoV protein", "PROTEIN", 9, 25], ["MERS", "TEST", 9, 13], ["CoV protein", "TEST", 14, 25], ["antibody binding", "PROBLEM", 74, 90]]], ["The MERS-CoV spike protein N terminal subunit (S1) contains 2 functional domains: the N-terminal domain (S1A), which binds sialic acid, the viral attachment factor; and the receptor-binding domain (RBD) (S1B), which binds dipeptidyl peptidase 4, the virus receptor (7,8).", [["sialic acid", "CHEMICAL", 123, 134], ["N", "CHEMICAL", 27, 28], ["sialic acid", "CHEMICAL", 123, 134], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 4, 12], ["N terminal subunit", "GENE_OR_GENE_PRODUCT", 27, 45], ["S1A", "GENE_OR_GENE_PRODUCT", 105, 108], ["sialic acid", "SIMPLE_CHEMICAL", 123, 134], ["receptor-binding domain", "GENE_OR_GENE_PRODUCT", 173, 196], ["S1B", "GENE_OR_GENE_PRODUCT", 204, 207], ["dipeptidyl peptidase 4", "GENE_OR_GENE_PRODUCT", 222, 244], ["MERS-CoV spike protein N terminal subunit", "PROTEIN", 4, 45], ["S1", "PROTEIN", 47, 49], ["N-terminal domain", "PROTEIN", 86, 103], ["S1A", "PROTEIN", 105, 108], ["viral attachment factor", "PROTEIN", 140, 163], ["receptor-binding domain", "PROTEIN", 173, 196], ["RBD", "PROTEIN", 198, 201], ["S1B", "PROTEIN", 204, 207], ["dipeptidyl peptidase 4", "PROTEIN", 222, 244], ["virus receptor", "PROTEIN", 250, 264], ["The MERS", "TEST", 0, 8], ["CoV spike protein N terminal subunit (S1)", "PROBLEM", 9, 50], ["the N-terminal domain (S1A)", "PROBLEM", 82, 109], ["sialic acid", "TEST", 123, 134], ["the viral attachment factor", "PROBLEM", 136, 163], ["binds dipeptidyl peptidase", "TREATMENT", 216, 242], ["the virus receptor", "TREATMENT", 246, 264], ["sialic acid", "OBSERVATION", 123, 134]]], ["Antibodies against those 2 domains can block MERS-CoV infection (9).", [["infection", "DISEASE", 54, 63], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 45, 53], ["MERS-CoV", "SPECIES", 45, 53], ["Antibodies", "TREATMENT", 0, 10], ["CoV infection", "PROBLEM", 50, 63], ["CoV", "OBSERVATION_MODIFIER", 50, 53], ["infection", "OBSERVATION", 54, 63]]], ["Based on this fundamental knowledge, we developed 2 recombinant protein-based functional assays.", [["recombinant protein", "PROTEIN", 52, 71]]]], "76f98707e63b25eac067f41379c4de823aec00d3": [], "PMC7261464": [["Authors\u2019 contributionsLC and HK devised the topic of the manuscript; HK, LC, EC drafted sections for and finalised the manuscript.Declaration of interestsLC is an editor for the British Journal of Anaesthesia.", [["Anaesthesia", "TREATMENT", 197, 208], ["LC", "ANATOMY", 73, 75]]], ["HK is a fellow with the British Journal of Anaesthesia Peer Review Fellowship Programme.FundingNational Institute for Health Research (HK).Uncited References", [["HK", "GENE_OR_GENE_PRODUCT", 0, 2]]]], "81e0f913333e2072251972b3fb103be9290d1b02": [["In the setting of a biological (or chemical) attack, similar to the setting of a MASCAL trauma event, such decisions may have life-and-death implications.", [["trauma", "DISEASE", 88, 94], ["death", "DISEASE", 135, 140], ["a biological (or chemical) attack", "PROBLEM", 18, 51], ["a MASCAL trauma event", "PROBLEM", 79, 100]]], ["In such situations, an algorithmic approach becomes invaluable.", [["an algorithmic approach", "TREATMENT", 20, 43]]]], "PMC6466414": []}